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Abstract 
 
A fundamental biological property of retroviruses and RNA viruses is their ability 
to rapidly mutate and evolve.  The ability of these viruses to generate high levels of 
genetic diversity during replication has clearly had a profound impact on their ability to 
maintain their niche in nature, and to rapidly adapt to changing environmental conditions 
or opportunities to expand their host range.  Previous reports with HIV-1 have indicated 
that the cell type in which HIV-1 replicates does not have a profound impact on HIV-1 
diversity.  However, due to differences in dNTP pool levels and expression levels of 
HIV-1 DNA editing enzymes, the hypothesis that cell type does influence the diversity of 
HIV-1 populations was formulated.  To test this, a panel of relevant cell types (i.e., CEM-
GFP, U373-MAGI, 293T, and SupT1) was analyzed for their ability to influence HIV-1 
mutant rate and spectra.  No differences were observed in overall mutation rate, but 
intriguingly, cell type differences impacted HIV-1 mutation spectra. These observations 
represent the first description of significant differences in HIV-1 mutation spectra 
observed in different cell types in the absence of changes in the viral mutation rate and, 
imply that such differences could have a profound impact on HIV-1 pathogenesis, 
immune evasion, and drug resistance. 
 The most common mutation type that arises during HIV-1 replication is transition 
mutations, particularly G-to-A mutations.  Apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like 3 (APOBEC3) proteins create G-to-A mutations at specific 
cytosine dinucleotides.  In order to better define the locations of APOBEC3G (A3G)-
mediated G-to-A mutations, we tested the hypothesis that sequence context and DNA 
secondary structure influence the creation of A3G-mediated G-to-A mutations.  Single-
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stranded DNA secondary structure as well as the bases directly 3’and 5’ of the cytosine 
dinucleotide were found to be critically important for A3G recognition.  These 
observations provide the first demonstration that A3G cytosine deamination hotspots are 
defined by both sequence context and the single-stranded DNA secondary structure.  This 
knowledge can be used to better trace the origins of mutations to A3G activity, and 
illuminate its impact on the generation of HIV-1 diversity, ultimately influencing the 
biological properties of the progeny virus variants. 
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GENERAL INTRODUCTION 
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History and Identification of Human Immunodeficiency Virus Type 1 
 Human immunodeficiency virus type 1 (HIV-1) has killed over thirty million 
people and currently infects thirty-five million people worldwide (4).  The virus infects 
and depletes cells of the immune system, which leads to a state of immunodeficiency 
referred to as AIDS (acquired immunodeficiency syndrome).  AIDS is characterized by 
low CD4+ T-cell count and the presence of opportunistic infections such as oral thrush 
and toxoplasmosis or AIDS-related malignancies such as Kaposi’s sarcoma or 
lymphoma.  Once the disease progresses to AIDS, untreated individuals typically die 
within eleven months (128). 
 The first reported cases of AIDS (at the time called gay-related immune deficiency) 
were reported in the early 1980s when five gay men in the Los Angeles area were 
diagnosed with a rare lung infection PCP (Pneumocystis carinii pneumonia) (3).  Around 
this same time an aggressive and rare form of cancer, Kaposi’s sarcoma was reported in 
forty-one gay men in New York City and Los Angeles (2).  At the time, the cause and 
origin of the opportunistic infections and cancer were not known.  However, in 1983 
HIV-1 was identified as the causative agent by Françoise Barré-Sinoussi, Luc 
Montagnier, and Robert Gallo (14, 79). 
 Further work by Robert Gallo, Françoise Barré-Sinoussi, and Luc Montagnier 
revealed that HIV-1 belonged to the Retroviridae, a family that includes other viruses 
such as HTLV (human T-cell leukemia virus), BLV (bovine leukemia virus), and MLV 
(murine leukemia virus) (14, 79).  HIV-1 was further defined as belonging to the 
lentivirus genus of the Retroviridae (reviewed in (181)) which includes viruses such as 
visna virus, feline immunodefiency virus (FIV), and simian immunodeficiency virus 
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(SIV).  Of these lentiviruses, SIV, a retrovirus of non-human primates, is believed to be 
the precursor to the virus we now know as HIV-1.  Specifically, it is thought that HIV-1 
was transferred from chimpanzees (i.e., SIVcpz) to humans early in the 20th century in 
sub-Saharan Africa.  An additional zoonotic event gave rise to a less transmissible form 
of HIV, referred to as HIV-2 and was likely transmitted to humans from sooty 
mangabeys (i.e., SIVsm) in the mid 20th century. 
 
HIV-1 Transmission and Mechanism of Pathology 
 Once transmitted from non-human primates to humans, HIV-1 was determined to 
be transmitted through sexual contact, breastfeeding, blood transfusions, contaminated 
needles, and perhaps through the oral cavity.  However, transmission by sexual contact 
and breastfeeding requires HIV-1 to cross mucosal barriers in order to come into contact 
with target cells.  To do this, HIV-1 “piggy-backs” on dendritic cells that transport the 
virus to target cells such as activated CD4+ T-cells (40, 88, 219).  The dendritic cell is 
not infected by the founder virus, but instead brings HIV-1 into contact with CD4+ T-
cells.  The virus interacts with the receptors on the T-cell and infects it.  Recently, HIV-1 
was proposed to diffuse through squamous epithelium (37); however further studies are 
needed to confirm and extend these observations.  In addition to infecting activated CD4+ 
T-cells, HIV-1 also infects resting CD4+ T-cells, macrophages, stromal fibroblasts, 
endothelial cells, gingival keratinocytes, astrocytes, fibroblasts in dental pulp and 
possibly dendritic cells (13, 30, 76, 81, 166, 197, 221). 
 Once HIV-1 has disseminated throughout the body, the virus depletes CD4+ T cells 
by at least four mechanisms including: 1) direct killing of infected cells; 2) decreased 
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naïve CD4+ cell production as a result of HIV-1 induced fibrosis of lymph tissue; 3) 
HIV-1-mediated damage to the lymph node fibroblastic reticular cell (FRC) network 
which decreases IL-7 production, thereby inducing apoptosis of naïve CD4+ cells (235), 
and; 4) apoptosis of CD4+ cells through chronic immune activation.  Chronic immune 
activation refers to HIV-1-mediated depletion of gut-associated lymph tissue (GALT) 
(33, 86, 148). Loss of GALT enables bacterial constituents (i.e. lipopolysaccharide) to 
translocate the intestinal wall and gain entry into circulation (32).  The presence of 
bacterial constituents in circulation causes systemic immune activation (32), which is 
characterized by release of proinflammatory cytokines and type I interferons.  Type I 
interferon induces the expression of TRAIL (TNF-related apoptosis-inducing ligand) and 
its death receptor 5 in CD4+ T-cells in the periphery and secondary lymphatic tissues 
(100-102), which induces apoptosis of uninfected T-cells and destroys the lymph node 
architecture.  Besides TRAIL, type I interferon also induces immunosuppressive enzymes 
(i.e., indoleamine-2,3-dioxygenase) that reduce T-cell proliferation and increase T-cell 
dysfunction (22, 23). The importance of chronic immune activation in the pathology of 
HIV-1 is demonstrated by the correlation between the degree of chronic immune 
activation and disease progression (80). 
 
HIV-1 Genome and Life Cycle 
 To infect target cells and spread to other cells, as well as mediate immune 
destruction, HIV-1 relies on numerous viral proteins.  Figure 1-1 depicts the HIV-1 
genomic organization and Figure 1-2 illustrates a mature HIV-1 virion.  Like all 
retroviruses, HIV-1 has three core genes including gag, pol, and env.  HIV-1 gag encodes 
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for a polyprotein that has three structural domains: 1) capsid (CA) which forms the viral 
core, 2) nucleocapsid (NC) which encapsidates the viral RNA and protects it from 
degradation, and 3) matrix (MA) which surrounds and protects the viral core.  The Gag 
polyprotein also includes smaller peptides, most notably p6, which plays important roles 
in the virus assembly pathway.  The Gag polyprotein is cleaved into the mature protein 
products by the viral-encoded protease.  The pol gene encodes a polyprotein that is 
translated from the full-length genomic RNA as a large Gag-Pol polyprotein that is 
created by ribosomal frameshifting.  The Pol polyprotein encodes for three enzymes: 1) 
reverse transcriptase (RT), which is a RNA-dependent, DNA polymerase that converts 
ssRNA into dsDNA without proofreading activity 2) integrase, which integrates the viral 
dsDNA into the host genome, and 3) protease, which cleaves the Gag and Gag-Pol 
polyprotein, a necessary step in virus maturation.  Finally, HIV-1, like all retroviruses, 
encodes for an envelope (env) gene that encodes for gp160, which is subsequently 
cleaved by a cellular protease into gp120 (a surface protein) and gp41(a transmembrane 
protein).  The viral envelope protein (consisting of gp41 and gp120) is essential for 
binding the receptor on the target cell for infection.  In addition to the conserved gag, pol, 
and env genes, HIV-1 encodes for six accessory proteins including Vpu (viral protein U), 
Nef (negative factor), Tat (transactivator of transcription), Vpr (viral protein R), Rev 
(regulator of viral protein expression), and Vif (viral infectivity factor).  These accessory 
proteins facilitate viral replication and immune system evasion. Vpu induces the 
degradation of CD4 and counteracts the host protein tetherin (160, 222).  Nef decreases 
the surface accumulation of MHC type I and II, which facilitates immune evasion.  Tat 
allows for efficient elongation of transcription of the provirus.  Vpr regulates the import 
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of the preintegration complex.  Rev exports unspliced RNA from the nucleus. Finally, Vif 
counteracts the host protein APOBEC3G (apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like 3G) (203).  Of the proteins encoded by the HIV-1 genome, the 
envelope protein is a key but not a sole determinant of cell tropism and initiates the first 
step in the viral life cycle (shown in Figure 1-3). Specifically, the envelope protein, 
gp120 interacts with CD4 receptors on the surface of host target cells. After binding to 
the CD4 receptor, gp120 undergoes a conformational change that exposes the fusion 
protein gp41, which interacts with the coreceptor CXCR4 or CCR5. The target cell and 
viral membranes fuse, and the viral core is deposited into the cytoplasm of the infected 
cell where the uncoating of the CA protein is initiated. During the uncoating of the viral 
core, the ssRNA genome is reverse transcribed into dsDNA by HIV-1 RT.  The lack of 
proofreading activity makes the enzyme error prone which results in a high mutation rate 
of 3.4x10-5 mutations/target base pair/replication cycle (141), which is approximately one 
mutation per every three genomes.  Viral dsDNA is then integrated into the host genome 
via the HIV-1 integrase to form the provirus.  The viral genes are transcribed by cellular 
RNA polymerase II and translated by the host translational machinery.  The full-length 
viral genomic RNA, the Gag and Gag-Pol polyproteins, and the Env proteins traffic to the 
plasma membrane to sites of virus assembly and release.  After virus particles are 
released from the cell, the particle undergoes maturation due to the autocatalytic cleavage 
by viral protease and subsequent cleavage events to convert the immature particle into a 
mature and infectious particle with mature MA, CA and NC proteins as well as RT, 
protease and integrase.  This maturation step gives rise to an infectious viral particle that 
can infect additional target cells.  Additional infection events give rise to cells that are 
	   7 
actively infected and actively producing virus.  However, a subset of infected cells harbor 
integrated proviruses but do not express viral RNA or proteins.  These cells are called 
latently infected.  At later points in time, some of these latently infected cells are 
reactivated (by mechanisms not completely understood), and active virus replication 
begins.  Due to these latently infected cells, anti-HIV-1 therapy does not cure the 
infection from an infected individual. 
 
Drug Treatment to Inhibit HIV-1 Replication 
 There are currently over 30 antiretroviral drugs approved by the Food and Drug 
Administration to treat HIV-1 (1).  These drugs target steps within the HIV-1 life cycle 
including virus entry, reverse transcription, integration, and protease activity.  Drugs that 
target viral entry do so by either blocking the HIV-1 coreceptor CCR5 (i.e., Maraviroc) 
or by preventing viral envelope gp41 fusion (i.e., Enfuvirtide). Maraviroc binds to CCR5 
and interferes with the interaction of gp120 with CCR5.  Enfuvirtide binds to gp41 and 
prevents the fusion of the viral and cell membranes.  Anti-HIV-1 drugs that target reverse 
transcription fall into one of two classes including nucleoside/nucleotide-analog reverse 
transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs).  Upon entry into cells, NRTIs are phosphorylated into their respective 
deoxyribonucleotide triphosphate (dNTP) analogs. The analog competes with 
endogenous dNTPs for incorporation into the viral DNA during reverse transcription.  
Once incorporated, NRTIs that lack a 3’-hydroxyl act as chain terminators to prevent 
elongation of viral DNA.  In contrast, NNRTIs are allosteric inhibitors rather than 
competitive inhibitors.  They bind to a hydrophobic pocket within reverse transcriptase, 
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which induces a conformational change that prevents elongation of the viral DNA (208).  
The exact mechanism by which reverse transcription is inhibited by NNRTI-induced 
conformational change is not known, however structural analysis of NNRTI-bound 
reverse transcriptase suggests that the conformational change may 1) change the position 
of the DNA primer in the active site (105), 2) decrease translocation of the 
primer/template and elongation of the nascent DNA strand (120, 215), or 3) prevent the 
positioning of dNTP relative to the primer/template (211, 231).  These conformational 
changes disrupt enzyme structure by changing the geometry of the active site.  The first 
integrase inhibitor (i.e., Raltegravir) interacts with the viral protein integrase, causing a 
delay in viral kinetics and subsequent inhibition.  Finally, there are 11 approved protease 
inhibitors that target the viral protease and inhibit the Gag and Gag-Pol proteins from 
being processed.  The virus particle cannot mature and therefore is unable to infect a new 
cell. 
 
HIV-1 Mutation Rate and the Emergence of Drug Resistance 
 Current anti-HIV-1 drugs are given to patients to suppress viral replication.  
However, early on in HIV-1 treatment it was recognized that viral replication was only 
temporarily suppressed. For example, 3’-azidothymidine (AZT, a NRTI) only extended a 
patient’s life about by six months when given as monotherapy. The lack of long-term 
efficacy was attributed to the rapid emergence of drug resistance. The speed at which the 
virus became drug resistant is in large part attributed to the high mutation rate of HIV-1 
(along with the high rates of recombination and replication). HIV-1 has a high mutation 
rate of 3.4x10-5 mutations/target base pair/replication cycle (141).  Mutations can occur at 
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a few different steps of the life cycle including transcription of the genomic RNA by 
RNA polymerase II, viral DNA synthesis by reverse transcriptase, and proviral DNA 
replication by DNA polymerase delta (along with other cellular DNA polymerases). 
Unlike DNA polymerase delta, RNA polymerase II and reverse transcriptase do not 
possess proofreading ability. This lack of proofreading ability is thought to be the 
primary contributor to HIV-1 mutations acquired during replication, though the 
contribution of HIV-1 RT is thought to be significantly greater than that of RNA 
polymerase II (164).  The high HIV-1 mutation, recombination, and replication rates lead 
to efficient immune evasion and drug resistance, and is the fundamental reason why no 
AIDS vaccine exists. As indicated above, in addition to the high mutation rate, HIV-1 
replicates rapidly and it has been estimated that 1-10 billion virions are produced each 
day in an untreated individual (177).  Given the high rates of replication and mutation, it 
is estimated that a mutation occurs at every nucleotide in the HIV-1 genome every day.  
In monotherapy, there is a high likelihood that a drug resistance-conferring mutation will 
develop rapidly considering the high mutation rate.  By combining multiple drugs, there 
is less likelihood that a virus will emerge possessing all the mutations to confer resistance 
while maintaining viability. Therefore, HAART (highly active antiretroviral therapy) is a 
clinical drug regimen paradigm in which three or four drugs from different classes are 
administered to patients to lower the probability of the emergence of antiretroviral drug 
resistance.  However, combination therapy decreases but does not eliminate the 
emergence of drug resistance.  For example, 6-16% of newly infected patients have been 
infected with a virus resistant to at least one class of anti-HIV-1 drugs (189).  HIV-1 
develops resistance to every anti-retroviral by acquiring mutations that lessen or ablate 
	   10 
the drug’s ability to inhibit the virus.  Some mutations confer resistance to the specific 
drug being used or a few drugs, while a combination of mutations can cause resistance to 
all the drugs in the class (ie. NRTIs).  The presence and prevalence of drug resistant HIV-
1 emphasizes the need to continue to identify new HIV-1 drug targets. 
 
Mutation Rate as a Drug Target – Lethal Mutagenesis 
 Studies with HIV-1 have demonstrated that virus variants with higher or lower 
mutation rates (i.e., mutator or antimutator phenotypes) have lower virus fitness (60). 
Such data help support the theory that HIV-1 infectivity can be reduced by altering 
mutation rate – particularly by the purposeful elevation of the HIV-1 mutation rate (26, 
62). The HIV-1 mutation rate represents a potentially novel drug target that has yet to be 
fully exploited (50). While the high mutation rate of HIV-1 enables the virus to acquire 
drug resistance or evade the immune system, it also leads to a large proportion of non-
infectious virions (See Figure 1-4) (52, 54, 59).  An initial study showed that a 2-fold 
increase in picornavirus mutation frequency reduced viral titers by 99% (103).  
Subsequent studies showed that even a 3-4 fold increase in the mutation rate of HIV-1 
and other RNA viruses renders the virus unable to replicate with enough fidelity to be 
viable or infectious, a processed referred to as lethal mutagenesis (54, 59, 69-71, 104, 
132). 
 Lethal mutagenesis has been shown to be a plausible strategy for inhibiting viruses 
that have an inherently high mutation rate.  For example, ribavirin has been shown to 
inhibit numerous RNA viruses in vitro (54, 123) through lethal mutagenesis.  Ribavirin is 
incorporated as a nucleoside analog into poliovirus RNA increasing G-to-A and C-to-T 
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mutations (54, 55).  Although ribavirin is used clinically to treat hepatitic C virus, it is not 
clear if the in vivo mechanism of action is lethal mutagenesis.  There have been several 
compounds that have been shown to lethally mutagenize HIV-1.  For example, Loeb et. 
al. first demonstrated lethal mutagenesis of HIV-1 using 5-hydroxydeoxycytidine (5-OH-
dC ) (132).  5-OH-dC inhibits replication through lethal mutagenesis of HIV- 1 by 
inducing G-to-A mutations.  However, 5-OH-dC is highly cytotoxic. Another mutagen, 
5-aza-5,6,-dihydro-2’-deoxycytidine (KP-1212 or prodrug KP-1461) was shown to 
inhibit HIV-1 in cell culture and increase the frequency of G-to-A and A-to-G mutations 
(94).  This was achieved with KP-1212 concentrations in the nanomolar to low 
micromolar range.  KP-1461 advanced to clinical trials where the drug was shown to be 
safe in vivo.  However, while KP-1461 did alter the mutation spectra in vivo there was not 
an increase in viral mutation rate in vivo and the clinical trials ceased.  More recently, 
three FDA-approved anti-cancer drugs have been shown to increase the mutation rate of 
HIV-1; 5-azacytidine (5-AZC), gemcitabine and decitibine (50, 59). 5- AZC is a 
ribonucleoside analog of cytosine that is clinically used to treat myelodysplastic 
syndromes (107, 233).  However, 5-AZC has also been shown to inhibit HIV-1 (27, 59) 
and this inhibition correlated with a threefold increase in mutation rate (59).  Two 
mechanisms could account for the increase in HIV-1 mutation rate mediated by 5- AZC.  
For example, in its ribonucleoside form 5-AZC may be incorporated into RNA, which 
could cause a mispairing of the base during viral DNA synthesis and subsequent 
mutations (59).  A second mechanism could be through incorporation of 5-AZC directly 
into the viral DNA. More specifically, 5-AZC could be either directly incorporated as a 
ribonucleotide or reduced into the 2’deoxynucleotide form by cellular ribonucleotide 
	   12 
reductase, which could then be incorporated into viral DNA in place of dCTP.  After 
incorporation into viral (–) sense DNA, the unstable 5-AZC triazine ring has been 
hypothesized to open due to a disruption of a bond between nitrogen-1 and carbon-6 and 
subsequent hydrolysis.  The ring opening allows base pairing with a cytosine that results 
in a G-to-C mutation.  Dapp et. al. observed a higher mutant frequency during the early 
phase of replication attributing to the reverse transcription step of the viral life cycle (59).  
Therefore, it was concluded that 5-AZC causes lethal mutagenesis by incorporation into 
the viral DNA.   
 Another nucleoside analog that causes lethal mutagenesis in vitro is decitabine (i.e., 
5-aza-2’-deoxycytidine) (50).  Like 5-AZC, treatment of HIV-infected cell with 
decitabine led to the observation of G-to-C transversion mutations in HIV-1 proviruses. 
Decitabine is the reduced form of 5-AZC and is thought to be directly incorporated into 
viral DNA during reverse transcription. In vivo, decitabine has been shown to inhibit 
DNA methylation and is approved clinically for the treatment of myelodysplastic 
syndrome (151-153).  Decitabine has been shown more recently to reduce HIV-1 
infectivity (50). The anti-HIV-1 activity of decitibine was shown to correlate with an 
increase in the HIV-1 mutation rate, specifically causing an increase in G-to-C 
transversion mutations in the viral DNA.  Due to the ability to be incorporated into DNA, 
mutagens are thought to have high cellular toxicity and carcinogenicity.  More 
specifically, decitabine has been shown to cause G-to-C mutations in the colonic DNA of 
transgenic mice containing Escherichia coli lac I transgene (109).  However, these 
mutations have not been observed in host genomes when used clinically, and decitabine 
was shown to not be genotoxic (38, 50, 153). 
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 Besides mutagenic nucleoside analogs, nucleoside analogs that alter cellular dNTP 
pools have also been shown to increase HIV-1 mutation rate. One of these nucleoside 
analogs, gemcitabine, alters dNTPs by inhibiting host ribonucleotide reductase.  
Ribonucleotide reductase is the enzyme that converts rNTPs into dNTPs.  If this enzyme 
is inhibited, then dNTP pools in the cell are imbalanced and the cell may be unable to 
complete DNA replication or increase the mutation rate by incorporation of incorrect 
bases.  Gemcitabine is a clinically approved drug for cancer therapy that is a 
ribonucleotide reductase inhibitor.  Gemcitabine has been shown to decrease infectivity 
of HIV-1 at drug concentrations without apparent toxicity in a cell culture system (50). 
Interestingly, when gemcitabine was combined with the mutagen decitabine at low 
concentration, there was a synergistic reduction of HIV-1 infectivity (50) that correlated 
with an increase in the mutant frequency.  A synergistic decrease in HIV-1 replication 
was also seen when decitabine was combined with another ribonucleotide reductase 
inhibitor, hydroxyurea (50).  However, hydroxyurea has been shown to be too toxic to be 
used clinically to treat HIV-1.  The ability to use decitabine in combination with other 
ribonucleotide reductase inhibitors such as gemcitabine enables each drug to be used at 
lower concentrations than would be required if the drugs were used individually and 
thereby potentially reduces the toxicity to the cells. 
 
Lethal Mutagenesis of HIV-1 by APOBEC Host Proteins 
 Some cellular proteins have evolved to restrict retroviral replication by inducing 
lethal mutagenesis.  For example, the APOBEC (apolipoprotein B mRNA-editing, 
enzyme-catalytic, polypeptide-like) family of proteins has been shown to lethally 
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mutagenize HIV-1, as well as induce mutations in both ssDNA and ssRNA.  The 
APOBEC family are cytidine deaminases that include 11 members; AID (activation-
induced deaminase), APOBEC1, APOBEC2, APOBEC3A-D/F-H, and APOBEC4. Of 
these, AID induces somatic hypermutation and class switch recombination by 
deaminating the switch region in the ssDNA of B-cells within the germinal centers (31, 
65, 134).  In contrast, APOBEC1 deaminates a cytosine in apolipoprotein B mRNA, 
which creates a truncated form of the mRNA that is important for the absorption and 
transport of dietary fats (228), while the function of APOBEC2 and APOBEC4 is 
unknown.  The APOBEC3 proteins have both anti-retroelement and antiviral activity.  
Some APOBEC3 members have been shown to inhibit both LTR (long terminal repeat) 
retrotransposons and non-LTR retrotransposons including long interspersed nuclear 
elements (LINEs) (24, 25, 46, 48, 75, 117, 156, 200, 213). 
 Structurally, there is high amino acid identity between the APOBEC3 family 
members with as much as 50% sequence homology.  The APOBEC3 family has two 
different protein structures with APOBEC3A, APOBEC3C, and APOBEC3H containing 
a single catalytic domain, while APOBEC3B, APOBEC3D, APOBEC3F, and 
APOBEC3G have two catalytic domains.  The catalytic domains are zinc coordinated and 
highly conserved between the APOBEC3 family containing a His-X-Glu-X23-28-Pro-Cys-
X2-4-Cys cytosine deaminase motif (110, 228). 
 Evolutionarily, the APOBEC3 proteins expanded in humans to seven compared to 
mice where there is only one APOBEC3 protein (110).  It is hypothesized that in primates 
the gene duplicated several times creating the expanded locus.  Interestingly, the 
expansion of the APOBEC3 locus coincides with the decreased activity of retroelements 
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in primates.  This decrease in retroelement activity may explain the finding that while 
humans have five times more retroelements in their genome than mice, their retroelement 
activity is 100 times lower (137).  This suggests that APOBEC3 proteins may be 
important in regulating retroelement activity.  Cell type expression of APOBEC3 proteins 
vary depending on the specific APOBEC.  For example, APOBEC3A is highly expressed 
in monocytes/macrophages while APOBEC3B is expressed in keratinocytes and the 
small intestine.   APOBEC3C, APOBEC3D, APOBEC3F, and APOBEC3G are all 
expressed in CD4+ T-cells while APOBEC3H is expressed in peripheral blood 
lymphocytes and the testis/ovaries.  Expression of the APOBEC proteins within their 
respective cell types may restrict and/or contribute to the evolution of viruses. 
 
APOBEC-Mediated Restriction of HIV-1 Replication 
 The APOBEC3 proteins have been implicated in restricting numerous viruses 
including adeno-associated virus, hepatitis B virus, human papilloma virus, murine 
leukemia virus, and most notably, HIV-1 (21, 46, 68, 95, 118, 140, 202, 214, 218, 224).  
In fact, HIV-1 is restricted by APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H, 
and modestly by APOBEC3C and the inhibition of HIV-1 is attributed to the catalytic 
activity (58, 106, 124, 240).  The most studied APOBEC3 proteins, APOBEC3F and 
APOBEC3G, are packaged into the viral core during assembly through possible 
interactions with the structural protein NC and RNA (6, 41, 198, 237).  HIV-1 has 
developed a mechanism to counteract an APOBEC3 assault through its accessory protein 
Vif. HIV-1 Vif interacts with APOBEC3 proteins and targets them for proteosomal 
degradation by the E3 ligase Ubiquination complex (203).  However, in the absence of 
	   16 
Vif, APOBEC3F and APOBEC3G deaminate cytosine residues to uracil residues in the 
minus (–) sense DNA during reverse transcription.  These uracil residues in the viral 
DNA attract the enzymes uracil DNA glycosylase and apurinic-apyrimidinic 
endonuclease, degrading the viral DNA.  As shown in Figure 1-5, the viral minus (-) 
sense DNA that escapes degradation completes reverse transcription resulting in the 
uracil residue base pairing with an adenine residue causing G-to-A mutations in the plus 
(+) sense DNA (95, 234).  As a result, the high amount of mutations, termed 
hypermutation, may alter open reading frames and introduce translational stop codons 
ceasing replication.  APOBEC3 proteins preferentially mutate cytosine residues within a 
given sequence context.  For example, APOBEC3G targets CC motifs in the (-) strand of 
DNA or what is observed as a GG dinucleotide in the (+) strand of DNA (underlined 
letter indicates mutation target).   The other members of the APOBEC3 family recognize 
TC motifs or GA dinucleotides. Interestingly, not all CC or TC dinucleotides are mutated 
by the APOBEC3 proteins.  The reasons why some dinucleotides are targeted and others 
are not is largely unknown.   
 Besides their ability to mutate viruses via cytosine deaminase activity, APOBEC3 
proteins have also been reported to restrict viruses through non-catalytic activity.  These 
functions include physical impairment of reverse transcription, decreasing the ability of 
tRNALys3 primers to initiate reverse transcription, and reducing tRNALys3 cleavage during 
the plus strand DNA transfer step of reverse transcription (20, 87, 147, 161, 162).  
However, these non-catalytic functions were discovered in an overexpression system 
where the APOBEC3 was not as physiological relevant levels leading some to doubt the 
in vivo relevance. 
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 Although APOBECs have been shown to lethally mutagenize HIV-1, APOBEC3G 
has also been shown to sublethally mutate HIV-1 (192).  Sublethal mutations occur at 
low A3G proteins levels.  These sublethal mutations may enhance the ability of the virus 
to survive selective pressure and facilitate the emergence of drug resistance.  As HIV-1 
drug resistance becomes increasingly prevalent, novel approaches and drugs are needed 
to treat virus infection. Lethal mutagenesis is a novel strategy to inhibit HIV-1 replication 
since none of the current anti-HIV-1 drugs inhibit replication by this mechanism. A better 
understanding of the mechanism by which APOBECs inhibit HIV- 1 replication or 
contribute to viral evolution is important for understanding how to aggressively combat 
the virus and inhibit its replication. 
 
Dissertation Objectives: 
 The goals of the following studies were to understand the effect of cell type, 
mutagenic drugs and host factors on HIV-1 evolution and infectivity.  Specifically, 
Chapter 2 examines if HIV-1 variation is cell type dependent while Chapter 3 sought to 
elucidate the nucleotide-specific context that is required for APOBEC3G-induced 
mutations.  The results presented in Appendices I and II examine the efficacy and toxicity 
of the ribonucleotide reductase inhibitor, gemcitabine, alone and in combination with the 
mutagen, decitabine, in a murine AIDS model.  Finally, Appendix III addresses how two 
mutagens, APOBEC3G and 5-AZC, that both target cytosine residues interact to decrease 
HIV-1 infectivity through lethal mutagenesis.  
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Figure 1-1.  HIV-1 genome.  Diagram of the human immunodeficiency virus type 1 
(HIV-1) proviral DNA and gene organization. The 5’ and 3’ long terminal repeats (LTR) 
are located at the ends of the HIV-1 proviral sequence and contain transcriptional 
regulatory elements within unique 3’ region (U3), repeat region (R), and unique 5’ region 
(U5). The HIV-1 proviral DNA encodes for structural (gag), enzymatic (pol), envelope 
(env), and accessory genes (vif, vpr, tat, vpu, rev, nef, tat).  The Gag protein contains 
matrix, capsid and nucleocapsid domains (not shown). The pol gene encodes for the viral 
protease, reverse transcriptase and integrase (not shown). 
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Figure 1-3.  HIV-1 genome organization.  Layout of a typical HIV-1 proviral DNA se-
quence.  Long terminal repeats (LTR) flank the structural (i.e., gag), enzymatic (i.e., pol), 
envelope (i.e., env), and accessory (i.e., tat, rev, vpr, vpu, vif, and nef) genes.  Genome 
length is 9719 and each row of genes represents a different reading frame.  The tat and 
rev genes require post-transcriptional splicing.  The pol gene encodes protease (PR), re-
verse transcriptase (RT, including the RNase H domain), and integrase (IN).  p51 and p66 
denote the heterodimeric subunits of RT.  R = repeat region; U5 = unique 5’ region; U3 = 
unique 3’ region 
gag vif 
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rev 
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Figure 1-2. Mature HIV-1 particle. Shown is a cartoon depiction of a cross section 
through a HIV-1 viral particle. The envelope proteins (gp120 and gp41) are shown as a 
dark grey circle or a grey rectangle respectively. Matrix protein is shown as dark purple 
circles that lines the inside of the lipid bilayer which is in grey-yellow.  The capsid 
protein is shown as small orange circles and forms the viral core. The two copies of 
genomic RNA, which are depicted as black lines, are contained within the CA and are 
coated by nuclecapsid protein, shown as red circles. Reverse transcriptase is also located 
within the viral core and shown as as blue circles. 
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Figure 1-3. HIV-1 life cycle. A mature HIV-1 viral particle interacts with and attaches to 
a CD4 receptor, and a CXCR4/CCR5 coreceptor (not shown), via the envelope protein 
gp120 (step 1). The virion fuses with the host cell through gp41 interactions and deposits 
its core with the RNA genome into the cell (step 2). The viral RNA (vRNA) genome 
undergoes reverse transcription via reverse transcriptase (step 3) and is converted into 
dsDNA that is transported through the cytoplasm and then imported into the nucleus 
where it is integrated into the host genome via integrase (step 4). The HIV-1 proviral 
DNA is transcribed by RNA polymerase II (step 5) and transported out of the nucleus 
(step 6).  The viral mRNA is translated by host cell translation machinery to produce the 
viral proteins (step 7).  Shown are the translation of the structural protein (Gag), reverse 
vRNA 
dsDNA 
Nucleus 
Cytoplasm 
Plasma membrane 
1. Attachment 
2. Entry 3. Reverse Transcription 
4. Integration 
7. Translation 
6. RNA transport 
9. Budding 
8. Assembly 
10. Maturation 
CD4 receptor 5. Transcription 
	   21 
transcriptase and envelope (gp120 and gp41).  The viral proteins assemble at the 
membrane of the cell (step 8). The immature virion buds (step 9) and undergoes a 
maturation process via viral protease (step 10) forming the viral core and rendering the 
viral particle infectious. 
 
 
 
Figure 1-4. HIV-1 lethal mutagenesis.  Shown is a figure describing lethal mutagenesis.  
HIV-1 has an optimal mutation rate in a given environment (shown as a black solid line) 
where the virus adapts to the changing environment and is able to escape the immune 
system. The left y-axis shows the mutation rate (µ) and its relationship to HIV-1 
infectivity on the right y-axis.  As the mutation rate decrease, the infectivity decreases 
due to a lack of ability to adapt quickly to the environment. As the mutation rate 
increases, the infectivity also decreases due to the additional acquisition of mutations. 
Above a certain mutation rate, known as the error threshold (shown as a dotted red line), 
 
 
Figure 1-3.  Lethal mutagenesis.  HIV-1 has an optimal mutation rate (shown as a black 
solid line) where as the infectivity is at its peak and the virus adapts to the changing 
environment and is able to escape the immune system.  As the mutation rate decrease, the 
infectivity decreases.  As the mutation rate increases, the infectivity also decreases.  
Above a certain point, known as the error threshold (shown as a dotted red line), the 
genome acquires too many mutations rendering the virus unviable. 
  
Error threshold 
M
ut
at
io
n 
R
at
e 
(µ
)  
Not able to reproduce genome with enough 
fidelity to remain viable/infectious 
In
fe
ct
iv
ity
 
Optimal HIV-1 mutation rate  
-able to adapt quickly to changing environment 
-able to develop drug resistance & escape immune system 
Adapted from Dapp, M.J., Patterson, S.E., and Mansky, 
L.M. Trends in Microbiology, 2012. 
	   22 
the viral genome acquires too many mutations rendering the virus unviable (ie. lethal 
mutagenesis). Adapted from Dapp et al, 2013 and C. Clouser (unpublished). 
 
 
	   
Figure 1-5. APOBEC3G-mediated mutagenesis of HIV-1 DNA. The plus (+) strand 
RNA genome is converted into minus (-) strand DNA by reverse transcriptase. The CC 
dinucleotide in the (-) strand DNA is recognized by APOBEC3G and the first cytosine is 
deaminated to a uracil (U). The uracil base pairs with an adenine (A) in the (+) strand 
DNA; this results in a G-to-A transition mutation in the (+) strand DNA. The “red” 
highlighted nucleotide base is the site of APOBEC3G –mediated mutagenesis. 
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CHAPTER II 
 
VARIATION OF HIV-1 MUTATION SPECTRA AMONG CELL TYPES 
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Text 
Human immunodeficiency virus type 1 (HIV-1) infection remains a serious threat 
to global public health, with over 34 million people infected worldwide 
(http://www.unaids.org). In the absence of an effective vaccine, antiretroviral drug 
therapy remains the primary means for preventing transmission and disease progression, 
as well as new infections (92). The error-prone nature of HIV-1 reverse transcriptase 
(RT) remains a key determinant in the generation of mutations during HIV-1 replication. 
HIV-1 RT plays a prominent role in the high genetic diversity and evolution of 
retroviruses, which are driven by high rates of viral replication, mutation, and 
recombination (142). High genetic diversity allows HIV-1 to evade the immune system 
and become resistant to drug therapy. This high mutation rate and the high rate of virus 
evolution impact virus transmission and disease progression, as well as promote the 
emergence of antiviral drug resistance (142). 
Cellular proteins can exploit the propensity of HIV-1 to rapidly mutate by 
enhancing viral mutagenesis to the point where the virus is unable to replicate with 
enough fidelity to remain infectious (62). The apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like 3 (APOBEC3) family of proteins, for instance, act as cytidine 
deaminases during reverse transcription, causing G-to-A hypermutation in Vif-deficient 
HIV-1 (202, 240). APOBEC3G (A3G) has been particularly well characterized for its 
ability to induce cytosine deamination during the minus-strand DNA synthesis step of 
reverse transcription, resulting in G-to-A mutations in the plus-strand viral DNA (95, 
234). The editing activities of APOBEC3G result in G-to-A hypermutation (and lethal 
mutagenesis), although sublethal mutagenesis has been demonstrated (192). 
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APOBEC3D, APOBEC3F, and APOBEC3H have also been demonstrated to restrict and 
cause G-to-A hypermutation of Vif-deficient HIV-1 (106). 
Previous studies have provided evidence that HIV-1 genetic variation is impacted 
by RNA polymerase II transcription errors as well as minus-strand and plus-strand 
mutations that arise during HIV-1 reverse transcription (143, 158, 239). Deoxynucleoside 
triphosphate (dNTP) levels have been shown to have direct effects on RT fidelity (17, 
113). Macrophages have been shown to have low dNTP levels, and this decreases the 
efficiency of viral DNA synthesis and increases the likelihood of mutations occurring 
during HIV-1 reverse transcription (66). A previous study investigated the differences in 
the HIV-1 mutation rate and mutation spectra observed between HIV-1 replication in 
HeLa cells versus that of CEM-A cells (141). No significant differences were observed in 
the viral mutation rates between these two cells. While the number of mutants that were 
characterized was small and prohibited a statistical analysis of potential differences in the 
rates of mutation for specific mutation types, the general trends suggested that there was 
no significant difference in the rates of base pair substitution mutations, frameshift 
mutations, and deletion or deletion-with-insertion mutations (141). 
In the present study, we sought to further investigate the role of how cell type 
affects the mutation rate of HIV-1 as well as the virus mutation spectra. For analysis of 
mutation rate and mutation spectra, CEM-GFP (green fluorescent protein-expressing T 
lymphoblast cell line; NIH AIDS Research and Reference Reagent Program via J. 
Corbeil), U373-MAGI-CXCR4CEM cells (glioblastoma cell line; via M. Emerman through 
the NIH AIDS Research and Reference Reagent Program), 293T cells (human embryonic 
kidney cells; American Type Culture Collection [ATCC]) and SupT1 cells (T 
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lymphoblast cell line; ATCC) were transduced with an HIV-1 vector, pHIG (192). 
Mutant detection was determined by detection of cells that had a mouse heat-stable 
antigen-negative (HSA−) GFP+ phenotype. The calculation of mutant frequency was 
determined by dividing the number of infected cells harboring a mutated provirus 
phenotype (i.e., HSA− GFP+) by the total number of cells infected (i.e., HSA− GFP+ and 
HSA+ GFP+). Using this analysis, it was determined that there was no significant 
difference (P > 0.05, Student's t test) in the frequencies of mutants recovered from these  
cell types in parallel analyses (Table 2-1). A similar lack of observed difference in 
mutation rates had previously been made in an analysis conducted comparing HeLa cells 
and CEM-A cells (141). 
To determine if the HIV-1 mutation spectra were influenced by cell type, proviral 
HSA mutation target sequences were analyzed from the four cell lines after parallel virus 
infections. Interestingly, a significant difference was noted when comparing T-to-C 
transition mutations between CEM-GFP and SupT1 cells (P < 0.05, Fisher's exact test) 
and G-to-A transition mutations between CEM-GFP and 293T (P < 0.01), CEM-GFP and 
SupT1 (P < 0.01), and U373-MAGI and 293T (P < 0.05) (Table 2-2) cells. No other 
significant differences (P > 0.05) between any of the other mutation types were detected  
in these analyses. The relatively high level of A-to-G mutations observed in all 4 cell 
lines could be due to either ADAR-1 or ADAR-2 activity (72, 73, 180). When sequences 
that possessed multiple G-to-A mutations in the proviral HSA mutation target gene 
sequence were removed from the analysis, no significant differences (P > 0.05) in G-to-A 
mutations among the 4 cell types analyzed were observed (data not shown). This 
indicates that the frequency of G-to-A transition mutations was significantly influenced 
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by the proviral sequences recovered that contained multiple G-to-A mutations in the 
target gene sequence. 
Proviral sequences with multiple G-to-A mutations in the target gene sequence 
were recovered from CEM-GFP, U373-MAGI, and 293T cells (Table 2-3). There were  
significant differences (Fisher's exact test) in the frequencies of sequences with multiple 
G-to-A mutations recovered between CEM-GFP and 293T cells (P = 0.03), CEM-GFP 
and SupT1 cells (P = 0.0005), and U373-MAGI and SupT1 cells (P = 0.006). The 
mutational load for G-to-A mutations per proviral sequence from each of the cell lines 
was analyzed (Fig. 2-1A). Although the average numbers of G-to-A mutations per 
sequence were not statistically different between CEM-GFP, U373-MAGI, and 293T 
cells, there was a trend toward a higher degree of G-to-A mutations per sequence in 
CEM-GFP and U373-MAGI cells relative to that of 293T cells. The locations of G-to-A 
mutations analyzed indicated that certain G residues were hot spots for G-to-A mutations 
(Fig. 2-1B). Of these mutations, 73% of the G-to-A mutations occurred at GA 
dinucleotides, while 17% occurred at GG dinucleotides, 5% occurred at GT 
dinucleotides, and 5% occurred at GC dinucleotides.  
The observation that G-to-A mutations preferentially occurred at GA 
dinucleotides suggested that these mutations may be due to the expression of APOBEC3 
proteins. In order to test whether there was a correlation between the frequency of 
recovered proviral sequences with multiple G-to-A mutations and that of APOBEC3 gene 
expression, mRNA expression levels of the APOBEC3 proteins were analyzed in each of 
the cell lines under study. The study of mRNA expression levels was done as a surrogate 
for assessment of APOBEC3 protein levels, given that antibodies that can readily 
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differentiate the family of proteins are not currently available. A3A, A3B, A3C, A3D/E, 
A3F, A3G, A3H, and TATA-binding protein expression vectors were used as control 
standards (184). Quantitative reverse transcriptase PCR (qRT-PCR) analysis was done on 
each cell line for A3A, A3B, A3C, A3D/E, A3F, A3G, and A3H (Fig. 2-1C). A3C 
mRNA expression levels suggested a possible correlation with the prevalence of proviral 
sequences harboring multiple G-to-A mutations from each cell line (i.e., CEM-GFP > 
U373-MAGI > 293T > SupT1). However, analysis using a Pearson correlation coefficient 
test did not support this correlation (P = 0.052). The A3G mRNA expression also 
appeared to have an expression pattern that appeared to correlate to the proviral 
sequences with multiple G-to-A mutations from each cell line. In particular, significant 
differences were observed in A3C expression between CEM-GFP and SupT1 (P = 
0.0015, Student's t test), CEM-GFP and 293T (P = 0.0213), U373-MAGI and 293T (P = 
0.0286), U373-MAGI and SupT1 (P < 0.001), and 293T and SupT1 (P < 0.001) cells. 
However, the observed dinucleotide specificity (i.e., GA) was not consistent with the 
dinucleotide specificity of A3G (i.e., GG). All of the other APOBEC3s either lacked 
mRNA expression in one of the cell lines where multiple G-to-A mutations were 
observed, or there was no significant difference in mRNA levels for a particular A3 
between the 4 cell lines analyzed. It is interesting to note that while both CEM-GFP and 
Sup T1 cells are T lymphoblast cell lines, these findings indicate that distinct virus 
mutation spectra were observed. Taken together, the origins of the multiple G-to-A 
mutations in recovered proviral sequences could not be directly attributed to A3 gene 
expression in the 4 target cell types. 
To date, the nature of how cell type influences the mutation rate and mutation 
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spectra of HIV-1 has not been extensively studied. The discovery of the APOBEC3 
proteins provided clear evidence of the potential for the host cell to extensively edit and 
mutate the HIV-1 genome, which may lead to mutations that can shape HIV-1 evolution 
(192). In this study, we have investigated several cell lines that are commonly used to 
study HIV-1 replication in cell culture. Using an HIV-1 vector to study the mutation rate 
and spectra, we observed that cell type did not influence the viral mutation rate, similar to  
an analysis of HIV-1 mutation rates between HeLa and CEM-A cells (141). Importantly, 
we observed for the first time distinct differences in HIV-1 mutation spectra in parallel 
analyses of 4 different target cell types. In particular, there was a significant difference in 
the frequency of G-to-A transition mutations observed between CEM-GFP and 293T 
cells, U373-MAGI and 293T cells, and between CEM-GFP and SupT1 cells. A 
significant difference in T-to-C transition mutations was also observed between CEM-
GFP and SupT1. Interestingly, analysis of the proviral sequences from CEM-GFP and 
U373-MAGI cells led to the characterization of sequences harboring multiple G-to-A 
mutations in the reporter gene sequence, ranging from 2 to 13 G-to-A mutations. 
Furthermore, there were significant differences in frequencies between CEM-GFP and 
293T cells, CEM-GFP and SupT1 cells, and U373-MAGI and SupT1 cells. The proviral 
sequences with multiple G-to-A mutations occurred mainly at GA dinucleotides (i.e., 
73%) and GG dinucleotides (i.e., 17%). 
Analysis of APOBEC3 mRNA expression levels did not allow for a correlation 
between the expression level of any one particular APOBEC3 and the observed 
sequences with multiple G-to-A mutations. There have been previous reports implicating 
an APOBEC3 protein as having a target cell effect in generating G-to-A mutations (28, 
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121). Koning et al. hypothesized that A3A was responsible for G-to-A editing of HIV-1 
cDNA in macrophages (121), while Bourara et al. hypothesized that A3C could mutate 
HIV-1 viral DNA in the target cell (28). In both studies, the G-to-A mutations were likely 
sublethal and did not result in G-to-A hypermutation. It is possible that in these previous 
studies, G-to-A hypermutation did occur but was at a low frequency and was not 
detected. 
Our studies here are distinct in that mutation spectrum differences involving both 
sequences containing multiple G-to-A mutations in the mutation target gene sequence 
(which is indicative of G-to-A hypermutation), and differences in the frequencies of other 
mutation types were observed. While the origins of these mutations were not determined, 
differences in cellular protein levels that could edit HIV-1 DNA or differences in the 
fidelity of HIV-1 reverse transcriptase and/or cellular RNA polymerase II are likely 
responsible for the changes in mutation spectra observed in this study. As indicated 
earlier, differences in nucleotide pool levels in various cell types can influence the 
likelihood of RT-mediated mutation (66). Further studies to determine the molecular 
basis for these differences in mutation spectra would be of particular interest, as well as 
studies that would extend these studies to human primary cells (e.g., primary T cells and 
macrophages). Additional studies to investigate the ability of APOBEC3 proteins are 
warranted and would be enhanced with antibody reagents that allow for specific detection 
of each APOBEC3 protein as well as specific small interfering RNAs (siRNAs) for 
mRNA depletion studies. 
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Figure  2-1. G-to-A mutational load and mutation location in HIV-1 proviruses with 
multiple G-to-A mutations. (A) G-to-A mutational load in HIV-1 proviruses from 
CEM-GFP, U373-MAGI, and 293T cells. Each provirus with a mutant HSA sequence 
rate andmutation spectra of HIV-1 has not been extensively stud-
ied. The discovery of the APOBEC3 proteins provided clear evi-
dence of the potential for the host cell to extensively edit and
mutate the HIV-1 genome, which may lead to mutations that can
shape HIV-1 evolution (8). In this study, we have investigated
several cell lines that are commonly used to study HIV-1 replica-
tion in cell culture. Using an HIV-1 vector to study the mutation
rate and mutation spectra, we observed that cell type did not in-
fluence the viralmutation rate, as had been observed in an analysis
of HIV-1 mutation rates between HeLa and CEM-A cells (16).
Importantly, we observed for the first time distinct differences in
HIV-1 mutation spectra in parallel analyses of 4 different target
cell types. In particular, there was a significant difference in the
frequency of G-to-A transition mutations observed between
CEM-GFP and 293T cells, U373-MAGI and 293T cells, and be-
tween CEM-GFP and SupT1 cells. A significant difference in T-
to-C transition mutations was also observed between CEM-GFP
and SupT1. Interestingly, analysis of the proviral sequences from
CEM-GFP and U373-MAGI cells led to the characterization of
sequences harboring multiple G-to-A mutations in the reporter
gene sequence, ranging from 2 to 13 G-to-A mutations. Further-
more, there were significant differences in frequencies between
CEM-GFP and 293T cells, CEM-GFP and SupT1 cells, and U373-
MAGI and SupT1 cells. The proviral sequences with multiple G-
to-A mutations occurred mainly at GA dinucleotides (i.e., 73%)
and GG dinucleotides (i.e., 17%).
Analysis of APOBEC3 mRNA expression levels did not allow
for a correlation between the expression level of any one particular
APOBEC3 and the observed sequences with multiple G-to-A
mutations. There have been previous reports implicating an
APOBEC3 protein as having a target cell effect in generating G-
to-A mutations (22, 23). Koning et al. hypothesized that A3A was
responsible for G-to-A editing of HIV-1 cDNA in macrophages
(23), while Bourara et al. hypothesized that A3C could mutate
HIV-1 viral DNA in the target cell (22). In both studies, the G-
to-A mutations were likely sublethal and did not result in G-to-A
hypermutation. It is possible that in these previous studies, G-
to-A hypermutation did occur but was at a low frequency and was
not detected.
Our studies here are distinct in that mutation spectrum differ-
ences involving both sequences containing multiple G-to-A mu-
tations in the mutation target gene sequence (which is indicative
of G-to-A hypermutation), and differences in the frequencies of
other mutation types were observed. While the origins of these
mutations were not determined, differences in cellular protein
levels that could edit HIV-1 DNA or differences in the fidelity of
HIV-1 reverse transcriptase and/or cellular RNApolymerase II are
likely responsible for the changes in mutation spectra observed in
this study. As indicated earlier, differences in nucleotide pool lev-
els in various cell types can influence the likelihood of RT-medi-
ated mutation (15). Further studies to determine the molecular
basis for these differences in mutation spectra would be of partic-
ular interest, as well as studies that would extend these studies to
human primary cells (e.g., primary T cells andmacrophages). Ad-
ditional studies to investigate the ability of APOBEC3 proteins are
warranted and would be enhanced with antibody reagents that
allow for specific detection of each APOBEC3 protein as well as
specific small interfering RNAs (siRNAs) for mRNA depletion
studies.
FIG 1 G-to-A mutational load and mutation location in HIV-1 proviruses
with multiple G-to-Amutations. (A) G-to-Amutational load in HIV-1 provi-
ruses from CEM-GFP, U373-MAGI, and 293T cells. Each provirus with a
mutantHSA sequence containingwithmultipleG-to-Amutations is indicated
by a black circle (CEM-GFP), black square (MAGI), or black triangle (293T).
The average G-to-Amutational load and standard deviation are indicated. (B)
Location of G-to-A mutations in recovered proviruses harboring multiple
G-to-A mutations. The red, green, and blue circles above G residues indicate
the locations of G-to-Amutations (o e circle per mutation identified) in pro-
viruses recovered from CEM-GFP, U373-MAGI, and 293T, respectively. The
start and stop codons of the HSA gene are identified by black rectangular
boxes. (C) Quantitative RT-PCR was performed to determine the relative lev-
els of APOBEC3 mRNA expression among the cell lines under investigation
(i.e., CEM-GFP, SupT1, U373-MAGI, and 293T). The asterisk indicates that
the APOBEC3C level from 293T cells was set to 1, and all other values are
relative to this measurement. ThemRNA expression levels were normalized to
TATA-binding protein (TBP) mRNA levels. For these analyses, data with a
difference in efficiencies between the APOBEC3 standard and TBP standard
were!10% andR2"0.98. Threshold cycle (CT) values were determined using
the regression method, and data were analyzed by E!"CT. Experiments were
conducted in triplicate with the standard deviation indicated.
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containing with multiple G-to-A mutations is indicated by a black circle (CEM-GFP), 
black square (MAGI), or black triangle (293T). The average G-to-A mutational load and 
standard deviation are indicated. (B) Location of G-to-A mutations in recovered 
proviruses harboring multiple G-to-A mutations. The red, green, and blue circles above G 
residues indicate the locations of G-to-A mutations (one circle per mutation identified) in 
proviruses recovered from CEM-GFP, U373-MAGI, and 293T, respectively. The start 
and stop codons of the HSA gene are identified by black rectangular boxes. (C) 
Quantitative RT-PCR was performed to determine the relative levels of APOBEC3 
mRNA expression among the cell lines under investigation (i.e., CEM-GFP, SupT1, 
U373-MAGI, and 293T). The asterisk indicates that the APOBEC3C level from 293T 
cells was set to 1, and all other values are relative to this measurement. The mRNA 
expression levels were normalized to TATA-binding protein (TBP) mRNA levels. For 
these analyses, data with a difference in efficiencies between the APOBEC3 standard and 
TBP standard were ≤10% and R2 ≥0.98. Threshold cycle (CT) values were determined 
using the regression method, and data were analyzed by E-ΔCT. Experiments were 
conducted in triplicate with the standard deviation indicated. 
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Table 2-1. Mutant frequency of HIV-1 among selected cell linesa 
Cell Line Mutant Frequency 
CEM-GFP 0.11 ± 0.04 
U373-MAGI 0.12 ± 0.03 
293T 0.11 ± 0.04 
SupT1 0.11 ± 0.01 
a Two million 293T cells were transfected with 10ug of pHIG and 1ug of pVSV-G using the calcium 
phosphate method as previously described (74). The viral supernatants were collected 48h posttransfection, 
filtered, and used to infect permissive target cells (1.4× 106). Twenty-four hours postinfection, the cells 
were harvested and prepared for flow cytometry as described previously (192). Infected cells, typically 20 
to 40% of the total for each target cell line, were analyzed by flow cytometry for expression of two marker 
genes, coding for HSA and GFP. Mutant frequencies were calculated from the cell population phenotypes 
identified by flow cytometry using the formula (HSA- GFP+)/[(HSA- GFP+) + (HSA- GFP+)]. For each 
target cell line, ~7×105 to 9×105 cells were identified as infected cells (i.e., HSA- GFP+ and HSA+ GFP+ 
cell populations) and ~8×104 cells were identified as infected cells with a mutation in the reporter gene 
(i.e., HSA- GFP+). 
 
 
Table 2-2. Mutation spectra in the HSA mutation target gene of HIV-1 
proviral sequencesa 
 
CEM-
GFPa 
U373-
MAGIb 293Tc SupT1d 
G-to-A 29% 26% 17% 17% 
A-to-G 27% 29% 29% 29% 
T-to-C 27% 29% 30% 36% 
C-to-T 10% 10% 14% 11% 
a Cells were transduced with an HIV-1 vector (HIG) pseudotyped with vesicular stomatitis virus protein G 
(VSVG), and the HSA reporter gene sequence from the provirus in infected cells was PCR amplified and 
sequenced. The percentage of mutations for each mutation type compared to the total mutations identified 
is indicated. 
b Total no. of sequences, 238; total no. of mutations, 365.  
c Total no. of sequences, 225; total no. of mutations, 329.  
d Total no. of sequences, 154; total no. of mutations, 199.  
e Total no. of sequences, 173; total no. of mutations, 219. 
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Table 2-3. Proportion of HIV-1 proviral sequences recovered per 
infected cell line analyzed possessing multiple G-to-A mutations in the 
HSA mutation target genea 
Target Cells 
No. (%) of mutant sequences with multiple   
G-to-A mutations/total mutants analyzed 
CEM-GFP 14/238= 5.9% 
U373-MAGI 10/225= 4.4% 
293T 2/155= 1.3% 
SupT1 0/173= 0% 
a Cells were transduced with an HIV-1 vector (HIG) pseudotyped with vesicular stomatitis virus protein G 
(VSVG), and the HSA reporter gene sequence from the provirus in infected cells was PCR amplified and 
sequenced. The number of proviral sequences having HSA reporter gene sequences with multiple G-to-A 
mutations from each cell type was divided by the total number of proviral sequences identified with 
mutations. 
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CHAPTER III 
 
APOBEC3G CYTOSINE DEAMINATION HOTSPOTS ARE DEFINED BY 
BOTH SEQUENCE CONTEXT AND SINGLE-STRANDED DNA SECONDARY 
STRUCTURE 
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Introduction 
Apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G 
(APOBEC3G or A3G) is an important host restriction factor that can inhibit human 
immunodeficiency virus type 1 (HIV-1) and other viruses via cytosine deamination of 
viral genomic DNA (138). In the presence of the HIV-1 vif protein, the activity of 
APOBEC3G is attenuated and the residual deamination activity of A3G may contribute 
to the high mutation rate of HIV-1, virus evolution and antiretroviral drug resistance (90, 
95, 111, 140, 192). However, when the activity of vif is moderated or extinguished, A3G 
highly restricts viral replication (83, 96, 138). This restriction largely results from the 
high level of deamination during HIV-1 reverse transcription, which can lead to 
degradation of DNA with abasic residues, a decrease in the specificity of plus-strand 
initiation, and accumulation of lethal G-to-A mutations on the plus strand (i.e., 
hypermutation) (95, 140, 238). Although it is known that A3G acts exclusively on single-
stranded DNA (ssDNA) and acts preferentially at specific sites in a sequence of DNA, 
termed ‘hotspots,’ the factors that create these critical restriction hotspots are not fully 
understood (119, 182). A3G requires a cytosine dinucleotide context on ssDNA and 
studies have shown that A3G tends to favor CCCA or T/CCC sequences (21, 234). 
Distinct restriction hotspots on the viral genome often occur outside this four base 
context, however, as A3G can deaminate at a variety of other sites (115). Interestingly, 
many CCCA or T/CCC sites are not edited by A3G (192). 
As indicated above, published observations to date indicate that hotspot 
specificity for A3G must be determined by more than the bases immediately 3′ and 5′ of 
the required cytosine dinucleotide sequence. Specific sequences far upstream or 
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downstream from a hotspot also cannot be necessary for recognition, since A3G can 
deaminate oligos as small as 16 or 13 nt efficiently in vitro (108, 216). However, it is 
formally possible that certain distal sequences could play some role in large ssDNAs in 
vivo. Given that cytosine residues in small oligos can be efficiently deaminated in a 
variety of sequence contexts, some other feature of ssDNA in cells is likely protecting 
otherwise favorable sites from deamination. For example, DNA-binding proteins could 
make some deamination sites inaccessible to A3G. In the case of an HIV-1 infection, the 
HIV-1 nucleocapsid (NC) protein is a known DNA-binding protein that has important 
functions in the HIV-1 life cycle (63, 82, 130, 150, 159, 217). However, HIV-1 NC and 
A3G binding is non-competitive on target oligonucleotides, suggesting that NC protein 
may not prevent access of A3G to a particular target site, and actually could enhance 
A3G binding (108). Another possibility is that certain HIV-1 ssDNA regions may be 
protected from A3G due to secondary structure folding that occurs during the reverse 
transcription process. A3G does not act on dsDNA templates, and therefore ssDNA 
secondary structure (e.g., stem structures) could act as an accessibility barrier for A3G 
(227). Also, cytosine bases in small loop structures may also be inaccessible targets, 
particularly if the proper contacts between enzyme and substrate are no longer in 
alignment due to physical constraints. 
In this study, we have investigated the nature of A3G target sites, in particular the 
impact of nucleotide bases adjacent to the cytosine dinucleotide target as well as the 
influence of secondary structure in ssDNAs. Here we demonstrate that by systematic 
nucleotide base changes on either side of the cytosine dinucleotide target that certain 
bases are preferred by A3G in order to be optimal targets for cytosine deamination. We 
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also observed that DNA stems represent poor targets for A3G, and can protect an 
otherwise desirable target sequence from cytosine deamination. Small loop structures can 
also protect potential A3G target sequences from cytosine deamination. Taken together, 
our findings provide the first demonstration that A3G cytosine deamination hotspots are 
defined by both the sequence context of the cytosine dinucleotide target as well as the 
ssDNA secondary structure. Such observations provide further information for predicting 
the locations of cytosine deamination by A3G, which is of particular importance in 
tracing the origins of HIV-1 genetic variation in vivo. 
 
Results 
Sequence context as well as ssDNA secondary structure define A3G cytosine deaminase 
hotspots 
Two sets of ssDNA oligonucleotides were initially tested in which the cytosine 
dinucleotide was located either in an open (unstructured) location or was located within a 
structured stem; representative examples of the oligonucleotide structures are shown in 
Figure 3-1A. The oligonucleotide design strategy helped to minimize sequence changes 
between the oligonucleotide pairs and distal to the deamination site. However, some 
additional nucleotide changes were required for some of the oligonucleotides tested in 
order for the CC dinucleotide to be in the correct structural location within the most 
stable structure (Table 3-1 and	  Supplemental Figure 3-1). In particular, the CccC Stem 
Set 1 has an extra base pair in the stem, though the oligonucleotide sequence is consistent 
with what is shown in Figure 3-1A. For the TccT Open Set 2 oligonucleotide, the number 
of loop bases was reduced from 6 to 4 bases, and the number of bases involved in the 
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stem decreased from 7 to 3 bases. Finally, for the 5 Loop CccC oligonucleotide, the 
bottom base in the ‘5 loop’ in Figure 2A was changed to a C residue rather than a G 
residue (Figure 3-2A). The specific predicted mFold structures using the default settings 
for these three oligonucleotides are indicated in Supplemental Figure 3-1. Other 
oligonucleotides were tested in which bases on either side of the cytosine dinucleotide 
were changed.  These adjacent bases represent the base locations that are most critical for 
A3G recognition (182).  Cell lysates prepared from A3G-expressing 293 cells or 293 
parental cells were used to incubate with each oligonucleotide along with UDG and 
RNase A as described in the Materials and Methods section. In the presence of A3G 
cytosine deaminase activity, creation of a uracil base would occur resulting in an abasic 
site following uracil base excision by UDG. Base hydrolysis of the abasic site would 
release a FAM signal from the FRET pair. 
Figure 3-1B demonstrates that the bases on either side of the cytosine dinucleotide 
are important for A3G activity when located in a non-structured region. In particular, we 
observed that adenine, cytosine or thymine bases on either side of the cytosine 
dinucleotide increased A3G activity (P < 0.05) whereas guanine bases on either side of 
the dinucleotide had a reduced but significant effect (P < 0.05). These results indicate that 
adenine, cytosine or thymine bases on either side of the cytosine dinucleotide enhance 
A3G activity and guanine bases limit A3G activity. 
We further explored the nature of the nucleotide bases on either side of the 
cytosine dinucleotide by investigating the base preference on 5′ or 3′ side of the 
dinucleotide site (Figure 3-1C). In particular, when the 5′ base was a guanine, there was 
little activity detected when the 3′ base was an adenine or thymine, but a high A3G signal 
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was observed when the 3′ base was a cytosine. When the 5′ base was an adenine, there 
was moderate A3G activity unless the 3′ base was a cytosine. Finally, when the 5′ base 
was a thymine, A3G activity was moderate to relatively high when the 3′ base was either 
a guanine or an adenine, and activity was enhanced if the 3′ base was a cytosine. 
Significantly reduced A3G activity was observed when cytosine dinucleotides were 
located within an oligonucleotide stem, indicating that A3G can have difficulty in 
accessing target bases located in regions in which secondary structure exists, in any 
sequence context (Figure 3-1C). Taken together, these observations indicate that both the 
nucleotide base on either side of the cytosine dinucleotide as well as their location in 
secondary structure can define A3G hotspots. 
 
Structural constraints in DNA loop bases can limit A3G hotspots 
Given our observation that ssDNA secondary structure can attenuate A3G 
activity, we further investigated how the location cytosine dinucleotides in ssDNA loop 
bases could impact A3G activity. To do this, we tested oligonucleotides in which the 
cytosine dinucleotide was in either a stem bulge or in a ssDNA loop that ranged from 3 
bases in size up to 10 bases in size (Figure 3-2A). A3G activity was not affected by the 
cytosine dinucleotide located in a stem bulge, but had low activity when the dinucleotide 
was located in a 3 nt base loop where either adenine or cytosine was flanking the cytosine 
dinucleotide (Figure 3-2B). This indicates that 3 nt base loops can protect A3G hotspots. 
Interestingly, when cytosine bases flanked the cytosine dinucleotide, high A3G activity 
was observed within 4–8 nt base loops, but not when adenines flanked the cytosine 
dinucleotide. Low activity was detected with adenines flanked the cytosine dinucleotide 
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in the 4 nt base loops, and moderate A3G activity detected when the cytosine 
dinucleotide was located in 5–7 nt base loops with adenine bases flanking (Figure 3-2B). 
Higher activity was observed in 8–10 base loops with adenines flanking. This indicates 
that nucleotide base loop structures can protect cytosine dinucleotides when flanked by 
adenine bases in seven base or smaller loops. When cytosine bases flank the cytosine 
dinucleotide, protection is observed only in a 3 nt base loop. Moderate or low A3G 
activity was observed with thymine or guanine bases flanking the cytosine dinucleotide, 
respectively. This observation complements the observations made in the absence of 
secondary structure. 
Since the binding of HIV-1 NC and A3G is non-competitive on target 
oligonucleotides, NC protein may not prevent access of A3G to a particular target site, 
and may enhance A3G binding (108). It is also formally possible that NC may protect 
certain HIV-1 ssDNA regions due to secondary structure folding that occurs during 
reverse transcription. Since A3G does not act on dsDNA templates, ssDNA secondary 
structure (e.g., stem structures) could act as an accessibility barrier for A3G (227). It is 
also conceivable that cytosine bases in small loop structures may be inaccessible due to 
physical constraints. To test for potential affects of HIV-1 NC on A3G activity, we 
selected an oligonucleotide pair in which there was a clearly significant difference in the 
FRET signal observed when the CC dinucleotide target was located in either a non-
structured or structured region (i.e., AccA set 2 open and stem oligonucleotides; Table 3-
1). A HIV-1 NC concentration (i.e., 5 nt per NC) was chosen that is physiologically 
relevant based upon what is predicted in the virus particle (99, 230). As indicated in 
Figure 3-3, the addition of NC was found to have no effect on A3G activity when the CC 
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dinucleotide was either in the AccA set 2 open or stem oligonucleotide. 
It has been previously demonstrated that UDG excises uracil residues more 
efficiently from ssDNA than dsDNA (122), and that the excision of uracil from loops is 
inefficient. In order to confirm that the FRET signal differences observed with the target 
cytosine base for cytosine deamination by A3G is in a non-paired region, or in a stem, 
bulge or DNA loop is actually due to A3G activity and not to UDG, we synthesized 
oligonucleotides that contain uracil in these different locations. Figure 3-4 shows that 
UDG is readily able to excise the uracil residue in each of these positions, indicating that 
the differences that we have observed are due to A3G activity and not due to UDG. 
 
Experimental confirmation of mFold ssDNA structural predictions 
The oligonucleotides that were used in this study were selected in part based upon 
their having a single structural prediction in the mFold program (241). Specific 
parameters have been designed into the mFold program for ssDNA folding that were 
based upon NMR data generated with ssDNA sequences (7-10, 178, 195). In order to 
experimentally validate that these predictions for the oligonucleotides used in this study, 
a small subset were analysed that possessed DNA secondary structures that created 
restriction enzyme sites. Confirmation of the presence of these restriction sites would 
provide one line of experimental evidence in support of the structure predicted by the 
mFold program for oligonucleotide test. Oligo GccG set 1 stem, when folded, creates a 
Msp I restriction site that is not present in the non-folded version of the oligonucleotide. 
Figure 3-5A resulted in a strong FRET signal when oligonucleotide GccG set 1 stem was 
incubated in the presence of Msp I, but not when the non-folding version of the 
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oligonucleotide (i.e., GccG set 1 open) was incubated with Msp I. This data suggest that 
the predicted structure for the GccG set 1 stem is correct. We conducted a similar 
analysis with GccG set 2 stem and GccG set 2 open, where the predicted folded structure 
for GccG set 2 stem resulted in the creation of an Aci I restriction site, which does not 
occur in GccG set 2 open (Figure 3-5B).  Incubation of each oligonucleotide with Aci I 
lead to a strong FRET signal only with the GccG set 2 stem oligonucleotide, which also 
suggests that the structural predictions by mFold for the oligonucleotides used in this 
study are correct. Although this data support the proposed intramolecular structural 
predictions, it is formally possible that stable structures could also arise using the set 1 
stem or set 2 stem oligonucleotides by the formation of intermolecular homodimers. For 
instance, the restriction enzyme analysis conducted above with Msp I and Aci I would 
not be able differentiate per se between a single intramolecular stem versus that of a 
intermolecular homodimer stem—though stem formation of the participating nucleotide 
bases would be confirmed. 
 
Discussion 
The goal of this study was to investigate the determinants for A3G hotspots. To 
do this, we used an experimental model system in which we used oligonucleotides that 
were dual-labeled with TAMRA and FAM fluorophores. Lysates from cells stably 
expressing A3G were incubated with these oligonucleotides, and A3G activity was 
detected by FRET. Oligonucleotides were designed to test (i) the role of nucleotide bases 
adjacent to the cytosine dinucleotide target site that is critical for cytosine deamination; 
and (ii) the role of ssDNA secondary structure, including DNA duplexes, loop sequences 
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and bulges. 
We observed that the ability of A3G to deaminate was found to be greatly 
dependent upon the nucleotide bases immediately adjacent to the cytosine dinucleotide. 
Specifically, A3G efficiently deaminates when cytosines, adenines or thymines are 
adjacent to the cytosine dinucleotide. A3G activity was low when guanine bases were on 
either side of the cytosine dinucleotide. Previous studies have indicated that A3G prefers 
a sequence context of 5′-CCCA-3′ or 5′-T/CCC-3′ (21, 234). This corresponds well with 
the data in our study. In addition, a study has been reported in which 5′-TCCA-3′, 5′-
ACCA-3′, and 5′-ACCG-3′ were found to be good substrates for A3G cytosine 
deaminase activity, whereas 5′-GCCA-3′ and 5′-ACCT-3′ were found to have no or 
minimal activity, respectively (16). Although these studies support parts of our current 
study, our observations represent a more extensive and complete study of the preferred 
bases, and therefore provides greater insight into being able to predict and identify A3G 
hotspots. 
The results from our studies are supported by studies investigating A3G hotspots 
identified in HIV-1 sequences recovered from infected individuals. Coffin and colleagues 
found that of the available sites for A3G-mediated cytosine deamination, 40% of 5′-
CCCC-3′ sequences, 21% of 5′-ACCA-3′ sequences, 11% of 5′-TCCT-3′ sequences and 
0% of 5′-GCCG-3′ sequences were A3G cytosine deamination sites, which is a striking 
correlation to our data (111). Furthermore, 5′-TCCA-3′, 5′-TCCC-3′ and 5′-ACCT-3′ 
sequences were found be locations that the authors concluded that A3G-mediated 
cytosine deamination had occurred, while no cytosine deamination occurred at 5′-
GCCT/A-3′ sequences. Finally, HIV-1 proviral sequencing data from our previous 
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studies of A3G-mediated cytosine deamination of HIV-1 in cell culture found G-to-A 
mutations (in the positive strand) at either 5′-GGGG-3′, 5′-TGGT-3′ or 5′-TGGA-3′ 
sequences and few or no mutations at either 5′-AGGA-3′, 5′-AGGT-3′, 5′-TGGC-3′ or 5′-
CGGC-3′ sequences (61, 192). Taken together, these data indicate that the A3G hotspot 
sequence preferences in our cell-free study using oligonucleotides corresponds with 
strong predictive power to the A3G hotspot preferences observed from HIV-1 proviral 
DNA sequencing. In addition, A3G mutational hot spot sites are clearly far more 
complex than the widely cited 5′-CCCA-3′ or 5′-T/CCC-3′ A3G nucleotide sequence 
preference. 
A recent study investigated the features of nucleotide bases that can help define 
the sequence preference of A3G (182). Exocyclic groups in pyrimidines that are located 1 
or 2 nt 5′ of the cytosine targeted by A3G were found to dictate substrate recognition. 
The exocyclic groups were speculated to be important for stacking or for electrostatic 
interactions among adjacent bases. When these interactions are disrupted, it was 
conjectured that it could affect the ability of A3G to recognize the substrate. This 
hypothesis is supported by our data with the sequence 5′-T/CCCG/A/C-3′. However, we 
observed that the sequence 5′-ACCA-3′ can also be an efficient target for A3G-mediated 
cytosine deamination. It is of particular interest to these observations that local sequence 
context has been found to influence the scanning ability of A3G and that A3G has been 
proposed to ‘hover’ over 5′-ACCCA-3′ sequences longer than 5′-TCCCT-3′ sequences 
(201). This observation suggests that additional features of adenine bases may be 
important in the attraction of A3G to sites of cytosine deamination. 
We have also demonstrated in this study that ssDNA secondary structure plays a 
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vital role in the identification of A3G hotspots. In particular, the data presented here 
indicate that A3G either has no or low deamination activity for the cytosine dinucleotides 
located in ssDNA oligonucleotide stem structures or cytosine dinucleotides located in 
three base loops. The low activity observed on stems may be due to base unzipping from 
the stem at a low frequency, which would expose the CC dinucleotide. Furthermore, only 
cytosine dinucleotides flanked by cytosines or adenines were efficiently deaminated 
when located in ssDNA loops up to 8 bases in size or 8–10 bases respectively, whereas 
cytosine dinucleotides flanked by adenines resulted in only moderate level of A3G-
mediated cytosine deamination in ssDNA oligonucleotide loops 5–7 bases. A related 
cytosine deaminase family member, AID, has also been reported to be inefficient in 
deaminating cytosines in ssDNA secondary structures involving stems and loops (125). 
Since A3G cannot deaminate dsDNA, we hypothesize that ssDNA stems mimic dsDNA 
in an efficient enough of a manner in order to avoid cytosine deamination. Furthermore, 
A3G has been previously demonstrated to be processive along ssDNA substrates by 
sliding and jumping (44, 45). When A3G encounters partially dsDNA, the sliding ability 
was lost but the jumping ability was retained (44). Therefore, it is tempting to speculate 
that A3G could ‘jump’ over stems and loops—and this could help explain at least part of 
the reduced level of cytosine deamination in those regions. However, the ability of A3G 
to ‘jump’ over stems and loops does not account for the differences observed with 5′-
CCCC-3′ and 5′-ACCA-3′ sequences in ssDNA loops. While the tortional bend of 
nucleotides in ssDNA loops may not allow for the proper contacts between A3G and the 
nucleotide bases, this may be more readily overcome with cytosines rather than adenines. 
Further studies are needed in order to determine the specific factors behind these 
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observations. It will be important and beneficial to compare the sequence and secondary 
structural preferences of other APOBEC3 family members to our findings on 
APOBEC3G. The addition of HIV-1 NC protein was found in our experiments to have no 
effect on A3G activity when the CC dinucleotide was either in the AccA set 2 open or 
stem oligonucleotide. These observations suggest that ssDNA secondary structure (e.g., 
stem structures) could act as an accessibility barrier for A3G, even in the presence of 
physiologically relevant concentrations of HIV-1 NC. It is presently unclear how 
generally applicable these observations are to other CC dinucleotide position locations. 
In summary, the observations made in this study provide the first demonstration 
that A3G cytosine deamination hotspots are defined by both the sequence context of the 
cytosine dinucleotide target as well as the ssDNA secondary structure. These 
observations provide useful information for predicting the locations of cytosine 
deamination by A3G. Such predictions are important for investigations directed at 
investigating the origins of mutations that are associated with HIV-1 genetic variation 
(115). Given the high HIV-1 mutation rate (143), and the high rate of G-to-A transition 
mutations (223), there is intense interest in the origins of mutations that arise during HIV-
1 replication. Knowledge on the origins of mutations during HIV-1 replication is 
important for developing a better understanding of HIV-1 genetic variation and evolution 
as well as for efforts to purposely elevate HIV-1 mutation to induce lethal mutagenesis 
(50, 62). 
 
Materials and Methods 
Preparation of cell lysates 
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A cell line stably expressing A3G, 293-A3G clone10 (192) was cultured in 
DMEM supplemented with 10% FetalClone3 (FC3, Hyclone) serum with 1% 
penicillin/streptomycin (Invitrogen), and 225 µg/ml neomycin (Invitrogen). The parental 
293 cells were maintained in DMEM with 10% FC3, 1% penicillin/streptomycin and 225 
µg/ml neomycin. Cells were incubated at 37°C in 5% CO2. Cell lysates for in vitro assays 
of A3G activity were prepared as previously described (216). Briefly, 5 × 106 cells (293 
or 293-A3G clone 10) were centrifuged at 1000 rpm for 5 min. Cells were resuspended in 
250 µl of lysis buffer (0.626% NP40, 10 mM tris-acetate pH 7.4, 50 mM potassium 
acetate, 100 mM NaCl and 10 mM EDTA) and 50 µl of protease inhibitor cocktail (Cat. # 
P2714-1BTL, Sigma-Aldrich), and incubated on ice for 15 min. Cell lysates were 
centrifuged at 1000 rpm for 2 min, and the supernatants transferred to a pre-chilled tube 
and centrifuged at 16,000 rpm for 10 min. The clarified cell supernatants were then 
transferred to a new pre-chilled tube and stored at −80°C prior to use. 
 
Oligonucleotide design and synthesis 
ssDNA oligonucleotide secondary structures were predicted by using mFold with 
the default DNA settings (http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form) 
(241). The oligonucleotides selected for synthesis had only a single predicted structure 
and were synthesized dual-labeled with TAMRA and FAM fluorophores (Sigma-
Aldrich). Table 3-1 indicates the oligonucleotides used in this study. 
 
A3G FRET assay 
A fluorescence resonance energy transfer (FRET) based assay was used to detect 
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cytosine deaminase activity of A3G using DNA oligonucleotides as a substrate using 
previously described assays with minor modifications (212, 216). Cell lysates were 
diluted 3:2 in lysis buffer, and 20 µl of the diluted lysates were used per assay using 96 
white-welled assay plates (Bio-Rad). A separate solution of 20 pmoles of 
oligonucleotide, 10 µg RNase A and 0.04 U uracil DNA glycosylase (UDG) were mixed 
together in 50 mM Tris pH 7.4, 10 mM EDTA buffer and adjusted to a total volume of 50 
µl, then transferred to the assay well. The assay plate was then incubated at 37°C for 5 h. 
Next, 30 µl of 2 M Tris-acetate, pH 7.9 was added to each well and the plate was 
incubated at 95°C for 2 min and at 4°C for 2.5 min with a CFX96 real-time PCR system 
(Bio-Rad). The fluorescence was then measured at 4°C. The endpoint fluorescence from 
the parental 293 cell lysate was subtracted from all experimental samples in order to 
calculate a relative change in fluorescence due to A3G activity. Experiments were 
conducted with three independent replicates. For assays involving HIV-1 NC protein 
(purified NC protein graciously provided by Dr. Rob Gorelick, SAIC, Frederick, MD), 
experiments were conducted in the presence of HIV-1 NC protein (5 nt per NC) for 1 hr  
on ice. Following incubation, cell lysates were prepared as described above, added to 
each well for 5 h at 37°C, and then fluorescence measured. 
 
Restriction enzyme FRET assay 
To further validate the predicted structures of the FRET oligos, select oligos were 
digested with restriction enzymes. Regions of the oligo in a stem secondary structure 
would be cut by the specific restriction enzyme and would release FRET signal. Briefly, 
20 pmoles of GccG set 2 open or stem oligo and 5U of Aci I (NEB) were added to a 
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solution of 1× Buffer 3 (NEB) in 100 ul total volume. For GccG set 1 open or stem oligo, 
20 pmoles were added with 2U of MspI (NEB) to a solution of 1× Buffer 4(NEB) in 100 
ul total volume. Mixes were added to white-welled 96-well plates (Biorad) and incubated 
at 37°C for 30 min in a C1000 thermal cycler with a CFX96 real-time system (Biorad). 
Subsequently, the temperature was adjusted to 4°C for 30 s and the plate was read. 
Experiments were conducted with three independent replicates. 
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Figure 3-1. Nucleotide sequence context and ssDNA secondary structure help to 
define A3G cytosine deaminase hotspots. (A) Oligonucleotides containing the cytosine 
dinucleotide targeted by A3G dual-labeled with TAMRA and FAM fluorophores. The red 
colored ‘CC’ dinucleotide bases represent the A3G target site. The blue colored ‘X’ bases 
represent the positions at which nucleotide bases were changed. The ‘open’ oligo- 
nucleotides are defined as the oligonucleotides in which the target cytosine dinucleotide 
is located in the unstructured region of the ssDNA, and the ‘stem’ oligonucleotides are 
defined as the oligonucleotides in which the target cytosine dinucleotide is located within 
the stem structure. (B) The change in relative fluorescence units (ΔRFU) was calculated 
oligonucleotides tested in order for the CC dinucleotide to
be in the correct structural location within the most stable
structure (Table 1 and Supplementary Figure S1). In par-
ticular, the CccC Stem Set 1 has an extra base pair in the
stem, though the oligonucleotide sequence is consistent
with what is shown in Figure 1A. For the TccT Open
Set 2 oligonucleotide, the number of loop bases was
reduced from 6 to 4 bases, and the number of bases
involved in the stem decreased from 7 to 3 bases.
Finally, for the 5 Loop CccC oligonucleotide, the
bottom bas in the ‘5 loop’ in Figu 2A was changed to
a C residue rather than a G residue (Figure 2A). The
specific predicted mFold structures using the default
settings for these three oligonucleotides are indicated in
Supplementary Figure S1. Other oligonucleotides were
tested in which bases on either side of the cytosine di-
nucleotide, which represent the base locations that are
most critical for A3G recognition (11).
Cell lysates prepared from 293-expressing A3G cells or
293 parental cells were used to incubate with each oligo-
nucleotide along with UDG and RNase A as described in
the Materials and Methods section. In the presence of
A3G cytosine deaminase activity, reation of a uracil
base would occur resulting in an abasic site following
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Figure 1. Nucleotide sequence context and ssDNA secondary structure help to define A3G cytosine deaminase hotspots. (A) Oligonucleotides
containing the cytosine dinucleotide targeted by A3G dual-labeled with TAMRA and FAM fluorophores. The red colored ‘CC’ dinucleotide
bases represent the A3G target site. The blue colored ‘X’ bases represent the positions at which nucleotide bases were changed. The ‘open’ oligo-
nucleotides are defined as the oligonucleotides in which the target cytosine dinucleotide is located in the unstructured region of the ssDNA, and the
‘stem’ oligonucleotides are defined as the oligonucleotides in which the target cytosine dinucleotide is located within the stem structure. (B) The
change in relative fluorescence units (!RFU) was calculated for each experiment by subtracting the RFU from the control 293 cell lysates (baseline
negative control) from the 293 cell lysates that stably express A3G. The error bars represent the standard deviation from three independent
experiments. The positive control for these experiments was an oligonucleotide previously reported to be cleaved by A3G in an oligonucleotide-
based FRET assay (15). (C) The !RFU was calculated as described above. The average and standard deviation from three independent experiments
is shown.
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for each experiment by subtracting the RFU from the control 293 cell lysates (baseline 
negative control) from the 293 cell lysates that stably express A3G. The error bars 
represent the standard deviation from three independent experiments. The positive 
control for these experiments was an oligonucleotide previously reported to be cleaved by 
A3G in an oligonucleotide- based FRET assay (216). (C) The ΔRFU was calculated as 
described above. The average and standard deviation from three independent experiments 
is shown. 
 
 
Figure 3-2. A3G cytosine deaminase activity against a target cytosine dinucloetide is 
influenced by location in ssDNA base loops but not in a DNA bulge. (A) 
uracil base excision by UDG. Base hydrolysis of the
abasic site would release a FAM signal from the FRET
pair.
Figure 1B demonstrates that the bases on either side
of the cytosine dinucleotide are important for A3G
activity when located in a non-structured region. In par-
ticular, we observed that adenine, cytosine or thymine
bases on either side of the cytosine dinucleotide increased
A3G activity (P< 0.05) whereas guanine bases on either
side of the dinucleotide had a reduced but significant effect
(P< 0.05). These results indicate that adenine, cytosine
or thymine bases on either side of the cytosine dinucleo-
tide enhance A3G activity and guanine bases limit A3G
activity.
We further explored the nature of the nucleotide
bases on either side of the cytosine dinucleotide by
investigating the base preference on 50 or 30 side of the
dinucleotide site (Figure 1C). In particular, when the 50
base was a guanine, there was little activity detected
when the 30 base was an adenine or thymine, but a high
A3G signal was observed when the 30 base was a cytosine.
When the 50 base was an adenine, there was moderate
A3G activity unless the 30 base was a cytosine. Finally,
when the 50 base was a thymine, A3G activity was
moderate to relatively high when the 30 base was either a
guanine or an adenine, and activity was enhanced if the 30
base was a cytosine.
Significantly reduced A3G activity was observed when
cytosine dinucleotides were located within an oligonucleo-
tide stem, indicating that A3G can have difficulty in
accessing target bases located in regions in which second-
ary structure exists, in any sequence context (Figure 1C).
Taken together, these observations indicate that both the
nucleotide base on either side of the cytosine dinucleotide
as well as their location in secondary structure can define
A3G hotspots.
Figure 2. A3G cytosine deaminase activity against a target cytosine dinucloetide is influenced by location in ssDNA base loops but not in a DNA
bulge. (A) Oligonucleotides used to investigate the influence of ssDNA loop size on A3G activity are shown. The red colored ‘CC’ dinucleotide bases
represent the A3G target site. The blue colored ‘X’ bases represent the positions at which nucleotide bases were changed. (B) The change in relative
fluorescence units (!RFU) was calculated for each experiment by subtracting the RFU from the control 293 cell lysates (baseline negative control)
from the 293 cell lysates that stably express A3G. The x-axis indicates the number of nucleotide bases in the ssDNA loop. The error bars represent
the standard deviation from three independent experiments.
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Oligonucleotides used to investigate the influence of ssDNA loop size on A3G activity 
are shown. The red colored ‘CC’ dinucleotide bases represent the A3G target site. The 
blue colored ‘X’ bases represent the positions at which nucleotide bases were changed. 
(B) The change in relative fluorescence units (ΔRFU) was calculated for each experiment 
by subtracting the RFU from the control 293 cell lysates (baseline negative control) from 
the 293 cell lysates that stably express A3G. The x-axis indicates the number of 
nucleotide bases in the ssDNA loop. The error bars represent the standard deviation from 
three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. No effect of HIV-1 NC protein on altering the efficiency of A3G 
deamination. The AccA set 2 open and stem oligonucleotides were incubated in the 
presence or absence of HIV-1 NC protein (concentration of 5 nt per NC protein). The 
change in relative fluorescence units (ΔRFU) was calculated for each experiment by 
subtracting the RFU from the control 293 cell lysates (baseline negative control) from the 
293 cell lysates that stably express A3G. Error bars represent the standard deviation from 
three independent experiments. 
 
Structural constraints in DNA loop bases can limit
A3G hotspots
Given our observation that ssDNA secondary structure
can attenuate A3G activity, we further investigated how
the location cytosine dinucleotides in ssDNA loop bases
could impact A3G activity. To do this, we tested oligo-
nucleotides in which the cytosine dinucleotide was in
either a stem bulge or in a ssDNA loop that ranged
from 3 bases in size up to 10 bases in size (Figure 2A).
A3G activity was not affected by the cytosine dinucleotide
located in a stem bulge, but had low activity when the
dinucleotide was located in a 3 nt base loop where either
adenine or cytosine was flanking the cytosine dinucleotide
(Figure 2B). This indicates that 3 nt base loops can protect
A3G hotspots. Interestingly, when cytosine bases flanked
the cytosine dinucleotide, high A3G activity was observed
within 4–8 nt base loops, but not when adenines flanked
the cytosine dinucleotide. Low activity was detected with
adenines flanked the cytosine dinucleotide in the 4 nt base
loops, and moderate A3G activity detected when the
cytosine dinucleotide was located in 5–7 nt base loops
with adenine bases flanking (Figure 2B). Higher activity
was observed in 8–10 base loops with adenines flanking.
This indicates that nucleotide base loop structures can be
protected cytosine dinucleotides when flanked by adenine
bases in seven base or smaller loops. When cytosine bases
flank the cytosine dinucleotide, protection is observed
only in a 3 nt base loop. Moderate or low A3G activity
was observed with thymine or guanine bases flanking the
cytosine dinucleotide, respectively. This observation com-
plements the observations made in the absence of second-
ary structure.
Since, the binding of HIV-1 NC and A3G is non-com-
petitive on target oligonucleotides, NC protein may not
prevent access of A3G to a particular target site, and may
enhance A3G binding (16). It is also formally possible that
NC may protect certain HIV-1 ssDNA regions due to
secondary structure folding that occurs during reverse
transcription. Since A3G does not act on dsDNA tem-
plates, ssDNA secondary structure (e.g., stem structures)
could act as an accessibility barrier for A3G (23). It is also
conceivable that cytosine bases in small loop structures
may be inaccessible due to physical constraints. To test
for potential affects of HIV-1 NC on A3G activity, we
selected an oligonucleotide pair in which there was a
clearly significant difference in the FRET signal
observed when the CC dinucleotide target was located in
either a non-structured or structured region (i.e., AccA set
2 open and stem oligonucleotides; Table 1). A HIV-1 NC
concentration (i.e., 5 nt per NC) was chosen that is physio-
logically relevant based upon what is predicted in the virus
particle (26,27). As indicated in Figure 3, the addition of
NC was found to have no effect on A3G activity when the
CC dinucleotide was either in the AccA set 2 open or stem
oligonucleotide.
It has been previously demonstrated that UDG excises
uracil residues more efficiently from ssDNA than dsDNA
(28), and that the excision of uracil from loops is ineffi-
cient. In order to confirm that the FRET signal differences
observed with the target cytosine base for cytosine de-
amination by A3G is in a non-paired region, or in a
stem, bulge or DNA loop is actually due to A3G
activity and not to UDG, we synthesized oligonucleotides
that contain uracil in these different locations. Figure 4
shows that UDG is readily able to excise the uracil residue
in each of these positions, indicating that the differences
that we have observed are due to A3G activity and not
due to UDG.
Experimental confirmation of mFold ssDNA structural
predictions
The oligonucleotides that were used in this study were
selected in part based upon their having a single struc-
tural prediction in the mFold program (24). Specific par-
ameters have been designed into the mFold program for
ssDNA folding that were based upon NMR data
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Figure 3. No effect of HIV-1 NC protein on altering the efficiency of
A3G deamination. The AccA set 2 open and stem oligonucleotides
were incubated in the presence or absence of HIV-1 NC protein (con-
centration of 5 nt per NC protein). The change in relative fluorescence
units (!RFU) was calculated for each experiment by subtracting the
RFU from the c ntrol 293 cell lysates (baseline negative control) from
the 293 cell lysates that stably express A3G. Error bars represent the
standard deviation from three independent experiments.
Figure 4. UDG activity is undiminished on ssDNA secondary struc-
tures. The effect of uracil location in oligonucleotides was investigated.
Four different oligonucleotides were used in which the target cytosine
was replaced with a uracil that was located in a non-paired, stem, bulge
or DNA loop region. The relative fluorescent units (RFU) from a uracil
in the open, stem, three base loop and bulge location in the presence of
UDG is shown. The average and standard deviation from three inde-
pendent experiments is shown.
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Figure 3-4. UDG activity is undiminished on ssDNA secondary structures. The effect 
of uracil location in oligonucleotides was investigated. Four different oligonucleotides 
were used in which the target cytosine was replaced with a uracil that was located in a 
non-paired, stem, bulge or DNA loop region. The relative fluorescent units (RFU) from a 
uracil in the open, stem, three base loop and bulge location in the presence of UDG is 
shown. The average and standard deviation from three independent experiments is 
shown. 
 
 	   
Figure 3-5. Experimental confirmation of ssDNA secondary structures. Two sets of  
 
generated with ssDNA sequences (29–34). In order to
experimentally validate that these predictions for the
oligonucleotides used in this study, a small subset were
analysed that possessed DNA secondary structures that
created restriction enzyme sites. Confirmation of the
presence of these restriction sites would provide one
line of experimental evidence in support of the structure
predicted by the mFold program for oligonucleotide test.
Oligo GccG set 1 stem, when folded, creates a Msp I
restriction site that is not present in the non-folded
version of the oligonucleotide. Figure 5a resulted in a
strong FRET signal when oligonucleotide GccG set 1
stem was incubated in the presence of Msp I, but not
when the non-folding version of the oligonucleotide
(i.e., GccG set 1 open) was incubated with Msp I. This
data suggest that the predicted structure for the GccG set
1 stem is correct. We conducted a similar analysis with
GccG set 2 stem and GccG set 2 open, where the pre-
dicted folded structure for GccG set 2 stem resulted in
the creation of an Aci I restriction site, which does not
occur in GccG set 2 open (Figure 5b). Incubation of each
oligonucleotide with Aci I lead to a strong FRET signal
only with the GccG set 2 stem oligonucleotide, which
also suggests that the structural predictions by mFold
for the oligonucleotides used in this study are correct.
Although this data support the proposed intramolecular
structural predictions, it is formally possible that stable
structures could also arise using the set 1 stem or set
2 stem oligonucleotides by the formation of intermolecu-
lar homodimers. For instance, the restriction enzyme
analysis conducted above with Msp I and Aci I would
not be able differentiate per se between a single intramo-
lecular stem versus that of a intermolecular homodimer
stem—though stem formation of the participating nucleo-
tide bases would be confir ed.
DISCUSSION
The goal of this study was to investigate the determinants
for A3G hotspots. To do this, we used an experimental
model system in which we used oligonucleotides that were
dual-labeled with TAMRA and FAM fluorophores.
Lysates from cells stably expressing A3G were incubated
with these oligonucleotides, and A3G activity was
detected by FRET. Oligonucleotides were designed to
test (i) the role of nucleotide bases adjacent to the
cytosine dinucleotide target site that is critical for
cytosine deamination; and (ii) the role of ssDNA second-
ary structure, including DNA duplexes, loop sequences
and bulges.
We observed that the ability of A3G to deaminate was
found to be greatly dependent upon the nucleotide bases
immediately adjacent to the cytosine dinucleotide.
Specifically, A3G efficiently deaminates when cytosines,
adenines or thymines are adjacent to the cytosine di-
nucleotide. A3G activity was low when guanine bases
were on either side of the cytosine dinucleotide. Previous
studies have indicated that A3G prefers a sequence
context of 50-CCCA-30 or 50- /CCC-30 (12,13). This cor-
responds well with the data in our study. In addition,
a study has been reported in which 50-TCCA-30,
50-ACCA-30, and 50-ACCG-30 were found to be good sub-
strates for A3G cytosine deaminase activity, whereas
50-GCCA-30 and 50-ACCT-30 were found to have no or
minimal activity, respectively (35). Although these
studies support parts of our current study, our observa-
tions represent a more extensive and complete study of the
preferred bases, and therefore provides greater insight into
being able to predict and identify A3G hotspots.
The results from our studies are supported by studies
investigating A3G hotspots identified in HIV-1 sequences
recovered from infected individuals. Coffin and colleagues
found that of the available sites for A3G-mediated
cytosine deamination, 40% of 50-CCCC-30 sequences,
21% of 50-ACCA-30 sequences, 11% of 50-TCCT-30 se-
quences and 0% of 50-GCCG-30 sequences were A3G
cytosine deamination sites, which is a striking correlation
to our data (2). Furthermore, 50-TCCA-30, 50-TCCC-30
and 50-ACCT-30 sequences were found be locations that
the authors concluded that A3G-mediated cytosine
Figure 5. Experimental confirmation of ssDNA secondary structures.
Two sets of oligonucleotides with restriction enzyme sites in the stem
oligonucleotide were used ((A) GCCG Set 2 Stem and GCCG Set 2
Open, and (B) GCCG Set 1 Stem and GCCG Set 1 Open). The stem
bases in the structured oligonucleotides create an Aci I restriction site
(A) or a Msp I restriction site (B). The oligonucleotides GCCG Set 2
Open and GCCG Set 1 Open did not fold to form the restriction
enzyme sites and remained intact. The average and standard deviation
from three independent experiments are shown.
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generated with ssDNA sequences (29–34). In order to
experimentally validate that these predictions for the
oligonucleotides used in this study, a small subset were
analysed that possessed DNA secondary structures that
created restriction enzyme sites. Confirmation of the
presence of these restriction sites would provide one
line of experimental evidence in support of the structure
predicted by the mFold program for oligonucleotide test.
Oligo GccG set 1 stem, when folded, creates a Msp I
restriction site that is not present in the non-folded
version of the oligonucleotide. Figure 5a resulted in a
strong FRET signal when oligonucleotide GccG set 1
stem was incubated in the presence of Msp I, but not
when the non-folding version of the oligonucleotide
(i.e., GccG set 1 open) was incubated with Msp I. This
data suggest that the predicted structure for the GccG set
1 stem is correct. We conducted a sim lar analysis wit
GccG set 2 stem and GccG set 2 open, where the pre-
dict d folded structure for GccG set 2 s em resulted in
the creation of an Aci I restriction site, which does not
occur in GccG set 2 open (Figure 5b). Incubation of each
oligonucleotide with Aci I lead to a strong FRET signal
only with the GccG set 2 stem oligonucleotide, which
also suggests that the structural predictions by mFold
for the oligonucleotides used in this study are correct.
Although this data support the proposed intramolecular
structural predictions, it is formally possible that stable
structures could also arise using the set 1 stem or set
2 stem oligonucleotides by the formation of intermolecu-
lar homodimers. For instance, the restriction enzyme
analysis conducted above with Msp I and Aci I would
not be able differentiate per se between a single intramo-
lecular stem versus that of a intermolecular homodimer
stem—though stem formation of the participating nucleo-
tide bases would be confirmed.
DISCUSSION
The goal of this study was to investigate the determinants
for A3G hotspots. To do this, we used an experimental
model system in which we used oligonucleotides that were
d l-labeled with TAMRA and FAM fluorophores.
Lysates from cells stably expressing A3G were incubated
with these oligonucleotides, and A3G activity was
detected by FRET. Oligonucleotides were designed to
test (i) the role of nucleotide bases adjacent to the
cytosine dinucleotide target site that is critical for
cyt sine deamination; and (ii) the role of ssDNA second-
ary structure, including DNA duplexes, loop sequences
and bulges.
We observed that the ability of A3G to deaminate was
found to be greatly dependent upon the nucleotide bases
immediately adjacent to the cytosine dinucleotide.
Specifically, A3G efficiently deaminates when cytosines,
adenines or thymines are adjacent to the cytosine di-
nucleotide. A3G activity was low when guanine bases
on either side of the cytosine dinucleotide. Previous
studies have indicated that A3G prefers a sequence
context of 50-CCCA-30 or 50-T/CCC-30 (12,13). This cor-
responds well with the data in our study. In addition,
a study has been reported in which 50-TCCA-30,
50-ACCA-30, and 50-ACCG-30 were found to be good sub-
strates for A3G cytosine deaminase activity, whereas
50-GCCA-30 and 50-ACCT-30 were found to have no or
minimal activity, respectively (35). Although these
studies support parts of our current study, our observa-
tion represent a more extensive and complete study of the
preferred bases, and therefore provides greater insight into
being able to predict and identify A3G hotspots.
The results from our studies are supported by studies
investigating A3G hotspots identified in HIV-1 sequences
recovered from infected individuals. Coffin and colleagues
found that of the available sites for A3G-mediated
cytosine deamination, 40% of 50-CCCC-30 sequences,
21% of 50-ACCA-30 sequences, 11% of 50-TCCT-30 se-
quences and 0% of 50-GCCG-30 sequences were A3G
cytosine deamination sites, which is a striking correlation
to our data (2). Furthermore, 50-TCCA-30, 50-TCCC-30
and 50-ACCT-30 sequences were found be locations that
the authors concluded that A3G-mediated cytosine
Figure 5. Experimental confirmation of ssDNA secondary structures.
Two sets of oligonucleotides with restriction enzyme sites in the stem
oligonucleotide were used ((A) GCCG Set 2 Stem and GCCG Set 2
Open, and (B) GCCG Set 1 Stem and GCCG Set 1 Open). The stem
bases in the structured oligonucleotides create an Aci I restriction site
(A) or a Msp I restriction site (B). The oligonucleotides GCCG Set 2
Open and GCCG Set 1 Open did not fold to form the restriction
enzyme sites and remained intact. The average and standard deviation
from three independent experiments are shown.
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Structural constraints in DNA loop bases can limit
A3G hotspots
Given our observation that ssDNA secondary structure
can attenuate A3G activity, we further investigated how
the location cytosine dinucleotides in ssDNA loop bases
could impact A3G activity. To do this, we tested oligo-
nucleotides in which the cytosine dinucleotide was in
either a stem bulge or in a ssDNA loop that ranged
from 3 bases in size up to 10 bases in size (Figure 2A).
A3G activity was not affected by the cytosine dinucleotide
located in a stem bulge, but had low activity when the
dinucleotide was located in a 3 nt base loop where either
adenine or cytosine was flanking the cytosine dinucleotide
(Figure 2B). This indicates that 3 nt base loops can protect
A3G hotspots. Interestingly, when cytosine bases flanked
the cytosine dinucleotide, high A3G activity was observed
within 4–8 nt base loops, but not when adenines flanked
the cytosine dinucleotide. Low activity was detected with
adenines flanked the cytosine dinucleotide in the 4 nt base
loops, and moderate A3G activity detected when the
cytosine dinucleotide was located in 5–7 nt base loops
with adenine bases flanking (Figure 2B). Higher activity
was observed in 8–10 base loops with adenines flanking.
This indicates that nucleotide base loop structures can be
protected cytosine dinucleotides when flanked by adenine
bases in seven base or smaller loops. When cytosine bases
flank the cytosine dinucleotide, protection is observed
only in a 3 nt base loop. Moderate or low A3G activity
was observed with thymine or guanine bases flanking the
cytosine dinucleotide, respectively. This observation com-
plements the observations made in the absence of second-
ary structure.
Since, the binding of HIV-1 NC and A3G is non-com-
petitive on target oligonucleotides, NC protein may not
prevent access of A3G to a particular target site, and may
enhance A3G binding (16). It is also formally possible that
NC may protect certain HIV-1 ssDNA regions due to
secondary structure folding that occurs during reverse
transcription. Since A3G does not act on dsDNA tem-
plates, ssDNA secondary structure (e.g., stem structures)
could act as an accessibility barrier for A3G (23). It is also
conceivable that cytosine bases in small loop structures
may be inaccessible due to physical constraints. To test
for potential affects of HIV-1 NC on A3G activity, we
selected an oligonucleotide pair in which there was a
clearly significant difference in the FRET signal
observed when the CC dinucleotide target was located in
either a non-structured or structured region (i.e., AccA set
2 open and stem oligonucleotides; Table 1). A HIV-1 NC
concentration (i.e., 5 nt per NC) was chosen that is physio-
logically relevant based upon what is predicted in the virus
particle (26,27). As indicated in Figure 3, the addition of
NC was found to have no effect on A3G activity when the
CC dinucleotide was either in the AccA set 2 open or stem
oligonucleotide.
It has been previously demonstrated that UDG excises
uracil residues more efficiently from ssDNA than dsDNA
(28), and that the excision of uracil from loops is ineffi-
cient. In order to confirm that the FRET signal differences
observed with the target cytosine base for cytosine de-
amination by A3G is in a non-paired region, or in a
stem, bulge or DNA loop is actually due to A3G
activity and not to UDG, we synthesized oligonucleotides
that contain uracil in these different locations. Figure 4
shows that UDG is readily able to excise the uracil residue
in each of these positions, indicating that the differences
that we have observed are due to A3G activity and not
due to UDG.
Experimental confirmation of mFold ssDNA structural
predictions
The oligonucleotides that were used in this study were
selected in part based upon their having a single struc-
tural prediction in the mFold program (24). Specific par-
ameters have been designed into the mFold program for
ssDNA folding that were based upon NMR data
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Figure 3. No effect of HIV-1 NC protein on altering the efficiency of
A3G deamination. The AccA set 2 open and stem oligonucleotides
were incubated in the presence or absence of HIV-1 NC protein (con
centration of 5 nt per NC protein). The change in relative fluorescence
units (!RFU) was calculated for each experiment by subtracting the
RFU from the control 293 cell lysates (baseline negative control) from
the 293 cell lysates that stably express A3G. Error bars represent the
standard deviation from three independent experiments.
Figure 4. UDG activity is undiminished on ssDNA secondary struc-
tures. The effect of uracil location in oligonucleotides was investigated.
Four differen ol gonucleotides wer used in which the target cytosine
wa replaced with a ur cil that was located in a non-paired, stem, bulge
or DNA loop r gion. The rel ve fluorescent units (RFU) from a uracil
in the open, stem, three base loop and bulge location in the presence of
UDG is shown. The average and standard deviation from three inde-
pendent experiments is shown.
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oligonucleotides with restriction enzyme sites in the stem oligonucleotide were used ((A) 
GCCG Set 2 Stem and GCCG Set 2 Open, and (B) GCCG Set 1 Stem and GCCG Set 1 
Open). The stem bases in the structured oligonucleotides create an Aci I restriction site 
(A) or a Msp I restriction site (B). The oligonucleotides GCCG Set 2 Open and GCCG 
Set 1 Open did not fold to form the restriction enzyme sites and remained intact. The 
average and standard deviation from three independent experiments are shown. 
 
 
Supplemental Figure 3-1.  Predicted oligonucleotide structures.  The most stable 
predicted structures of oligonucleotides where  additional bases changes were needed to 
maintain the CC dinucleotide in the correct structural location in the most stable 
structure, as determined by using mFold with the default settings.  The structures for the 
CccC Stem Set 1, TccT Open Set 2, and the 5 Loop CccC oligonucleotides are shown. 
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Table 3-1. Oligonucleotide sequences used in the analysis of the influence of nucleotide 
sequence and ssDNA secondary structure on the in vitro activity of APOBEC3G 
 
 
 
 
 
 
 
 
 
 
 
structure would be cut by the specific restriction enzyme
and would release FRET signal. Briefly, 20 pmoles of
GccG set 2 open or stem oligo and 5U of Aci I (NEB)
were added to a solution of 1! Buffer 3 (NEB) in 100 ul
total volume. For GccG set 1 open or stem oligo, 20
pmoles were added with 2U of MspI (NEB) to a
solution of 1! Buffer 4(NEB) in 100 ul total volume.
Mixes were added to white-welled 96-well plates
(Biorad) and incubated at 37"C for 30min in a C1000
thermal cycler with a CFX96 real-time system (Biorad).
Subsequently, the temperature was adjusted to 4"C for
30 s and the plate was read. Experiments were conducted
with three independent replicates.
RESULTS
Sequence context as well as ssDNA secondary structure
define A3G cytosine deaminase hotspots
Two sets of ssDNA oligonucleotides were initially tested
in which the cytosine dinucleotide was located either in an
open (unstructured) location or was located within a
structured stem; representative examples of the oligo-
nucleotide structures are shown in Figure 1A. The oligo-
nucleotide design strategy helped to minimize sequence
changes between the oligonucleotide pairs and distal
to the deamination site. However, some additional nucleo-
tide changes were required for some of the
Table 1. Oligonucleotide sequences used in the analysis of the influence of nucleotide sequence and ssDNA secondary structure on the in vitro
activity of APOBEC3G
Oligonucleotide Sequence 50-30 Oligonucleotide Sequence 50-30
AccA Open Set 1 ATTGAACCAGAATGATGTCATTGAATATG AccC Open AAACCCCGAGAGAGATCGGACTAAG
!G=#1.90 !G=#3.35
CccC Open Set 1 ATTGACCCCGAATGATGTCATTGAATATG TccA Open AATCCACGAGACAGATCGTACTAAG
!G=#1.90 !G=#2.36
TccT Open Set 1 ATTGATCCTGAATGATGTCATTGAATATG TccA Stem AATCCACGAGACAGATCGTGGAAAG
!G=#1.90 !G=#6.67
GccG Open Set 1 ATTGAGCCGGAATGATGTCATTGAATATG TccC Open AATCCCCGAGAGAGATCGGACTAAG
!G=#1.90 !G=#3.35
AccA Stem Set 1 ATTGAACCAGAATGATGTCTGGGAATATG TccG Open AATCCGCGAGAGAGATCGCATCAAG
!G=#3.77 !G=#3.47
CccC Stem Set 1 ATTGACCCCGAATGATGTCGGGGAATATG 3 Loop AccA ATTGATGCTGACCATCAGCTAATATG
!G=#7.37 !G=#3.85
TccT Stem Set 1 ATTGATCCTGAATGATGTCAGGTAATATG 3 Loop CccC ATTGATGCTGCCCCGCAGCTAATATG
!G=#3.30 !G=#4.84
GccG Stem Set 1 ATTGAGCCGGAATGATGTCCGGGAATATG 4 Loop AccA ATTGATGCTGAACCATCAGCTAATATG
!G=#4.81 !G=#4.60
AccA Open Set 2 AAACCACGAGAGAGATCGTACTAAG 4 Loop CccC ATTGATGCTGACCCCTCAGCTAATATG
!G=#2.36 !G=#4.10
CccC Open Set 2 AACCCCCGAGAGAGATCGGATGAAG 5 Loop AccA ATTGATGCTGAACCAGTCAGCTAATATG
!G=#3.35 !G=#4.60
TccT Open Set 2 AATCCTCGAGAGATATCTATAAAAG 5 Loop CccC ATTGATGCTGAACCCCTCAGCTAATATG
!G=#2.23 !G=#4.40
GccG Open Set 2 AAGCCGCGAGAGAGATCGCATCAAG 6 Loop AccA ATTGATGCTGAAACCAGTCAGCTAATATG
!G=#3.47 !G=#3.90
AccA Stem Set 2 AAACCACGAGAGAGATCGTGGTAAG 6 Loop CccC ATTGATGCTGAACCCCGTCAGCTAATATG
!G=#7.18 !G=#3.90
CccC Stem Set 2 AACCCCCGAGAGAGATCGGGGGAAG 7 Loop CccC ATTGATGCTGAGACCCCGTCAGCTAATATG
!G=#9.31 !G=#3.50
TccT Stem Set 2 AATCCTCGAGAGAGATCGAGGAAAG 7 Loop AccA ATTGATGCTGAGAACCAGTCAGCTAATATG
!G=#6.36 !G=#3.50
GccG Stem Set 2 AAGCCGCGAGAGAGATCGCGGCAAG 8 Loop AccA ATTGATGCTGAGAACCAGATCAGCTAATATG
!G=#9.96 !G=#3.70
GccA Open AAGCCACAAGAGAGATCTTGCTAAG 8 Loop CccC ATTGATGCTGAGACCCCGATCAGCTAATATG
!G=#4.42 !G=#3.70
GccT Open AAGCCTAAAGAGAGATCTTTGAAAG 8 Loop TccT ATTGATGCTGAGATCCTGATCAGCTAATATG
!G=#3.94 !G=#3.70
GccC Open AAGCCCGAAGAGAGATTCGAATAAG 8 Loop GccG ATTGATGCTGAGAGCCGGATCAGCTAATATG
!G=#2.51 !G=#3.70
GccC Stem AAGCCCGAAGAGAGATTCGGGCAAG 9 Loop AccA ATTGATGCTGAGAACCAAGATCAGCTAATATG
!G=#8.39 !G=#3.70
AccG Open AAACCGCGAGAGAGATCGCACTAAG 10 Loop AccA ATTGATGCTGACGAACCAAGATCAGCTAATATG
!G=#3.47 !G=#3.70
AccT Open AAACCTCGAGACAGATCGAACTAAG dU Open AAACUACGAGAGAGATCGTGCTAAG
!G=#1.46 !G=#2.67
CccC Bulge AATGAAGCCCCGAGCAACTCGGCTTCTATG dU Stem ATTGATCCUTGAATGATGTCAGGGGATATG
!G=#5.30 !G=#1.72
dU Bulge AATGAAGCCUCGAGCAACTCGGCTTCTATG dU 3 Loop ATTGATGCTGACUATCAGCTAATATG
!G=#3.85!G=#5.30
Nucleic Acids Research, 2013 3
 by guest on M
ay 9, 2013
http://nar.oxfordjournals.org/
Downloaded from 
	   57 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
 
DISCUSSION AND FUTURE DIRECTIONS 
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 The studies conducted in this dissertation have led to an increased understanding of 
the origins of mutations that arise during HIV-1 replication and result in genetic diversity 
in virus populations. In Chapter II of this dissertation, an investigation of cell type and 
its influence on HIV-1 diversity was conducted.  The results specifically demonstrated 
that target cell type had a significant influence on HIV-1 vector mutation spectra.  In 
particular, there were significant differences in the frequency of G-to-A and T-to-C 
transition mutations between the target cell types infected with vector virus.  
Furthermore, it was observed that numerous G-to-A mutations occurred within the same 
proviral sequence (i.e., hypermutation).  These G-to-A mutations were found to occur at 
distinct sites (i.e., hotspots) across numerous proviral sequences among the different 
target cell types analyzed.  When these G-to-A hypermutated sequences were removed 
from the analysis of the virus mutation spectra, there were no longer significant 
differences in this mutation type among the cell lines.  Taken together, these observations 
suggest that the recovered G-to-A hypermutated proviral sequences are likely attributed 
to a cellular nucleic acid editing enzyme rather than to HIV-1 reverse transcriptase.  
However, it should be noted that imbalances in cellular nucleotide pools could also lead 
to elevated levels of viral mutation, including hypermutation.  Nucleic acid editing 
enzymes, such as the APOBEC3 proteins, mutate specific C residues in the minus-strand 
DNA during reverse transcription and can lead to C-to-U mutation hotspots (i.e., G-to-A 
mutation hotspots in the plus-strand DNA).  The G-to-A mutations from the 
hypermutated proviral sequences follow a GA dinucleotide specificity, which provides 
one line of evidence for involvement of the APOBEC3 proteins.  This observation is 
novel because the G-to-A hypermutation observed in this study was target cell dependent.  
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This is in contrast to the mechanism of action for APOBEC3 proteins, which have been 
shown to be dependent on the virus-producing cell.  In particular, APOBEC3 proteins 
have to be packaged into the budding virion within the virus-producing cell in order for 
subsequent G-to-A hypermutation to be observed.  
 Future experiments should be directed at investigating the basis for the target cell-
associated G-to-A hypermutation phenotype observed.  One initial step towards this goal 
would be to analyze the HIV-1 mutation rate and mutation spectra in the absence of 
APOBEC3 expression.  The analysis from this study has demonstrated that SupT1 cells 
do not express these proteins.  Therefore, HIV-1 vector virus production from SupT1 
cells and subsequent infection of fresh SupT1 cells would allow for the analysis of HIV-1 
mutation spectra in the absence of APOBEC3 expression.  In addition, such an 
experiment would eliminate expression of APOBEC3 proteins from the virus-producing 
cell.  This would be an important control experiment to begin analysis of a target cell 
effect responsible for G-to-A hypermutation.  Subsequent experiments would then 
produce HIV-1 vector virus from SupT1 cells and infect CEM-GFP, U373-MAGI, and 
293T cells.  These experiments would be important control experiments to produce HIV-
1 vector virus from cells that do not express APOBEC3 proteins.  There are examples of 
small molecule inhibitors reported in the literature that have the ability to inhibit 
APOBEC3 protein activity.  Conducting experiments in the presence of such an inhibitor 
would allow for the analysis of the APOBEC3 protein expressing cell lines to determine 
if differences are observed in the presence of such small molecule inhibitors.  Another 
approach could be the use of siRNAs to knock down APOBEC3 protein expression in 
both the virus-producing cells as well as the target cells.  The experiments described in 
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Chapter II were conducted with a HIV-1 vector expressing the Vif protein.  This should 
limit if not eliminate the ability of APOBEC3 protein incorporation into virus particles.  
Experiments with vector virus containing a mutation that prevents Vif protein expression 
would allow for an analysis of the HIV-1 mutation spectra with viruses that would readily 
allow for APOBEC3 protein incorporation.  This would be a useful control to include 
with the other experiments described above.  Finally, experiments conducted in human 
primary cells (i.e., primary T-cells and macrophages) as well as comparative studies with 
human immunodeficiency virus type 2 (HIV-2) would be important extensions of these 
studies that would further enhance the biological relevance of the observations made in 
Chapter II. 
 Present data is limited regarding the role of other cellular enzymes that could result 
in G-to-A hypermutation.  Given this limitation in the literature, experiments 
investigating other cellular enzymes that could result in the same phenotype are limited.  
As alluded to above, imbalances in nucleotide pools represents another potential 
mechanism that could help explain the G-to-A hypermutation phenotype.  The central 
enzyme involved in the creation of nucleotide pools is ribonucleotide reductase.  
Differential activity in the reduction of NTPs to form dNTPs is an alternative explanation 
for the differences in G-to-A hypermutation observed among the target cell types 
investigated in Chapter II.  The analysis of dNTP pools and the selective use of 
ribonucleotide inhibitors could help provide information to determine whether nucleotide 
pool differences could help explain the data in Chapter II. 
 The studies described in Chapter III investigated the structural and sequence 
requirements necessary for the formation of an APOBEC3G hotspot.  Since APOBEC3G 
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can induce sublethal mutations, identifying the sequence and structural features that 
enable hotspot formation could help identify locations where G-to-A mutations arise that 
contribute to HIV-1 diversity.  The ability to sort out the sources of G-to-A mutations 
would help to better establish what roles the APOBEC3 proteins play in HIV-1 evolution. 
Further experiments with sequences from HIV-1 proviruses where G-to-A mutations 
have been well characterized and are associated with important phenotypes (e.g., HIV-1 
drug resistance) would be a logical extension of the studies in Chapter III.  Another 
experimental approach would be to introduce the nucleotide sequence studied in Chapter 
III into a HIV-1 vector and produce in 293T cells stably overexpressing APOBEC3G in 
order to analyze in vivo the ability of APOBEC3G to edit in sequences predicted to be in 
either loop or stem sequences. 
 The role of the nucleocapsid protein in changing the accessibility of CC 
dinucleotide sites to APOBEC3G should be further investigated with different 
oligonucleotides.  The studies described in Chapter III with nucleocapsid protein were 
not exhaustive and it is expected that there would be ssDNA secondary structures that 
could be altered by nucleocapsid protein and lead to CC dinucleotide sites accessible to 
the action of APOBEC3G.  Such studies should be conducted to further investigate these 
possibilities. 
 The studies presented in Chapter III should be extended to other APOBEC3 
proteins in order to better understand the influence of ssDNA structure on the ability of 
these proteins to edit ssDNA templates.  APOBEC3G is unique in its CC dinucleotide 
site specificity and the other family members have a TC dinucleotide specificity.  Other 
oligonucleotides would therefore be needed to analyze the other APOBEC3 proteins.  A 
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key observation made in Chapter III is that APOBEC3G prefers C>A>T>G overall 
flanking the CC dinucleotide target site.  Additionally, 5’- TCCA/G/C-3’ results in strong 
APOBEC3G activity while minimal APOBEC3G activity was observed with 5’-
GCCA/T/G-3’.  Interestingly, when the target CC site was put in a stem or a 3-base loop, 
there was little APOBEC3G activity, indicating that ssDNA secondary structure is also 
important for APOBEC3G recognition.  In addition, with A residues flanking the CC in a 
loop, there was low activity on a 4-base loop and moderate activity on a 5- to 7-base 
loop.  However, with C residues flanking, there was strong activity on a 4- to 8-base loop.   
 The results from Chapter III reveal the structural and sequence preferences of 
APOBEC3G that had not been previously reported.  These new insights help to better 
understand the relationship between sequence context, ssDNA structure and APOBEC3G 
activity.  Such information provides key information for predicting sites in the HIV-1 
genome where APOBEC3G editing will occur.  Such information is useful for 
determining the influence of APOBEC3G on HIV-1 diversity.  Extending such studies to 
the other APOBEC3 proteins would provide further insight into the sequence context and 
ssDNA structure that influences site selection for other APOBEC3 proteins.  A technical 
challenge currently is the creation of stable 293T cell lines that overexpress the other 
APOBEC3 proteins.  For the studies in Chapter III, 293T cell lines overexpressing 
APOBEC3G were already available and characterized.  Extending such studies to other 
APOBEC3 proteins would require the creation of new cell lines.  There may be technical 
challenges due to cell toxicity. If this is the case, the use of transient transfection for 
creating 293T cells overexpressing a particular APOBEC3 protein of interested should be 
explored.  Ultimately, analysis in cell culture would be important to help to validate 
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observations made with purified oligonucleotides with experiments conducted in the 
context of viral replication. 
 As outlined above, Chapters II and III of this dissertation have described new 
information regarding the origins of mutations that can influence HIV-1 diversity and 
evolution.  Such basic knowledge provides new insights into the determinants of HIV-1 
mutation, which can contribute to HIV-1 diversity and ultimately influence the 
emergence of HIV-1 drug resistance, immune evasion, viral pathogenesis and virus 
evolution. 
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Introduction 
 
Retroviruses are a significant source of morbidity and mortality worldwide. For 
example, there are 33 million people infected with human immunodeficiency virus type 1 
(HIV-1) whereas the retrovirus, xenotropic murine leukemia virus like-virus (XMRV), 
has recently been proposed to be linked to prostate cancer and chronic fatigue syndrome 
(CFS) (133, 220).  Although there are a number of drugs available for HIV-1 
chemotherapy, the efficacy of these treatments is limited by the emergence of drug 
resistance, cost of treatment, and off-target effects. These limitations necessitate the 
development of new drugs and novel drug targets for HIV as well as other retroviruses. 
Similarly, if XMRV is shown to be the etiological agent of either prostate cancer and/or 
CFS, the development of new drugs could reduce morbidity and mortality. 
Current anti-retroviral drugs target viral proteins that are necessary for viral 
replication and production. Under suboptimal therapy, the combination of both the high 
rates of replication and mutation leads to the emergence of drug resistance. Although 
drugs that target host proteins could delay or prevent the emergence of drug resistance, 
there are significant side effects associated with inhibiting host proteins. While cellular 
deoxynucleoside triphosphates (dNTPs) are necessary for host cell function, even small 
changes in dNTP pools appear to affect viral replication without significant cellular 
toxicity (17). 
Previous studies have shown that hydroxyurea, which inhibits the cellular enzyme 
ribonucleotide reductase effectively decreases replication of HIV-1 and was recently 
shown to also inhibit hepatitis C virus replication as well (135, 146, 163).  Nonetheless, 
several factors make hydroxyurea undesirable as an antiviral including 1) 
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pharmacokinetics of hydroxyurea vary from person to person making its plasma levels 
unpredictable and 2) significant toxicities (pancreatitis, hepatotoxicity) are associated 
with the use of hydroxyurea when used to treat HIV-1 infection. The toxicity of 
hydroxyurea is further emphasized in the murine AIDS (MAIDS) model in which all 
animals treated with hydroxyurea died from drug-related toxicities (146). 
Alternatives to hydroxyurea that have a more desirable pharmacokinetic profile 
and lower toxicity concerns may offer a new and useful treatment for retroviral 
infections. In fact, other ribonucleotide reductase inhibitors have been shown to be more 
effective and less toxic in the MAIDS model (145).	   However, no follow up studies have 
been published regarding their potential for clinical use.   
2′,2′-Difluoro-2′-deoxycytidine, commonly referred to as gemcitabine represents a 
potential alternative to hydroxyurea as it has been shown to have two mechanisms of 
action including inhibition of ribonucleotide reductase (98, 229).	   Gemcitabine is 
clinically-approved for cancer therapy and its anti-cancer mechanism is attributed to its 
ability to inhibit ribonucleotide reductase thereby limiting dNTP pools available for DNA 
synthesis in cancer cells. Since retroviruses may be more sensitive to dNTP pool 
alterations than cellular polymerases, we hypothesized that gemcitabine would be an 
alternative to hydroxyurea that could be translated to clinical use for the treatment of 
retroviral infections when used in combination with current anti-retroviral therapies. 
In a recent study, we identified two clinically-approved drugs, decitabine and 
gemcitabine, that had potent anti-HIV activity in cell culture. The potency by which 
gemcitabine inhibited infectivity suggested that it may be useful for the treatment of 
retroviral infections when used with decitabine or in combination with current 
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antiretroviral therapies. 
In this study, we examined the ability of gemcitabine to inhibit replication of 
another retrovirus, murine leukemia virus in cell culture. Additionally, we examined the 
efficacy and toxicity of gemcitabine in vivo using LP-BM5 murine leukemia virus (LP-
BM5 MuLV, a murine AIDS model). We chose this animal model as it has been used 
extensively to screen potential anti-HIV drugs and has been validated with a number of 
clinically approved anti-HIV drugs such as AZT and PMPA (tenofovir) that have 
relatively broad antiretroviral activity (67, 165, 191).  In this study, we show that 
gemcitabine decreased infectivity of MuLV in cell culture with no detectable 
cytotoxicity. Similarly, gemcitabine decreased disease progression in the MAIDS model 
at non-toxic doses although toxicities were detected at doses just three times that of the 
effective dose. Our findings, along with previous observations (50), indicate that 
gemcitabine has relatively broad antiretroviral activity with minimal toxicity and could 
be useful for in vivo antiretroviral combination therapy. 
 
Results 
 
Gemcitabine inhibits MuLV in cell culture 
Before examining the antiviral activity of gemcitabine in vivo, we first examined 
the ability of gemcitabine to inhibit MuLV in cell culture. To do this, a GFP-tagged 
MuLV was pseudotyped with VSV-G and used to infect target cells that had been 
pretreated with increasing concentrations of gemcitabine. Flow cytometry was then used 
to determine the percentage of infected cells. As shown in Fig. A1-1A, gemcitabine 
potently decreased MuLV infectivity in a concentration-dependent manner with an EC50 
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in the low nM range. Additionally, there was no toxicity seen at the concentrations of  
gemcitabine needed to inhibit viral replication when the cells were exposed to 
gemcitabine for the same time as was used to assess gemcitabine's effect on infectivity 
(Fig. A1-1B). 
 
Gemcitabine inhibits progression of MAIDS as detected by spleen weight and 
histopathology 
The data from Fig. A1-1 indicate that gemcitabine inhibits replication of MuLV in 
cell culture. To examine the ability of gemcitabine to inhibit MuLV in an in vivo system, 
we treated mice infected with LP-BM5 with increasing doses of gemcitabine (Table A1-
1). Progression of MAIDS was characterized by extensive lymphoproliferation, 
splenomegaly, increased IgM levels, the development of lymphoma, and increased 
susceptibility to infection (155, 172, 207, 232). 
Proliferation of lymphoid cells in the spleen contributes to the splenomegaly 
observed in mice infected with LP-BM5 and is an indicator of disease progression and 
disease severity (232).  To determine if gemcitabine decreases splenomegaly, spleens 
were obtained and weighed at the time of sacrifice. As expected, the ratio of spleen to  
body weight was significantly increased in infected animals that did not receive treatment 
(Fig. A1-2). Mice treated with 1 or 2 mg/kg/day had an average ratio of spleen to body 
weight that was significantly lower than the infected, untreated mice. In fact, there was 
no significant difference in the spleen to body weight ratio between the treated mice and 
those that were not infected (Fig. A1-2). 
Since gemcitabine significantly decreased spleen size in mice infected with LP-
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BM5, we next examined whether the decrease in spleen size correlated with a decrease in 
the histopathological changes characteristic of MAIDS. Table A1-2 demonstrates that 
there were no significant findings in spleen from two of the four uninfected mice. The 
spleens of the other two uninfected mice were identified as either reactive or as having a 
score of 1 (see Materials and Methods for scoring system). Of all other groups, the 
infected, untreated mice had the most severe lesions as the spleens from all four of the 
mice in this group received a score of 2 or higher, indicating extensive changes in splenic 
architecture and significant expansion of lymphoid cells. In general, there was a decrease 
in splenic lesion score as the dose of administered gemcitabine increased. For example, 
all spleens from mice receiving the highest dose of gemcitabine were normal, while 5 of 
the 6 mice in the 3 mg/kg/day treatment group had spleens with no significant findings 
and 4 of the 6 mice in the 2 mg/kg/day treatment group were within normal limits. 
Finally, 1 of the 7 mice from the 1 mg/kg/day treatment group had a spleen with normal 
histology while the other 6 spleens received a score of 1, indicating mild lesions. 
 
Treatment with gemcitabine decreases MAIDS-associated lesions in the lymph nodes 
Infection with LP-BM5 destroys the architecture of lymph nodes and alters the 
composition (232).  When detected, the lymph nodes from infected or uninfected mice 
were examined by histopathology as described in the Materials and Methods section. 
Lymph nodes were only detectable in one of the four uninfected mice (Table A1-3). 
These lymph nodes were scored as a 1, indicating an enlargement of the lymph nodes 
with diffuse sheets of medium to large lymphoid cells while maintaining 
corticomedullary architecture. Consistent with the spleen data, the size and lesions of the 
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lymph nodes was greatest in mice that were infected but not treated (Table A1-3). 
Additionally, lymph nodes became more difficult to detect as the dose of gemcitabine 
increased, indicating that gemcitabine decreased the extent of lymph node enlargement. 
Consistent with this, the pathology of lymph nodes from mice treated with the higher 
doses of gemcitabine had lower scores indicating less severe lesions. For example, 6 of 
the 7 mice treated with 1 mg/kg/day of gemcitabine received a score of 1, whereas all of 
the lymph nodes from mice treated with either 2 or 3 mg/kg/day received scores that were 
consistent with a decrease in disease progression when compared to the untreated but 
infected mice or mice treated with 1 mg/kg/day of gemcitabine. 
 
Effect of gemcitabine on plasma IgM levels 
Soon after infection with LP-BM5, mice demonstrate a significant increase in 
plasma IgM levels that peak approximately 8–9 weeks post-infection (172, 232).  
Subsequently, IgM levels decrease, but remain elevated compared to uninfected animals. 
To examine the effect of gemcitabine on IgM levels, plasma was isolated from whole 
blood collected from mice at the time of sacrifice. As expected, infected but untreated 
animals demonstrated a significant increase in IgM levels compared to the uninfected 
animals (Fig. A1-3). In contrast, treatment with 1 or 2 mg/kg/day of gemcitabine 
significantly decreased IgM levels compared to the untreated animals. Surprisingly, IgM 
levels from mice treated with 2 mg/kg/day of gemcitabine were significantly lower than 
that seen in the uninfected animals. 
 
Gemcitabine decreases provirus levels 
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The data pathology indicated that gemcitabine decreases the severity or 
progression of murine AIDS. However, to more directly determine if gemcitabine inhibits 
replication of LP-BM5, provirus levels were quantified from spleen obtained at the time 
of sacrifice. Levels of the defective provirus were normalized to 18S rRNA levels as 
previously described (39).  The data shown in Fig. A1-4 revealed high levels of provirus 
in mice that were infected, but untreated. Mice treated with either 1 or 2 mg/kg/day of 
gemcitabine had negligible provirus levels that were comparable to the uninfected control 
mice, indicating reduced viral replication. 
 
Toxicity of gemcitabine as determined by changes in body weight 
Body weight is often used as an indicator of toxicity in laboratory animals. In this 
study, animals losing 15% or more of their body mass were euthanized and such loss of 
weight was attributed to drug-related toxicity. All mice treated with 3 and 4 mg/kg/day of 
gemcitabine, regardless of infection status, lost 15% or more body mass and were 
euthanized before the end of the study. Fig. A1-5 shows the change in body weight of all 
mice at the time of euthanasia. The data demonstrates that mice treated with 2 mg/kg/day 
of gemcitabine or higher lost body weight while untreated mice or mice treated with 1 
mg/kg/day of gemcitabine gained body weight throughout the study. 
 
Discussion 
 
In the absence of a cure or vaccine for HIV-1 infection, the identification of novel 
drug targets and the development of new drugs is the best approach to address the 
emergence of resistance as well as the complications associated with current therapies. 
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Drugs that target cellular proteins are less likely to be susceptible to the emergence of 
drug resistance compared to the current anti-HIV therapies which target viral proteins. 
However, drugs that target cellular proteins are likely to be associated with an increase in 
toxicity which may limit their clinical use. For example, hydroxyurea has been used 
alone and in combination with nucleoside reverse transcriptase inhibitors (NRTIs) to 
decrease viral loads in HIV-1 infected individuals. The side effects associated with 
hydroxyurea has significantly curtailed its clinical use. Less toxic alternatives to 
hydroxyurea would offer important alternatives for the treatment of HIV-1 as well as 
other retroviral infections. 
A recent study demonstrated that two clinically approved drugs, decitabine and 
gemcitabine have potent anti-HIV activity in cell culture when used alone or in 
combination (50).  Importantly, based on gemcitabine's potency and lack of toxicity, the 
data suggest that gemcitabine may be a clinically relevant alternative to hydroxyurea for 
the treatment of retroviral infections. 
In this study, we examined the antiretroviral activity of gemcitabine in vivo and ex 
vivo using the LP-BM5 MuLV model (a murine AIDS model). Murine AIDS is caused 
by a combination of three murine leukemia viruses including BM5-eco, BM5def, and 
mink cell focus inducing virus (MCF) (42, 43).  BM5def is a retrovirus that is unable to 
replicate due to deletion of most of the pol gene. However, its intact gag gene is thought 
to be responsible for MAIDS pathogenesis. Although LP-BM5 is not a perfect model for 
AIDS pathogenesis, it is well characterized, safe, inexpensive, and has been validated 
with a number of clinically approved anti-HIV-1 drugs and has been useful for 
identifying drugs with broad antiretroviral activity (for review see (67)). 
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Our studies found that gemcitabine decreased replication of MuLV in cell culture 
as well as in vivo using the MAIDS model. In fact, all measures of MAIDS-associated 
pathogenesis including splenomegaly, histopathology of spleen and lymph nodes and 
levels of IgM and provirus indicated reduced viral replication. The reduction of provirus 
by gemcitabine further supported the gemcitabine-mediated reduction in viral replication. 
There are at least two mechanisms that could account for the decrease in disease 
progression. First, gemcitabine could decrease dNTP levels enough to decrease 
proliferation of infected cells. Second, gemcitabine could alter dNTP levels such that 
viral replication is inhibited without inhibition of cellular proliferation. These 
mechanisms are likely to be dose dependent with low gemcitabine doses preferentially 
inhibiting viral replication and higher doses inhibiting both viral replication and cell 
proliferation. In support of this, 2 mg/kg/day of gemcitabine caused a significant 
reduction in IgM levels compared to the uninfected animals. This is likely due to 
gemcitabine-mediated decrease in B cell proliferation. In contrast, IgM levels from mice 
treated with 1 mg/kg/day had levels comparable to the uninfected animals which suggest 
there was not a significant reduction in B cell numbers compared to the uninfected mice. 
The cell culture data also supported this assertion as the decrease in replication was not 
associated with a significant loss of cell numbers (Fig. A1-1B). These data indicate that 
gemcitabine's antiviral activity is distinct from its activity used to treat human cancers. 
Furthermore, doses of gemcitabine used clinically in cancer treatment are significantly 
higher than those used in our study. For example, gemcitabine's anti-cancer activity is 
achieved with a dosing regimen that includes 1000 mg/m2 given once every week for 
seven weeks, followed by one week without drug and additional rounds of treatment as 
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needed (193).  In our study, an antiviral effect was seen in animals at doses as low as 1 
mg/kg which correlates to 3 mg/m2 when using the BSA method to convert the mouse 
dose to the human equivalent dose (mouse dose multiplied by mouse km of 3) (183). 
Although the metabolism of gemcitabine in mice is likely different compared to humans, 
the significant difference in dosing further supports that the antiviral activity seen here is 
not due to inhibition of cell proliferation. 
Toxicity of gemcitabine was significant at higher doses. In fact, all mice treated 
with 3 and 4 mg/kg/day lost 15% or greater of their body weight during the study and as a 
result were prematurely euthanized. However, the 1mg/kg/day dose of gemcitabine 
decreased disease pathology with no detectable toxicity. Specifically, all of these animals 
gained body weight similar to the uninfected animals. Additionally, these animals did not 
show any signs of hepatotoxicity as detected by histopathological analysis (data not 
shown). The 2 mg/kg/day dose was also effective at decreasing disease progression. 
However, some of the mice in this treatment group showed signs of toxicity in the loss of 
body weight while others in this group appeared to tolerate gemcitabine well. Like the 
animals treated with 1 mg/kg/day gemcitabine, there was no hepatotoxicity observed in 
animals treated with 2 mg/kg/day gemcitabine. The extent to which gemcitabine effected 
the animals in the 2 mg/kg group was not limited to toxicity as the efficacy of 
gemcitabine's antiviral activity also varied (see Figure A1-2). Although it is not clear why 
the mice could have such different responses to the drug, the affect of this variation could 
be minimized by increasing the number of animals in each treatment group. 
Although gemcitabine has been used as cancer chemotherapy for many years, it 
has likely been neglected as an antiviral due to its poor oral bioavailability, which would 
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necessitate drug delivery by injection. However, a prodrug for gemcitabine has been 
described recently, making gemcitabine a more attractive candidate for use in treatment 
of retroviral infections, including highly drug-resistant HIV-1 (18).  If its bioavailability 
is improved, gemcitabine could serve as a novel anti-HIV drug for those resistant to the 
current therapies. 
In summary, the findings of our study indicate that gemcitabine has potent 
antiretroviral activity in vivo and ex vivo using the LP-BM5 MuLV model. These 
findings, along with previous ex vivo HIV-1 studies with gemicitabine and decitabine, 
suggest that gemcitabine has broad antiretroviral activity and could be particularly useful 
in vivo when used in combination drug therapy. 
 
Materials and Methods 
 
Materials 
SC-1/MuLV LP-BM5 cells, chronically infected with LP-BM5, were obtained 
through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH from Dr. Herbert Morse and Dr. Janet Hartley (42, 97, 154).  293T cells 
were obtained from American Tissue Type Culture (ATCC). C57Bl/6 mice were 
purchased from Jackson Laboratories. DMEM was purchased from MediaGrow. 
Gemcitabine was obtained from Carbosynth (Berkshire, U.K.). The IgM Elisa kit was 
from Assay Designs (Ann Arbor, MI). The plasmids, pCR-DEF and pCR-18S were a 
kind gift from Dr. Mauro Magnani (University of Urbino, Urbino, Italy) and have 
previously been described (39).  U373-MAGI-CXCR4CEM cells were obtained from Dr. 
Michael Emerman through the AIDS Research and Reference Reagent Program, Division 
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of AIDS, NIAID, NIH (93, 226).  The plasmid, pIRES2-EGFP was obtained from 
Clontech (Mountain View, CA). The plasmids pMIGR1, pJK3, pL-VSV-G, and CMV-
Tat were kind gifts from Vineet Kewal Ramani (NCI-Fredrick). The plasmid pMIGR1 is 
an MLV vector containing an IRES-GFP element (173); pJK3 contains GagPol driven off 
HIV-1 LTR (15). pL-VSV-G is also driven off the HIV-1 LTR (15); and CMV-Tat 
allows transcription off the HIV-1 LTR (15). 
 
Cell culture 
SC-1/MuLV LP-BM5 cells and 293T cells were maintained in DMEM containing 
10% fetal clone 3 (FC3) serum (Hyclone, Logan, VT) and pen/strep at 37°C in 5% CO2. 
U373-MAGI-CXCR4CEM cells expressing the CD4 receptor and the CXCR4 co-
receptor were maintained at 37°C in 5% CO2 in selection media composed of DMEM 
with 10% FC3, 1 µg/mL puromycin, 0.1 mg/mL hygromycin, and 0.2 mg/mL neomycin. 
 
Transfection of 293T cells 
pMIGR1 (13.9 µg), pJK3 (6.9 µg), pL-VSV-G (5.54 µg) and CMV-Tat (1 µg) 
were transfected into 293T cells using the calcium phosphate method. Forty-eight hours 
after transfection, cell culture supernatant was collected and frozen at −80°C. 
 
Drug Treatment/Flow Cytometry 
U373-MAGI-CXCR4CEM cells (62,000) were plated in 12-well dishes 24 h prior 
to drug treatment. Twenty-four hours later, gemcitabine was added to the cultures at the 
concentrations indicated in the legend to Fig. A1-1. Two hours post-drug treatment, 500 
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µl of virus was added to each culture. Twenty-four hours later, the medium containing 
gemcitabine (or DMSO) was removed replaced with new media. Twenty-four hours after 
the media change, the U373-MAGI-CXCR4CEM cells were collected and analyzed by 
flow cytometry to determine the percentage of cells expressing GFP. Infectivity was 
normalized for each individual experiment by setting the infectivity of the untreated cells 
to 100 for each experiment and then multiplying the data from the other individual 
treatments by the number used to convert the no drug treated cells to 100. 
 
Cellular Proliferation 
Cellular proliferation was examined using the CellTiter-Glo kit from Promega 
according to the manufacturer's instructions. U373-MAGI-CXCR4 cells (4,500/well) 
were plated in a 96-well dish 24 h prior to drug treatment. Cells were treated (or not) with 
gemcitabine for 24 h before proliferation was assessed by luciferase activity. DMSO was 
used as a control for the untreated cells. Ethanol (20%) was used as a positive control for 
cellular toxicity. The data were converted to relative cell number by setting the no drug 
treated cells at 100 for each experiment and then multiplying each other sample data by 
the number used to convert the no drug treated cells to 100. This conversion was 
normalized for differences in luciferase activity among different experiments. 
 
Mice 
Female C57BL/6 mice aged 8–10 wk old were purchased from Jackson 
Laboratories (Sacramento, California) and were housed in standard rodent shoebox 
caging without a filter top at 22±1°C with a 12 h light/dark cycle, 60±5% humidity, and 
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12 air changes/h. Mice were fed lab chow and water ad libitum. The experimental 
protocol was approved by the Department of Veterans Affairs Medical Center 
(Minneapolis, MN) IACUC committee (IACUC protocol number 0803A28341). 
 
Infection of mice with LP-BM5 MuLV 
LP-BM5 was produced from confluent SC-1 cells by filtering the cell supernatant 
through a 0.25 µm syringe. The filtered viral supernatant was maintained at −80°C until 
inoculation was performed. C57BL/6 mice were inoculated with two intraperitoneal 
injections of 0.25 mL of viral supernatant or DMEM spaced three days apart. 
 
Treatment of LP-BM5 MuLV infected mice with gemcitabine 
C57BL/6 mice were randomly divided into 7 groups including: 1) uninfected 
untreated; 2) uninfected treated with 4 mg/kg/day gemcitabine; 3) infected, untreated; 4) 
infected treated with 1 mg/kg/day; 5) infected with 2 mg/kg/day; 6) infected, treated with 
3 mg/kg/day; and 7) infected, treated with 4 mg/kg/day. All mice were treated daily with 
either gemcitabine or phosphate buffered saline (PBS) for 8 wk beginning 1 wk post-
infection. Animals were weighed daily to achieve proper dosing and to detect changes in 
body mass due to toxicity or infection. Animals did not receive drug treatment 24 h prior 
to sacrifice. 
 
Sacrifice of animals 
Animals were euthanized either 8 wk post-drug treatment or when animals lost 
15% or greater body mass due to toxicity associated with treatment. Animals were 
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weighed and anesthetized with 100 mg/kg ketamine plus 10 mg/kg xylazine prior to 
blood collection from the submandibular vein. After euthanasia, spleens were removed, 
weighed, and sectioned for histopathological analysis as well as for the quantification of 
proviral levels. Lymph nodes, when detected, were obtained and sectioned for 
histopathological analysis as was liver. Necropsy was performed to assess any gross 
abnormalities in any organs. 
 
Splenic histopathology 
Histological examination and scoring of spleen was performed by A.C.V.P. board 
certified veterinary pathologists from the University of Minnesota Masonic Cancer 
Center Comparative Pathology Shared Resource. The severity of lymphoproliferation 
within the spleen was scored based on a previously published scoring system (97), with 
slight modifications as follows: 1) Normal spleen (N) demonstrated normal architecture 
and a ratio of while pulp to red pulp (W R) of ≤ ~1 1. 2) Spleens designated as reactive 
(R) were defined as having reactive germinal center expansion with a W R ratio of ~2 1. 
Germinal centers in these spleens were prominent and expanded. 3) Spleens designated 
as a score of 1 were characterized by more extensive germinal center expansion that those 
in the reactive group, with a W R ratio of ~3 1. Lymphoid nodules in these spleens were 
not coalescent and had prominent mantle zones. 4) Spleens designated with a score of 2 
contained multifocal large lymphoid nodules that coalesced and resulted in effacement of 
red pulp and mantle zones. The W R ratio in these spleens was ~4 1. 5) Spleens 
designated as a score of 3 were characterized by extensive proliferation of medium to 
large lymphoid cells that nearly completely effaced the red pulp and mantle zones of the 
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lymphoid nodules. The W R ratio in these spleens was >4 1. 6) Finally, spleens defined 
as D were characterized by lymphoid depletion within white pulp. 
 
Lymph node histopathology 
A scoring system for lymph nodes in MAIDS mice has not been previously 
reported. Scoring of lymph node lesions was similar to that described for the spleen and 
was done using following grading scheme: 1) Normal (N) was defined as lymph nodes 
demonstrating normal architecture. 2) Reactive (R) was defined as lymph nodes in which 
the corticomedullary architecture was maintained, but the lymphoid follicles had enlarged 
germinal centers 3) A score of 1 was defined by moderately enlarged lymph nodes with 
diffuse sheets of medium to large lymphoid cells while still maintaining some follicular 
structures and corticomedullary architecture. 4) A score of 2 was defined as diffusely 
enlarged lymph node where the corticomedullary architecture was absent, but a rim of 
small lymphocytes was present beneath the capsule. Finally, 5) lymph nodes designated 
with a score of 3 were diffusely enlarged, and contained medium to large lymphocytes 
that infiltrated the lymph node capsule and extended into adjacent tissues. 
 
Serum immunoglobulin M determination 
After 8 wk of treatment, IgM levels were determined by ELISA as per the 
manufacturers' instructions (Assay Designs, Ann Arbor, MI). Plasma was isolated from 
whole blood by centrifugation at 1,000×g for 10 minutes at room temperature and stored 
at −80°C until the assay was performed. A standard curve was generated using a standard 
IgM of known concentration and a correlation coefficient (R2) of >0.98 was considered 
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acceptable data for analysis. All samples were run in triplicate and to confirm 
reproducibility between assays, a subset of samples was run in three independent 
experiments. 
 
Determination of provirus levels from spleen 
At 8 wk post-treatment, BM5d DNA content was assayed from genomic DNA 
isolated from spleen. Total cellular DNA was isolated using the Roche kit as per the 
manufacturers' instructions. BM5d DNA was quantified by real-time PCR assay as 
previously described (39).  The amount of BM5d DNA in spleen was calculated by 
interpolation of the experimentally determined plasmid standard curve and was 
normalized to 18S rRNA. SYBR green mastermix (Applied Biosystems) containing 
genomic DNA (1 µl) and 25 pM of primers. The primers used to detect BM5def were 5′ 
CCTTTATCGACACTTCCCTTTT 3′ and 5′ TGGCAGAGGAGGAAGGTT3′. The 
primers used to detects 18S rRNA were: 5′ GTAACCCGTTGAACCCCATT (forward) 
and 5′CCATCCAATCGGTAGTAGGG (reverse). Conditions for amplification of 
BM5Def and 18S rRNA included an initial heat activation of the polymerase at 95°C for 
13 min followed by 40 cycles of 95°C for 15 sec and 62°C for one min. Samples were 
then heated to 72°C for 5 min, 95°C for 1 min prior to performing a melt curve analysis 
from 55°C to 95°C. Data was used for analysis only when the standard curve for each 
primer set yielded an R2 of >0.99 with an efficiency of 90–110%, single peaks were 
observed in the melt curves and template controls gave no detectable amplification. 
Proviral levels normalized to 18S rRNA levels by the Pfaffel method of quantification 
and were determined in triplicate for each set of reactions and three independent assays 
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were performed with each sample. 
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Figure A1-1. Gemcitabine inhibits MuLV replication in cell culture in the absence of 
toxicity. A. Infectivity of MuLV. MuLV containing GFP were produced from 293T cells 
and used to infect U373-MAGI-CXCR4CEM cells that were treated with the indicated 
concentrations of gemcitabine. The data represents the average 6 SD of three independent 
experiments. B. Toxicity of gemcitabine in U373-MAGI-CXCR4CEM cells treated with 
the indicated concentrations of gemcitabine. The data represents the average 6 SD of 
three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1-2. Ratio of spleen weights to body from mice infected with LP-BM5 
MuLV. Each symbol (circles, squares, and triangles) represents one mouse. The average 
6 SD is shown. Treatment groups labeled with the same letter (eg. the 1 and 2 mg/kg/day 
29,29-Difluoro-29-deoxycytidine, commonly referred to as gem-
citabine represents a potential alternative to hydroxyurea as it has
been shown to have two mechanisms of action including inhibition
of ribonucleotide reductase [10,11]. Gemcitabine is clinically-
approved for cancer therapy and its anti-cancer mechanism is
attributed to its ability to inhibit ribonucleotide reductase thereby
limiting dNTP pools available for DNA synthesis in cancer cells.
Since retroviruses may be more sensitive to dNTP pool alterations
than cellular polymerases, we hypothesized that gemcitabine
would be an alternative to hydroxyurea that could be translated to
clinical use for the treatment of retroviral infections when used in
combination with current anti-retroviral therapies.
In a recent study, we identified two clinically-approved drugs,
decitabine and gemcitabine, that had potent anti-HIV activity in
cell culture. The potency by which gemcitabine inhibited
infectivity suggested that it may be useful for the treatment of
retroviral infections when used with decitabine or in combination
with current antiretroviral therapies.
In this study, we examined the ability of gemcitabine to inhibit
replication of another retrovirus, murine leukemia virus in cell
culture. Additionally, we examined the efficacy and toxicity of
gemcitabine in vivo using LP-BM5 murine leukemia virus (LP-
BM5 MuLV, a murine AIDS model). We chose this animal model
as it has been used extensively to screen potential anti-HIV drugs
and has been validated with a number of clinically approved anti-
HIV drugs such as AZT and PMPA (tenofovir) that have relatively
broad antiretroviral activity [12,13,14]. In this study, we show that
gemcitabine decreased infectivity of MuLV in cell culture with no
detectable cytotoxicity. Similarly, gemcitabine decreased disease
progression in the MAIDS model at non-toxic doses although
toxicities were detected at doses just three times that of the
effective dose. Our findings, along with previous observations ([1]),
indicate that gemcitabine has relatively broad antiretroviral
activity with minimal toxicity and could be useful for in vivo
antiretroviral combination therapy.
Results
Gemcitabine inhibits MuLV in cell culture
Before examining the antiviral activity of gemcitabine in vivo, we
first examined the ability of gemcitabine to inhibit MuLV in cell
culture. To do this, a GFP-tagged MuLV was pseudotyped with
VSV-G and used to infect target cells that had been pretreated
with increasing concentrations of gemcitabine. Flow cytometry
was then used to determine the percentage of infected cells. As
shown in Fig. 1A, gemcitabine potently decreased MuLV
infectivity in a concentration-dependent manner with an EC50
in the low nM range. Additionally, there was no toxicity seen at
the concentrations of gemcitabine needed to inhibit viral
replication when the cells were exposed to gemcitabine for the
same time as was used to assess gemcitabine’s effect on infectivity
(Fig. 1B).
Gemcitabine inhibits progression of MAIDS as detected
by spleen weight and histopathology
The data from Fig. 1 indicate that gemcitabine inhibits
replication of MuLV in cell culture. To examine the ability of
gemcitabine to inhibit MuLV in an in vivo system, we treated mice
infected with LP-BM5 with increasing doses of gemcitabine
(Table 1). Progression of MAIDS was characterized by extensive
lymphoproliferation, splenomegaly, increased IgM levels, the
development of lymphoma, and increased susceptibility to
infection [15,16,17,18].
Proliferation of lymphoid cells in the spleen contributes to the
splenomegaly observed in mice infected with LP-BM5 and is an
indicator of disease progression and disease severity [18]. To
determine if gemcitabine decreases splenomegaly, spleens were
obtained and weighed at the time of sacrifice. As expected, the
ratio of spleen to body weight was significantly increased in
infected animals that did not receive treatment (Fig. 2). Mice
treated with 1 or 2 mg/kg/day had an average ratio of spleen to
body weight that was significantly lower than the infected,
untreated mice. In fact, there was no significant difference in the
spleen to body weight ratio between the treated mice and those
that were not infected (Fig. 2).
Since gemcitabine significantly decreased spleen size in mice
infected with LP-BM5, we next examined whether the decrease in
spleen size correlated with a decrease in the histopathological
changes characteristic of MAIDS. Table 2 demonstrates that there
were no significant findings in spleen from two of the four
uninfected mice. The spleens of the other two uninfected mice
were identified as either reactive or as having a score of 1 (see
Materials and Methods for scoring system). Of all other groups,
the infected, untreated mice had the most severe lesions as the
Figure 1. Gemcitabine inhibits MuLV replication in cell culture in the absence of toxicity. 1A. Infectivity of MuLV. MuLV containing GFP
were produced from 293T cells and used to infect U373- AGI-CXCR4CEM cells that were treated with the indicated concentrations of gemcitabine.
The data represents the average 6 SD of three independent experiments. 1B. Toxicity of gemcitabine in U373-MAGI-CXCR4CEM cells treated with the
indicated concentrations of gemcitabine. The data represents the average 6 SD of three independent experiments.
doi:10.1371/journal.pone.0015840.g001
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spleens from all four of the mice in this group received a score of 2
or higher, indi ating xtensive changes in splenic archite ture and
significant expansion of lymphoid cells. In general, there was a
decrease in splenic lesion score as the dose of administered
gemcitabine increased. For example, all spleens from mice
receiving the highest dose of gemcitabine were normal, while 5
of the 6 mice in the 3 mg/kg/day treatment group had spleens
with no significant findings and 4 of the 6 mice in the 2 mg/kg/
day treatment group were within normal limits. Finally, 1 of the 7
mice from the 1 mg/kg/day treatment group had a spleen with
normal histology while the other 6 spleens received a score of 1,
indicating mild lesions.
Treatment with gemcitabine decreases MAIDS-
associated lesions in the lymph nodes
Infection with LP-BM5 destroys the architecture of lymph
nodes and alters the composition [18]. When detected, the
lymph no es from infect d or uninf cted mice were examined by
histopathology as described in the Materials and Methods
section. Lymph nodes were only detectable in one of the four
uninfected mice (Table 3). These lymph nodes were scored as a
1, indicating an enlargement of the lymph nodes with diffuse
sheets of medium to large lymphoid cells while maintaining
corticomedullary architecture. Consistent with the spleen data,
the size and lesions of the lymph nodes was greatest in mice that
were infected but not treated (Table 3). Additionally, lymph
nodes b came mor ifficult to detect as the dose of gemcitabine
increased, indicating that gemcitabine decreased the extent of
lymph node enlargement. Consistent with this, the pathology of
lymph nodes from mice treated with the higher doses of
gemcitabine had lower scores indicating less severe lesions. For
example, 6 of the 7 mice treated with 1 mg/kg/day of gemcita-
bine received a score of 1, whereas all of the lymph nodes from
mice treated with either 2 or 3 mg/kg/day received scores that
were consistent with a decrease in disease progression when
compared to the untreated but infected mice or mice treated
with 1 mg/kg/day of gemcitabine.
Effect of gemcitabine on plasma IgM levels
Soon after infection with LP-BM5, mice demonstrate a
significant increase in plasma IgM levels that peak approximately
8–9 weeks post-infection [16,18]. Subsequently, IgM levels
decrease, but remain elevated compared to uninfected animals.
To examine the effect of gemcitabine on IgM levels, plasma was
isolated from whole blood collected from mice at the time of
sacrifice. As expected, infected but untreated animals demonstrat-
ed a significant increase in IgM levels compared to the uninfected
animals (Fig. 3). In contrast, treatment with 1 or 2 mg/kg/day of
gemcitabine significantly decreased IgM levels compared to the
untreated animals. Surprisingly, IgM levels from mice treated with
2 mg/kg/day of gemcitabine were significantly lower than that
seen in the uninfected animals.
Gemcitabine decreases provirus levels
The data pathology indicated that gemcitabine decreases the
severity or progression of murine AIDS. However, to more
directly determine if gemcitabine inhibits replication of LP-BM5,
provirus levels were quantified from spleen obtained at the time of
sacrifice. Levels of the defective provirus were normalized to 18S
rRNA levels as previously described [19]. The data shown in Fig. 4
revealed high levels of provirus in mice that were infected, but
untreated. Mice treated with either 1 or 2 mg/kg/day of
gemcitabin had negligible provirus levels that were comparable
to the uninfected control mice, indicating reduced viral
replication.
Table 1. Treatment groups for ex vivo analysis of gemcitabine*.
Treatment Group Infection Status Treatment
Number in group
at start of study
Number of surviving
mice at end of study
1 Not infected Saline 4 4
2 Infected Saline 4 4
3 Infected 1 mg/kg/day gemcitabine 7 7
4 Infected 2 mg/kg/day gemcitabine 7 4
5 Infected 3 mg/kg/day gemcitabine 7 0
6 Infected 4 mg/kg/day gemcitabine 7 0
7 Not Infected 4 mg/kg/day gemcitabine 4 0
*Treatment Groups, number of animals at the start of the study and the number of animals surviving at the end of the study.
doi:10.1371/journal.pone.0015840.t001
Figure 2. Ratio of spleen weights to body from mice infected
with LP-BM5 MuLV. Each symbol (circles, squares, and triangles)
represents one mouse. The average 6 SD is shown. Treatment groups
labeled with the same letter (eg. the 1 and 2 mg/kg/day groups are
both labeled with ‘‘b’’) are not statistically different from one another
whereas treatment groups labeled with different letters (eg. ‘‘a’’ from
one group and ‘‘b’’ for another group) are statistically different from
one another as determined by One-Way ANOVA with Tukey-Kramer
post-test p,0.05. n = 4 for the untreated groups, n = 7 for the mice
treated with 1 mg/kg/day and n= 3 for mice treated with 2 mg/kg/day.
doi:10.1371/journal.pone.0015840.g002
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groups are both labeled with ‘‘b’’) are not statistically different from one another whereas 
treatment groups labeled with different letters (eg. ‘‘a’’ from one group and ‘‘b’’ for 
another group) are statistically different from one another as determined by One-Way 
ANOVA with Tukey-Kramer post-test p<0.05. n=4 for the untreated groups, n=7 for the 
mice treated with 1 mg/kg/day and n = 3 for mice treated with 2 mg/kg/day. 
 
 
 
 
 
 
 
Figure A1-3. Serum IgM levels from mice infected with LP-BM5 MuLV. Each 
symbol (circles, squares and triangles) represent one animal. Treatment groups labeled 
with different letters are not statistically different from one another while treatment 
groups labeled with different letters are statistically different as determined by One- Way 
ANOVA with Tukey-Kramer post-test p<0.05. n = 4 for both the untreated groups, n = 7 
for animals treated with 1 mg/kg/day, and n = 5 for animals treated with 2 mg/kg/day 
gemcitabine. 
 
 
 
 
fact, all measures of MAIDS-associated pathogenesis including
splenomegaly, histopathology of spleen and lymph nodes and
levels of IgM and provirus indicated reduced viral replication. The
reduction of provirus by gemcitabine further supported the
gemcitabine-mediated r duction in viral replica ion. There are
at least two mechanisms that could account for the decrease in
disease progression. First, gemcitabine could decrease dNTP levels
enough to decrease proliferation of infected cells. Second,
gemcitabine could alter dNTP levels such that viral replication is
inhibited without inhibition of cellular proliferation. These
mechanisms are likely to be dose dependent with low gemcitabine
doses preferentially inhibiting viral replication and higher doses
inhibiting both viral replication and cell proliferation. In support
of this, 2 mg/kg/day of gemcitabine caused a significant reduction
in IgM levels compared to the uninfected animals. This is likely
due to gemcitabine-mediated decrease in B cell proliferation. In
contrast, IgM levels from mice treated with 1 mg/kg/day had
levels comparable to the uninfected animals which suggest there
was not a significant reduction in B cell numbers compared to the
uninfected mice. The cell culture data also supported this assertion
as the decrease in replication was not associated with a significant
loss of cell numbers (Fig. 1B). These data indicate that
gemcitabine’s antiviral activity is distinct from its activity used to
treat human cancers. Furthermore, doses of gemcitabine used
clinically in cancer treatment are significantly higher than those
used in our study. For example, gemcitabine’s anti-cancer activity
is achieved with a dosing regimen that includes 1000 mg/m2 given
once every week for seven weeks, followed by one week without
drug and additional rounds of treatment as needed [22]. In our
study, an antiviral effect was seen in animals at doses as low as
1 mg/kg which correlates to 3 mg/m2 when using the BSA
method to convert the mouse dose to the human equivalent dose
(mouse dose multiplied by mouse km of 3) [23]. Although the
metabolism of gemcitabine in mice is likely different compared to
humans, the significant difference in dosing further supports that
the antiviral activity seen here is not due to inhibition of cell
proliferation.
Toxicity of gemcitabine was significant at higher doses. In fact,
all mice treated with 3 and 4 mg/kg/day lost 15% or greater of
their body weight during the study and as a result were
prematurely euthanized. However, the 1 mg/kg/day dose of
gemcitabine decreased disease pathology with no detectable
toxicity. Specifically, all of these animals gained body weight
similar to the uninfected animals. Additionally, these animals did
not show any signs of hepatotoxicity as detected by histopatho-
logical analysis (data not shown). The 2 mg/kg/day dose was also
effective at decreasing disease progression. However, some of the
mice in this treatment group showed signs of toxicity in the loss of
body weight while others in this group appeared to tolerate
gemcitabine well. Like the animals treated with 1 mg/kg/day
gemcitabine, there was no hepatotoxicity observed in animals
treated with 2 mg/kg/day gemcitabine. The extent to which
gemcitabine effected the animals in the 2 mg/kg group was not
limited to toxicity as the efficacy of gemcitabine’s antiviral activity
also varied (see Figure 2). Although it is not clear why the mice
Figure 3. Serum IgM levels from mice infected with LP-BM5
MuLV. Each symbol (circles, squares and triangles) represent one
animal. Treatment groups labeled with different letters are not
statistically different from one another while treatment groups labeled
with different letters are statistically different as determined by One-
Way ANOVA with Tukey-Kramer post-test p,0.05. n = 4 for both the
untreated groups, n = 7 for animals treated with 1 mg/kg/day, and n=5
for animals treated with 2 mg/kg/day gemcitabine.
doi:10.1371/journal.pone.0015840.g003
Figure 4. Provirus levels in mice infected with LP-BM5 MuLV.
Genomic DNA was extracted from mouse spleen and quantitative real
time PCR was performed to detect the defective MAIDS provirus.
Provirus levels were normalized to the 18S rRNA gene. Each symbol
(squares, circles, and triangles) represents one animal. The Pfaffel
modification of the DDCt method was used to assess gene expression.
Statistical significance was assessed by One-Way ANOVA with Tukey-
Kramer post-test with p,0.05 designated as significant.
doi:10.1371/journal.pone.0015840.g004
Figure 5. Change in body weights of mice infected with LP-BM5
MuLV and treated with the indicated doses of gemcitabine.
Each symbol (triangles, squares, circles, diamonds, and hatch marks)
represent one mouse. The average 6 SD is shown for each treatment
group.
doi:10.1371/journal.pone.0015840.g005
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Figure A1-4. Provirus levels in mice infected with LP-BM5 MuLV.  Genomic DNA 
was extracted from mouse spleen and quantitative real time PCR was performed to detect 
the defective MAIDS provirus. Provirus levels were normalized to the 18S rRNA gene. 
Each symbol (squares, circles, and triangles) represents one animal. The Pfaffel 
modification of the DDCt method was used to assess gene expression. Statistical 
significance was assessed by One-Way ANOVA with Tukey-Kramer post-test with 
p<0.05 designated as significant. 
 
 
 
 
 
 
Figure A-5. Change in body weights of mice infected with LP-BM5 MuLV and 
treated with the indicated doses of gemcitabine. Each symbol (triangles, squares, 
fact, all measures of MAIDS-associated pathogenesis including
splenomegaly, histopathology of spleen and lymph nodes and
levels of IgM and provirus indicated reduced viral replication. The
reduction of provirus by gemcitabine further supported the
gemcitabine-mediated reduction in viral replication. There are
at least two mechanisms that could account for the decrease in
disease progression. First, gemcitabine could decrease dNTP levels
enough to decrease proliferation of infected cells. Second,
gemcitabine could alter dNTP levels such that viral replication is
inhibited without inhibition of cellular proliferation. These
mechanisms are likely to be dose dependent with low gemcitabine
doses preferentially inhibiting viral replication and higher doses
inhibiting both viral replication and cell proliferation. In support
of this, 2 mg/kg/day of gemcitabine caused a significant reduction
in IgM levels compared to the uninfected animals. This is likely
due to gemcitabine-mediated decrease in B cell proliferation. In
contrast, IgM levels from mice treated with 1 mg/kg/day had
levels comparable to the uninfected animals which suggest there
was not a significant reduction in B cell numbers compared to the
uninfected mice. The cell culture data also supported this assertion
as the decrease in replication was not associated with a significant
loss of cell numbers (Fig. 1B). These data indicate that
gemcitabine’s antiviral activity is distinct from its activity used to
treat human cancers. Furthermore, doses of gemcitabine used
clinically in cancer treatment are significantly higher than those
used in our study. For example, gemcitabine’s anti-cancer activity
is achieved with a dosing regimen that includes 1000 mg/m2 given
once every week for seven weeks, followed by one week without
drug and additional rounds of treatment as needed [22]. In our
study, an antiviral effect was seen in animals at doses as low as
1 mg/kg which correlates to 3 mg/m2 when using the BSA
method to convert the mouse dose to the human equivalent dose
(mouse dose multiplied by mouse km of 3) [23]. Although the
metabolism of gemcitabine in mice is likely different compared to
humans, the significant difference in dosing further supports that
the antiviral activity seen here is not due to inhibition of cell
proliferation.
Toxicity of gemcitabine was significant at higher doses. In fact,
all mice treated with 3 and 4 mg/kg/day lost 15% or greater of
their body weight during the study and as a result were
prematurely euthanized. However, the 1 mg/kg/day dose of
gemcitabine decreased disease pathology with no detectable
toxicity. Specifically, all of these animals gained body weight
similar to the uninfected animals. Additionally, these animals did
not show any signs of hepatotoxicity as detected by histopatho-
logical analysis (data not shown). The 2 mg/kg/day dose was also
effective at decreasing disease progression. However, some of the
mice in this treatment group showed signs of toxicity in the loss of
body weight while others in this group appeared to tolerate
gemcitabine well. Like th ani als treated with 1 mg/kg/day
gemcitabine, there was no hepatotoxicity observed in animals
treated with 2 mg/kg/day gemcitabine. The extent to which
gemcitabine effected the animals in the 2 mg/kg group was not
limited to toxicity as the efficacy of gemcitabine’s antiviral activity
also varied (see Figure 2). Although it is not clear why the mice
Figure 3. Serum IgM levels from mice infected with LP-BM5
MuLV. Each symbol (circles, squares and triangles) represent one
animal. Treatment groups labeled with different letters are not
statistically different from one another while treatment groups labeled
with different letters are statistically different as determined by One-
Way ANOVA with Tukey-Kramer post-test p,0.05. n = 4 for both the
untreated groups, n = 7 for animals treated with 1 mg/kg/day, and n=5
for animals treated with 2 mg/kg/day gemcitabine.
doi:10.1371/journal.pone.0015840.g003
Figure 4. Provirus levels in mice infected with LP-BM5 MuLV.
Genomic DNA was extracted from mouse spleen and quantitative real
time PCR was performed to det ct the defective MAIDS provirus.
Provirus levels were normalized to the 18S rRNA gene. Each symbol
(squares, circles, and triangles) represents one animal. The Pfaffel
modification of the DDCt method was used to assess gene expression.
Statistical significance was assessed by One-Way ANOVA with Tukey-
Kramer post-test with p,0.05 designated as significant.
doi:10.1371/journal.pone.0015840.g004
Figure 5. Change in body weights of mice infected with LP-BM5
MuLV and treated with the indicated doses of gemcitabine.
Each symbol (triangles, squares, circles, diamonds, and hatch marks)
represent one mouse. The average 6 SD is shown for each treatment
group.
doi:10.1371/journal.pone.0015840.g005
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fact, all measures of MAIDS-associated pathogenesis including
splenomegaly, histopathology of spleen and lymph nodes and
levels of IgM and provirus indicated reduced viral replication. The
reduction of provirus by gemcitabine further supported the
gemcitabine-mediated reduction in viral replication. There are
at least two mechanisms that could account for the decrease in
disease progression. First, gemcitabine could decrease dNTP levels
enough to decrease proliferation of infected cells. Second,
gemcitabine could alter dNTP levels such that viral replication is
inhibited without inhibition of cellular proliferation. These
mechanisms are likely to be dose dependent with low gemcitabine
doses preferentially inhibiting viral replication and higher doses
inhibiting both viral replication and cell proliferation. In support
of this, 2 mg/kg/day of gemcitabine caused a significant reduction
in IgM levels compared to the uninfected animals. This is likely
due to gemcitabine-mediated decrease in B cell proliferation. In
contrast, IgM levels from mice treated with 1 mg/kg/day had
levels comparable to the uninfected animals which suggest there
was not a significant reduction in B cell numbers compared to the
uninfected mice. The cell culture data also supported this assertion
as the decrease in replication was not associated with a significant
loss of cell numbers (Fig. 1B). These data indicate that
gemcitabine’s antiviral activity is distinct from its activity used to
treat human cancers. Furthermore, doses of gemcitabine used
clinically in cancer treatment are significantly higher than those
used in our study. For example, gemcitabine’s anti-cancer activity
is achieved with a dosing regimen that includes 1000 mg/m2 given
once every week for seven weeks, followed by one week without
drug and additional rounds of treatment as needed [22]. In our
study, an antiviral effect was seen in animals at doses as low as
1 mg/kg which correlates to 3 mg/m2 when using the BSA
method to convert the mouse dose to the human equivalent dose
(mouse dose multiplied by mouse km of 3) [23]. Although the
metabolism of gemcitabine in mice is likely different compared to
humans, the significant difference in dosing further supports that
the antiviral activity seen here is not due to inhibition of cell
proliferation.
Toxicity of gemcitabine was significant at higher doses. In fact,
all mice treated with 3 and 4 mg/kg/day lost 15% or greater of
their body weight during the study and as a result were
prematurely euthanized. However, the 1 mg/kg/day dose of
gemcitabine decreased disease pathology with no detectable
toxicity. Specifically, all of these animals gained body weight
similar to the uninfected animals. Additionally, these animals did
not show any signs of hepatotoxicity as detected by histopatho-
logical analysis (data not shown). The 2 mg/kg/day dose was also
effective at decreasing disease progression. However, some of the
mice in this treatment group showed signs of toxicity in the loss of
body weight while others in this group appeared to tolerate
gemcitabine well. Like the animals treated with 1 mg/kg/day
gemcitabine, there was no hepatotoxicity observed in animals
treated with 2 mg/kg/day gemcitabine. The extent to which
gemcitabine effected the animals in the 2 mg/kg group was not
limited to toxicity as the efficacy of gemcitabine’s antiviral activity
also varied (see Figure 2). Although it is not clear why the mice
Figure 3. Serum IgM levels from mice infected with LP-BM5
MuLV. Each symbol (circles, squares and triangles) represent one
animal. Treatment groups labeled with different letters are not
statistically different from one another while treatment groups labeled
with different letters are statistically different as determined by One-
Way ANOVA with Tukey-Kramer post-test p,0.05. n = 4 for both the
untreated groups, n = 7 for animals treated with 1 mg/kg/day, and n=5
for animals treated with 2 mg/kg/day gemcitabine.
doi:10.1371/journal.pone.0015840.g003
Figure 4. Provirus levels in mice infected with LP-BM5 MuLV.
Genomic DNA was extracted from mouse spleen and quantitative real
time PCR was performed to detect the defective MAIDS provirus.
Provirus levels were normalized to the 18S rRNA gene. Each symbol
(squares, circles, and triangles) represents one animal. The Pfaffel
modification of the DDCt method was used to assess gene expression.
Statistical significance was assessed by One-Way ANOVA with Tukey-
Kramer post-test with p,0.05 designated as significant.
doi:10.1371/journal.pone.0015840.g004
Figure 5. Change in body weights of mice infected with LP-BM5
MuLV and treated with the indicated doses of gemcitabine.
Each symbol (triangles, squares, circles, diamonds, and hatch marks)
represent one mouse. The average 6 SD is shown for each treatment
group.
doi:10.1371/journal.pone.0015840.g005
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circles, diamonds, and hatch marks) represent one mouse. The average 6 SD is shown for 
each treatment group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A1-1. Treatment groups for ex vivo analysis of gemcitabine*. 
spleens from all four of the mice in this group received a score of 2
or higher, indicating extensive changes in splenic architecture and
significant expansion of lymphoid cells. In general, there was a
decrease in splenic lesion score as the dose of administered
gemcitabine increased. For example, all spleens from mice
receiving the highest dose of gemcitabine were normal, while 5
of the 6 mice in the 3 mg/kg/day treatment group had spleens
with no significant findings and 4 of the 6 mice in the 2 mg/kg/
day treatment group were within normal limits. Finally, 1 of the 7
mice from the 1 mg/kg/day treatment group had a spleen with
normal histology while the other 6 spleens received a score of 1,
indicating mild lesions.
Treatment with gemcitabine decreases MAIDS-
associated lesions in the lymph nodes
Infection with LP-BM5 destroys the architecture of lymph
nodes and alters the composition [18]. When detected, the
lymph nodes from infected or uninfected mice were examined by
histopathology as described in the Materials and Methods
section. Lymph nodes were only detectable in one of the four
uninfected mice (Table 3). These lymph nodes were scored as a
1, indicating an enlargement of the lymph nodes with diffuse
sheets of medium to large lymphoid cells while maintaining
corticomedullary architecture. Consistent with the spleen data,
the size and lesions of the lymph nodes was greatest in mice that
were infected but not treated (Table 3). Additionally, lymph
nodes became more difficult to detect as the dose of gemcitabine
increased, indicating that gemcitabine decreased the extent of
lymph node enlargement. Consistent with this, the pathology of
lymph nodes from mice treated with the higher doses of
gemcitabine had lower scores indicating less severe lesions. For
example, 6 of the 7 mice treated with 1 mg/kg/day of gemcita-
bine received a score of 1, whereas all of the lymph nodes from
mice treated with either 2 or 3 mg/kg/day received scores that
were consistent with a decrease in disease progression when
compared to the untreated but infected mice or mice treated
with 1 mg/kg/day of gemcitabine.
Effect of gemcitabine on plasma IgM levels
Soon after infection with LP-BM5, mice demonstrate a
significant increase in plasma IgM levels that peak approximately
8–9 weeks post-infection [16,18]. Subsequently, IgM levels
decrease, but remain elevated compared to uninfected animals.
To examine the effect of gemcitabine on IgM levels, plasma was
isolated from whole blood collected from mice at the time of
sacrifice. As expected, infected but untreated animals demonstrat-
ed a significant increase in IgM levels compared to the uninfected
animals (Fig. 3). In contrast, treatment with 1 or 2 mg/kg/day of
gemcitabine significantly decreased IgM levels compared to the
untreated animals. Surprisingly, IgM levels from mice treated with
2 mg/kg/day of gemcitabine were significantly lower than that
seen in the uninfected animals.
Gemcitabine decreases provirus levels
The data pathology indicated that gemcitabine decreases the
severity or progression of murine AIDS. However, to more
directly determine if gemcitabine inhibits replication of LP-BM5,
provirus levels were quantified from spleen obtained at the time of
sacrifice. Levels of the defective provirus were normalized to 18S
rRNA levels as previously described [19]. The data shown in Fig. 4
revealed high levels of provirus in mice that were infected, but
untreated. Mice treated with either 1 or 2 mg/kg/day of
gemcitabine had negligible provirus levels that were comparable
to the uninfected control mice, indicating reduced viral
replication.
Table 1. Treatment groups for ex vivo analysis of gemcitabine*.
Treatment Group Infection Status Treatment
Number in group
at start of study
Number of surviving
mice at end of study
1 Not infected Saline 4 4
2 Infected Saline 4 4
3 Infected 1 mg/kg/day gemcitabine 7 7
4 Infected 2 mg/kg/day gemcitabine 7 4
5 Infected 3 mg/kg/day gemcitabine 7 0
6 Infected 4 mg/kg/day gemcitabine 7 0
7 Not Infected 4 mg/kg/day gemcitabine 4 0
*Treatment Groups, number of animals at the start of the study and the number of animals surviving at the end of the study.
doi:10.1371/journal.pone.0015840.t001
Figure 2. Ratio of spleen weights to body from mice infected
with LP-BM5 MuLV. Each symbol (circles, squares, and triangles)
represents one mouse. The average 6 SD is shown. Treatment groups
labeled with the same letter (eg. the 1 and 2 mg/kg/day groups are
both labeled with ‘‘b’’) are not statistically different from one another
whereas treatment groups labeled with different letters (eg. ‘‘a’’ from
one group and ‘‘b’’ for another group) are statistically different from
one another as determined by One-Way ANOVA with Tukey-Kramer
post-test p,0.05. n = 4 for the untreated groups, n = 7 for the mice
treated with 1 mg/kg/day and n= 3 for mice treated with 2 mg/kg/day.
doi:10.1371/journal.pone.0015840.g002
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Table A1-2. Histopathological analysis of spleen from gemcitabine-treated animals with LP-BM5.* 	  
Toxicity of gemcitabine as determined by changes in
body weight
Body weight is often used as an indicator of toxicity in
laboratory animals. In this study, animals losing 15% or more of
their body mass were euthanized and such loss of weight was
attributed to drug-related toxicity. All mice treated with 3 and
4 mg/kg/day of gemcitabine, regardless of infection status, lost
15% or more body mass and were euthanized before the end of
the study. Fig. 5 shows the change in body weight of all mice at the
time of euthanasia. The data demonstrates that mice treated with
2 mg/kg/day of gemcitabine or higher lost body weight while
untreated mice or mice treated with 1 mg/kg/day of gemcitabine
gained body weight throughout the study.
Discussion
In the absence of a cure or vaccine for HIV-1 infection, the
identification of novel drug targets and the development of new
drug is the best approach to ddress the emergence of resistance
as well as the co plications associated with current therapies.
Drugs that target cellular proteins are less likely to be susceptible to
the emergence of drug resistance compared to the current anti-
HIV therapies which target viral proteins. However, drugs that
target cellular proteins a e likely to b associated with an increas
in toxicity which m limit their clinical use. For example,
hydroxyurea has been used alone and in combination with
nucleoside reverse transcriptase inhibitors (NRTIs) to decrease
viral loads in HIV-1 infected individuals. The side effects
associated with hydroxyurea has significantly curtailed its clinical
use. Less toxic alternatives to hydroxyurea would offer important
alternatives for the treatment of HIV-1 as well as other retroviral
infections.
A recent study demonstrated that two clinically approved drugs,
decitabine and gemcitabine have potent anti-HIV activity in cell
culture when used alone or in combination [1]. Importantly, based
on gemcitabine’s potency and lack of toxicity, the data suggest that
gemcitabine may be a clinically relevant alternative to hydroxy-
urea for the treatment of retroviral infections.
In this study, we examined the antiretroviral activity of
gemcitabine in vivo and ex vivo using the LP-BM5 MuLV model
(a murine AIDS model). Murine AIDS is caused by a combination
of three murine leukemia viruses including BM5-eco, BM5def, and
mink cell focus inducing virus (MCF) [20,21]. BM5def is a
retrovirus that is unable to replicate due to deletion of most of the
pol gene. However, its intact gag gene is thought to be responsible
for MAIDS pathogenesis. Although LP-BM5 is not a perfect
model for AIDS pathogenesis, it is well characterized, safe,
inexpensive, and has been validated with a number of clinically
approved anti-HIV-1 drugs and has been useful for identifying
drugs with broad antiretroviral activity (for review see [12].
Our studies found that gemcitabine decreased replication of
MuLV in cell culture as well as in vivo using the MAIDS model. In
Table 2. Histopath logical analysis of spl en from g mcitabine-treate nimals infected with LP-BM5.*
Not infected Infected, untreated
1 mg/kg/day
gemcitabine
2 mg/kg/ ay
gemcitabine
3 mg/kg/day
gemcitabine
4 mg/kg/day
gemcitabine
NSF 2 1 NSF NSF NSF
NSF 2 1 NSF NSF NSF
R 2 1 Ab NSF NSF
1 3 NSF NSF NSF NC
1 NSF NSF NC
1 D Ab NC
1 NC NC NC
*Sections of spleen were analyzed as described in Materials and Methods. NSF = no significant findings; R = reactive, Ab =Abnormal composition; D= depleted white
pulp. NC = tissue was not collected. Score of 3 = high pathology; score of 2 = intermediate pathology; score of 1 = low degree of pathology. Each box corresponds to
a different animal.
doi:10.1371/journal.pone.0015840.t002
Table 3. Histopathological analysis of lymph nodes from gemcitabine-treated animals infected with LP-BM5 MuLV*.
Not infected Infected, untreated
1 mg/kg/day
gemcitabine
2 mg/kg/day
gemcitabine
3 mg/kg/day
gemcitabine
4 mg/kg/day
gemcitabine
ND 3 NSF NSF NSF N/A
ND 3 NSF NSF NSF N/A
ND 3 1 ND NSF N/A
1 2 1 ND N/A N/A
1 ND N/A N/A
1 N/A ND N/A
2 N/A ND N/A
*Sections of lymph nodes were analyzed as described in Materials and Methods. NSF = no significant findings; N/A = not applicable because tissues were not collected.
ND = lymph nodes from these animals were not detected. Scores of 3 = high degree of pathology; score of 2 = intermediate degree of pathology; score of 1 = low
degree of pathology. Each box corresponds to a different animal.
doi:10.1371/journal.pone.0015840.t003
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Table A1-3. Histopathological analysis of lymph nodes from gemcitabine-treated anima  with LP-
M5 MuLV.* 	  
Toxicity of gemcitabine as determined by changes in
body weight
Body weight is often used as an indicator of toxicity in
laboratory animals. In this study, animals losing 15% or more of
their body mass were euthanized and such loss of weight was
attributed to drug-related toxicity. All mice treated with 3 and
4 mg/kg/day of gemci abine, regardless of infect on status, lost
15% or more body mass and were euthanized before the end of
the study. Fig. 5 shows the change in body weight of all mice at the
time of euthanasia. The data demonstrates that mice treated with
2 mg/kg/day of gemcitabine or higher lost body weight while
untreated mice or mice treated with 1 mg/kg/day of gemcitabine
gained body weight throughout the study.
Discussion
In the absence of a cure or vaccine for HIV-1 infection, the
identification of novel drug targets and the development of new
drugs is the best approa h to address the emergence of resistance
well as th c mplica ions associated with current therapies.
Drugs that target cellular proteins are less likely to be susceptible to
the mergence of drug resistance compared to the current anti-
HIV therapies which target viral prot ins. Ho ver, drugs that
target cellular protei s are likely to be associated with an increase
in toxicity which may limit their clinical use. For example,
hydroxyurea has been used alone and in combination with
nucleoside reverse transcriptase inhibitors (NRTIs) to decrease
viral loads in HIV-1 infected individuals. The side effects
associated with hydroxyurea has significantly curtailed its clinical
use. Less toxic alternatives to hydroxyurea would offer important
alternatives for the treatment of HIV-1 as well as other retroviral
infections.
A recent study demonstrated that two clinically approved drugs,
decitabine and gemcitabine have potent anti-HIV activity in cell
culture when used alone or in combination [1]. Importantly, based
on gemcitabine’s potency and lack of toxicity, the data suggest that
gemcitabine may be a clinically relevant alternative to hydroxy-
urea for the treatment of retroviral infections.
In this study, we examined the antiretroviral activity of
gemcitabine in vivo and ex vivo using the LP-BM5 MuLV model
(a murine AIDS model). Murine AIDS is caused by a combination
of three murine leukemia viruses including BM5-eco, BM5def, and
mink cell focus inducing virus (MCF) [20,21]. BM5def is a
retrovirus that is unable to replicate due to deletion of most of the
pol gene. However, its intact gag gene is thought to be responsible
for MAIDS pathogenesis. Although LP-BM5 is not a perfect
model for AIDS pathogenesis, it is well characterized, safe,
inexpensive, and has been validated with a number of clinically
approved anti-HIV-1 drugs and has been useful for identifying
drugs with broad antiretroviral activity (for review see [12].
Our studi s found that gemcitabine decr ased replication of
MuLV in cell culture as well as in vivo using the MAIDS model. In
Table 2. Histopathological analysis of spleen from gemcitabine-treated animals infected with LP-BM5.*
Not infected Infected, untreated
1 mg/kg/day
gemcitabine
2 mg/kg/day
gemcitabine
3 mg/kg/day
gemcitabine
4 mg/kg/day
gemcitabine
NSF 2 1 NSF NSF NSF
NSF 2 1 NSF NSF NSF
R 2 1 Ab NSF NSF
1 3 NSF NSF NSF NC
1 NSF NSF NC
1 D Ab NC
1 NC NC NC
*Sections of spleen were analyzed as d scribed in Materials and Methods. NSF = no significa t findings; R = reactive, Ab =Abnormal composition; D= depleted white
pulp. NC = tissue was not collected. Score of 3 = high pathology; score of 2 = intermediate pathology; score of 1 = low degree of pathology. Each box corresponds to
a different animal.
doi:10.1371/journal.pone.0015840.t002
Table 3. His opathological an lysis of lymph n des from gemcitabine-treated animals infected with LP-BM5 MuLV*.
Not infected Infected, untreated
1 mg/kg/day
gemcitabine
2 mg/kg/day
gemcitabine
3 mg/kg/day
gemcitabine
4 mg/kg/day
ge citabine
ND 3 NSF NSF NSF N/A
ND 3 NSF NSF NSF N/A
ND 3 1 ND NSF N/A
1 2 1 ND N/A N/A
1 ND N/A N/A
1 N/A ND N/A
2 N/A ND N/A
*Sections of lymph nodes were analyzed as described in Materials and Methods. NSF = no significant findings; N/A = not applicable because tissues wer not collected.
ND = lymph nodes from these animals were not detected. Scores of 3 = high degree of pathology; score of 2 = intermediate degree of pathology; score of 1 = low
degree of pathology. Each box corresponds to a different animal.
doi:10.1371/journal.pone.0015840.t003
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Introduction 
 
The efficacies of current anti-HIV-1 therapies are limited by the emergence of 
drug-resistant virus, which necessitates the development of drugs that exploit novel drug 
targets. The development of anti-HIV-1 drugs has been relatively rapid and efficient, 
which has expanded the repertoire of drugs available to HIV-1-infected individuals. The 
HIV-1 mutation rate represents a potential drug target that has yet to be successfully 
exploited. Compounds that intentionally increase the mutation rate have been shown to 
render the virus unable to replicate with enough fidelity to remain infectious, a process 
termed lethal mutagenesis (36, 59, 85, 132, 209).  Although a number of compounds have 
been shown to lethally mutagenize HIV-1 and one has even made it to clinical trials, none 
have yet been efficacious and safe enough to be approved for clinical use. 
Our previous work identified a combination of clinically approved drugs, 
decitabine and gemcitabine, that when used together synergistically inhibited HIV-1 
replication in cell culture (50).  Furthermore, lethal mutagenesis accounted for at least 
part of the mechanism of action for this drug combination. Besides having a novel 
mechanism of action, the concentrations of decitabine and gemcitabine necessary to 
inhibit viral replication were significantly lower than those required to inhibit cell 
proliferation, suggesting that these drugs may be clinically relevant (50). 
In this study, we examined the efficacy and toxicity of decitabine and gemcitabine 
in the LP-BM5/murine AIDS (MAIDS) model of HIV-1. LP-BM5, the infectious agent 
of MAIDS, is composed of three different viruses that, upon infection of C57BL/6 mice, 
cause a syndrome that mimics the immunodeficiency seen with HIV-1 (112, 154).  
Important similarities between HIV-1/AIDS and MAIDS include (i) a dependence on 
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CD4+ T cells for disease initiation, (ii) early onset of hypergammaglobulinemia, (iii) loss 
of B and T cell responses with disease progression, (iv) splenomegaly, and (v) increased 
susceptibility to opportunistic infections with disease progression. Besides similarities in 
disease initiation and progression, the MAIDS model has been validated with anti-HIV-1 
drugs such as zidovudine and tenofovir, making it a suitable model for screening 
potential new anti-HIV-1 drugs that have shown promise in a cell culture system (67, 
165, 190, 191).  We previously used this model to demonstrate the antiretroviral activity 
of gemcitabine. Specifically, the data demonstrated that both 1 and 2 mg of gemcitabine 
per kg of body weight decreased disease progression; however, 2 mg/kg was superior in 
measurements of spleen and lymph node histopathology (49).  In preliminary studies, we 
examined the antiviral activity of decitabine using the MAIDS model and found that 0.15 
mg/kg of decitabine decreased disease progression in MAIDS mice, while 0.1 mg/kg had 
minimal antiviral activity (data not shown). In this study, we hypothesized that using a 
dose of gemcitabine (1 mg/kg) in combination with a dose of decitabine (0.1 mg/kg) that 
would be suboptimal if used individually would significantly decrease disease 
progression using measurements such as provirus levels, spleen weights, and spleen and 
lymph node histopathology. 
Although the MAIDS model is not a perfect model for HIV/AIDS, we show here 
that the similarities between the potency of decitabine and gemcitabine against HIV and 
murine leukemia virus (MuLV) in cell culture validate the use of this model for 
examining the efficacy and toxicity of decitabine and gemcitabine. Here we demonstrate 
the in vitro and in vivo activities of decitabine and gemcitabine using the MAIDS model. 
In cell culture, both gemcitabine and decitabine potently inhibit MuLV replication. In 
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vivo, the combination of decitabine and gemcitabine inhibited progression of MAIDS at 
doses that did not demonstrate toxicity, as determined by changes in body weight and 
liver histopathology. Additionally, certain indicators of disease progression indicate that 
the drug combination was more effective than the individual drugs, as would be predicted 
on the basis of the cell culture data. 
 
Results 
 
The combination of decitabine and gemcitabine inhibits MuLV infectivity in cell culture.   
Our previous studies showed that decitabine and gemcitabine have potent anti-
HIV-1 activity in cell culture (50) and that gemcitabine alone has anti-MuLV activity 
using the MAIDS model (49). To determine if the LP-BM5/MAIDS model was an 
acceptable model with which to examine the efficacy and toxicity of decitabine and 
gemcitabine, we first examined the anti-MuLV activities of the drugs alone and in 
combination in cell culture. To do this, MuLV expressing GFP was pseudotyped with 
vesicular stomatitis virus glycoprotein G (VSV-G) and then used to infect target cells that 
had been pretreated with decitabine, gemcitabine, or the combination of the two. Flow 
cytometry was then used to determine the percentage of infected cells. Figure II-1A and 
B show that both decitabine and gemcitabine potently inhibit MuLV infectivity, with 
EC50s in the nanomolar range. Figure A2-1C further demonstrates that the antiviral 
activity of decitabine and gemcitabine was potentiated when they were used in 
combination. Although the potentiation was not as great as what is seen with HIV-1 (50), 
similarities in the potencies of these drugs (Table A2-1) suggested that the MAIDS model 
would be a valid model for examining the efficacy and toxicity of these drugs. 
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The combination of decitabine and gemcitabine inhibits progression of MAIDS as 
detected by spleen weight and histopathology.   
The data shown in Fig. A2-1 demonstrate that decitabine and gemcitabine inhibit 
MuLV infectivity in cell culture. To determine if decitabine and gemcitabine inhibit 
MuLV in vivo, mice were infected with LP-BM5 and treated daily with saline (control), a 
low dose of decitabine, a low dose of gemcitabine, or low doses of both decitabine and 
gemcitabine (Table A2-2). The dose of gemcitabine was chosen on the basis of our 
previously published dose-response analysis performed in the MAIDS model (49). The 
dose of decitabine was chosen on the basis of our preliminary studies showing that 0.15 
mg/kg decitabine decreased the ratio of spleen weight to body weight, while 0.1 mg/kg 
had minimal effect on the spleen weight to body weight in mice with MAIDS (data not 
shown). These low doses that demonstrated minimal anti-MuLV activity were chosen so 
that any potentiation of the drugs when used in combination would be easily observed, as 
we have previously described (50).  Infection of mice with LP-BM5 is characterized by 
lymphoproliferation, which is detected histologically as a marked expansion of white 
pulp in the spleen. This expansion also leads to splenomegaly, which is another indicator 
of disease progression (232). Thus, to examine the extent of disease progression, spleens 
were removed and weighed immediately after sacrifice. The effect of drug treatment on 
disease progression was examined by comparing the ratio of spleen weight to body 
weight. As expected, infected but untreated animals demonstrated splenomegaly, as 
indicated by the high ratio of spleen weight to body weight compared to the uninfected 
animals (Fig. A2-2). Treatment with the individual drugs had no effect on the ratio of 
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spleen weight to body weight, whereas the combination of decitabine and gemcitabine 
significantly decreased spleen weight compared to the infected but untreated group. 
Spleens from these animals were further examined for histopathological changes 
associated with LP-BM5 infection. Lymphoproliferation was scored using a previously 
described system (49, 97). Briefly, LP-BM5 causes proliferation of lymphoid cells, 
leading to marked expansion of the spleen's white pulp (Fig. A2-3; compare Fig. A2-3A 
and B). Therefore, the histopathological changes in the spleen are based on the ratio of 
white pulp to red pulp, which increases with disease progression. Animals with normal 
spleen histopathology were rated with an N, while animals with increasing 
lymphoproliferation were given a score of 1, 2, or 3, indicating mild, moderate, and 
severe lymphoproliferation, respectively. Table A2-3 demonstrates the number and 
percentage of animals identified as having significant lymphoproliferation (as indicated 
by a score of 2 or 3). None of the uninfected animals had significant lymphoproliferation 
(Table A2-3 and Fig. A2-3A), whereas all spleens from the infected but untreated 
animals had significant lymphoproliferation (Table A2-3 and Fig. A2-3B). Treatment 
with a low dose of decitabine or gemcitabine alone had little effect on spleen 
histopathology compared to that for the untreated but infected animals. In contrast, the 
combination of decitabine and gemcitabine reduced the number of animals identified as 
having significant lymphoproliferation within the spleen (Table A2-3 and Fig. A2-3C). 
 
Treatment with the combination of decitabine and gemcitabine decreases MAIDS-
associated lesions in the lymph nodes.   
Infection with LP-BM5 markedly alters lymph node architecture, making lymph 
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node histopathology a useful indicator of disease progression (232). When detected, the 
lymph nodes were also evaluated for lymphoproliferation, which was scored on the basis 
of the extent to which the lymph node architecture and content differed from that 
expected of a normal, uninfected animal (49). Similar to the spleen scoring system, 
lymph nodes from animals with increasing lymphoproliferation were given scores of 1, 2, 
or 3, indicating mild, moderate, and severe lymphoproliferation, respectively. As 
expected, lymph nodes were difficult to detect in the uninfected animals, whereas lymph 
nodes were enlarged and easily detected in infected but untreated animals. In fact, all of 
the infected but untreated animals demonstrated moderate to severe lymphoproliferation 
(Table A2-3). Treatment of animals with low doses of either decitabine or gemcitabine 
alone had little effect on the percentage of animals with scores of 2 or 3 (Table A2-3). In 
contrast, the combination of decitabine and gemcitabine reduced the percentage of 
animals with lymphoproliferation scores of 2 or 3 compared to animals treated with the 
drugs individually (Table A2-3). 
 
Effects of decitabine and gemcitabine on provirus levels.   
The decrease in LP-BM5-mediated spleen lymphoproliferation and splenomegaly 
suggests that treatment with decitabine and gemcitabine reduced disease progression, 
which is expected to correlate with a reduction in provirus levels in animals treated with 
the combination of decitabine and gemcitabine. To examine provirus levels in the 
infected mice, genomic DNA was isolated from spleen sections and proviral DNA was 
assessed by real-time quantitative PCR using the 18S rRNA gene for normalization. 
Consistent with the histopathology data, neither treatment with decitabine alone nor 
	   112 
treatment with gemcitabine alone reduced provirus levels compared to those in the 
infected but untreated animals (Fig. A2-4). In contrast, the combination of decitabine and 
gemcitabine significantly reduced provirus levels compared to those in infected but 
untreated animals (Fig. A2-4). Although the average provirus level from animals treated 
with both decitabine and gemcitabine was lower than the average provirus level from  
gemcitabine-treated mice, the averages were not statistically significantly different 
between these two treatment groups. 
 
Toxicity of decitabine and gemcitabine determined by changes in body weight and liver 
histopathology.   
Loss of body weight is often used as an indicator of drug-associated toxicity in 
mice. Therefore, all mice were weighed daily, and the change in body weight during the 
course of the study was compared among the treatment groups. None of the treatment 
groups showed a significant loss of body weight during the study, indicating that the 
drugs were well tolerated (data not shown). Similarly, no significant changes in liver 
histopathology were seen in animals treated with the combination of decitabine and 
gemcitabine (data not shown), further supporting the suggestion that these drugs were 
well tolerated in these animals. 
 
Discussion 
 
The high mutation rate combined with the rapid replication of HIV-1 drives the 
emergence of drug resistance under suboptimal treatment conditions. Resistance to one 
drug often confers drug resistance to other drugs in the same drug class, emphasizing the 
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need for new drugs that exploit novel drug targets. Our previous studies demonstrated the 
anti-HIV-1 activity of two FDA-approved drugs, decitabine and gemcitabine (50), that 
appear to inhibit HIV-1 replication through lethal mutagenesis, a process where the 
mutation rate prevents the virus from replicating with enough fidelity to remain viable. In 
this study, we examined the antiretroviral activity of decitabine and gemcitabine in vivo 
using the LP-BM5 MuLV model (a murine AIDS model). This is an efficient model with 
which to examine the in vivo efficacy and toxicity of potential anti-HIV-1 compounds 
and has been validated with approved anti-HIV-1 drugs (67, 165, 190, 191). The disease 
induced by LP-BM5, the infectious agent of MAIDS, has striking similarities to that 
induced by HIV-1, including (i) a dependence on CD4+ T cells for disease initiation, (ii) 
early onset of hypergammaglobulinemia, (iii) loss of B and T cell responses with disease 
progression, (iv) splenomegaly, and (v) increased susceptibility to opportunistic 
infections with disease progression. However, there are notable differences in the 
diseases induced by MuLV and HIV-1, which emphasizes the need to confirm the anti-
MuLV activity in cell culture before moving into the animal model. 
The results presented here show that decitabine and gemcitabine inhibited MuLV 
in cell culture at nanomolar concentrations (Fig. A2-1 and Table A2-1), indicating that 
the LP-BM5/MAIDS model would be a suitable model for examining the efficacies and 
toxicities of these drugs in vivo. While the potency of the individual drugs was similar 
when comparing MuLV and HIV-1, the combination of decitabine and gemcitabine did 
not synergistically inhibit MuLV replication, as determined by the FIC method of 
evaluating synergy (78, 91). This is in contrast to HIV-1, where the combination of 
decitabine and gemcitabine synergistically inhibits HIV-1 replication (50). This 
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difference may indicate that one or both drugs use a different mechanism of action to 
inhibit MuLV compared to the mechanism used to inhibit HIV-1. Similar to the cell 
culture data, the antiviral activities of decitabine and gemcitabine were potentiated in 
vivo according to certain indices of disease progression, including the histopathology of 
spleen and lymph nodes. While the average spleen weight (Fig. A2-2) was reduced in 
animals treated with the combination of decitabine and gemcitabine, the provirus levels 
were not statistically significantly different from those in animals treated with 
gemcitabine alone. Similarly, the provirus levels were not statistically significantly 
different when comparing the animals treated with gemcitabine alone to the animals 
treated with both decitabine and gemcitabine. This lack of potentiation in vivo may be 
due to the variation within each group as well as the small number of animals per 
treatment group, or it may indicate a different mechanism of action when comparing the 
mechanism for these drugs in MuLV infection to those in HIV infection. 
Although MuLV and HIV-1 have similar life cycles and mechanisms of 
replication, they also demonstrate some notable differences that may explain why the 
combination of decitabine and gemcitabine does not act synergistically to inhibit MuLV 
replication in vivo. Since each drug exhibited similar (decitabine) or lower (gemcitabine) 
potencies when comparing activities against MuLV and HIV-1 (Table A2-1), the 
difference in the ability of these drugs to work in combination suggests a difference in 
their antiviral mechanism of action when comparing the mechanism against HIV-1 to that 
against MuLV. 
As previously described (50), decitabine and gemcitabine are proposed to inhibit 
HIV-1 replication by lethal mutagenesis, a process where the mutation rate is increased to 
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a level that prevents viral replication with enough fidelity for the virus to remain viable. 
In the proposed model, decitabine is incorporated into HIV-1 DNA during reverse 
transcription, where it forms noncanonical base pairs, thereby increasing the mutation 
frequency, which can be detected experimentally as an increase in G-to-C mutations in 
the provirus. Gemcitabine's anti-HIV-1 activity is attributed to its inhibition of 
ribonucleotide reductase, which alters deoxynucleoside triphosphate (dNTP) pools, where 
it potentiates decitabine in one of two ways: (i) gemcitabine reduces dCTP levels, thereby 
increasing incorporation of decitabine, a cytidine analog, or (ii) gemcitabine increases 
mutation frequency simply by altering dNTP pools, as would be suggested by previous 
studies that showed that alterations in dNTP pools alone increased HIV-1 mutation 
frequency (17, 149). 
While gemcitabine's reduction or alteration of dNTP pools is likely to increase the 
HIV-1 mutation frequency and/or increase incorporation of decitabine, gemcitabine may 
have a different effect on MuLV replication. For example, the Km of MuLV reverse 
transcriptase (RT) for dNTPs is higher than that for HIV RT, indicating that MuLV is less 
efficient at reverse transcribing viral DNA under conditions of low dNTP levels. Thus, 
gemcitabine's reduction in dNTP pools may inhibit MuLV reverse transcription since 
MuLV is unable to efficiently reverse transcribe under lower dNTP concentrations. In 
contrast, HIV-1 is able to efficiently reverse transcribe viral DNA in the presence of low 
dNTP levels, supporting the suggestion that gemcitabine's anti-HIV activity is likely due 
to an increase in mutation frequency either through alterations in dNTP pools or by 
increases in the incorporation of decitabine. Further biochemical studies will be 
performed to determine if gemcitabine's anti-MuLV activity is due to inhibition of the 
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enzymatic activity of reverse transcriptase. 
 While the antiviral mechanism of gemcitabine is likely to differ when comparing 
MuLV to HIV-1, we do not believe that the antiviral activity of decitabine would differ 
between the two viruses. Decitabine is a cytidine analog that is incorporated into viral 
DNA during reverse transcription. Since the EC50s of decitabine for MuLV and HIV-1 
are similar (Table II-1) and decitabine does not have an altered sugar moiety (a common 
feature of nucleoside RT inhibitors that are less potent in MuLV) (29, 210), there is no 
reason to believe that decitabine would have a different affinity for MuLV RT than HIV-
1 RT. 
Although both decitabine and gemcitabine are used as anticancer drugs, the 
concentrations needed to inhibit viral replication are significantly lower (100 to 1,000 
times lower) than the concentrations needed to inhibit cell growth in vitro. Our results 
show that the doses needed to inhibit viral replication in vivo were well tolerated, with no 
signs of toxicity. The dose of gemcitabine used in cancer chemotherapy in humans is 
1,000 mg/m2 once per week for 7 weeks with a 1-week break (193). In contrast, the dose 
of gemcitabine used in this study, 1 mg/kg, is equivalent to 3 mg/m2 in humans when 
using the body surface area method to convert mouse dosing to human dosing (183). The 
standard decitabine dosing is 15 mg/m2 every 8 h for 3 days, with this cycle repeated 
every 6 weeks for a minimum of 4 cycles. In contrast, the dose of decitabine used in this 
study, 0.1 mg/kg, is equivalent to 0.3 mg/m2, which, like the dose of gemcitabine, is well 
below the therapeutic dose used to inhibit cell growth in humans. 
One limitation for the use of decitabine and gemcitabine as antiretrovirals is that 
both are currently administered intravenously. However, Eli Lilly has developed a 
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gemcitabine prodrug that is currently in clinical trials. Although no decitabine prodrugs 
are currently in clinical trials, it has been demonstrated that with appropriate oral dosing, 
it is possible to achieve pharmacologically relevant plasma concentrations for cancer 
treatment (126). Since the dose of decitabine needed to inhibit HIV replication is 
expected to be lower, it is possible that a prodrug would not be needed, although without 
a prodrug, it is likely that decitabine would have to be taken multiple times per day, 
which is not reasonable for anti-HIV drugs. 
In summary, the findings presented here indicate that the combination of 
decitabine and gemcitabine has potent antiretroviral activity in vivo and ex vivo using the 
LP-BM5/MAIDS model. These findings, along with previous HIV-1 studies in cell 
culture with gemcitabine and decitabine, suggest that this drug combination has broad 
antiretroviral activity that is well tolerated at doses that exhibit antiviral activity. 
 
Materials and Methods 
 
Materials.   
U373-MAGI-CXCR4CEM cells (93, 226) and SC-1/MuLV LP-BM5 cells (42, 97, 
154) were obtained through the NIH AIDS Research and Reference Reagent Program. 
293T cells were obtained from the American Type Culture Collection (ATCC). C57BL/6 
mice were purchased from Jackson Laboratories. Dulbecco modified Eagle medium 
(DMEM) was purchased from MediaGrow. Gemcitabine and decitabine were obtained 
from Carbosynth (Berkshire, United Kingdom). The IgM enzyme-linked immunosorbent 
assay kit was from Assay Designs (Ann Arbor, MI). The plasmids pCR-DEF and pCR-
18S were a kind gift from Mauro Magnani (University of Urbino, Urbino, Italy) and have 
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previously been described (39).  The plasmid pIRES2-EGFP was obtained from Clontech 
(Mountain View, CA). The plasmids pMIGR1, pJK3, pL-VSV-G, and CMV-Tat were 
kind gifts from Vineet Kewal Ramani (NCI-Fredrick). The plasmid pMIGR1 is an MuLV 
vector containing an internal ribosome entry site (IRES)-green fluorescent protein (GFP) 
element (173); pJK3 contains Gag Pol driven off the HIV-1 long terminal repeat (LTR) 
(15).  pL-VSV-G is also driven off the HIV-1 LTR (15), and CMV-Tat allows 
transcription off the HIV-1 LTR (15). 
 
Cell culture.   
SC-1/MuLV LP-BM5 cells and 293T cells were maintained in DMEM containing 
10% fetal clone 3 (FC3) serum (HyClone, Logan, UT) and penicillin-streptomycin at 
37°C in 5% CO2. U373-MAGI-CXCR4CEM cells expressing the CD4 receptor and the 
CXCR4 coreceptor were maintained at 37°C in 5% CO2 in selection medium composed 
of DMEM with 10% FC3, 1 µg/ml puromycin, 0.1 mg/ml hygromycin, and 0.2 mg/ml 
neomycin. 
 
Transfection of 293T cells.   
For production of MuLV, pMIGR1 (13.9 µg), pJK3 (6.9 µg), pL-VSV-G (5.54 
µg), and CMV-Tat (1 µg) were transfected into 293T cells using the calcium phosphate 
method. Forty-eight hours after transfection, cell culture supernatant was collected and 
frozen at −80°C. Similar conditions were used to produce envelope-deficient HIV-1, 
except that 293T cells were transfected with the envelope-deficient HIV containing GFP, 
as previously described (50), and the CXCR4–HIV-1 envelope. 
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Drug treatment/flow cytometry.   
U373-MAGI-CXCR4CEM cells (62,000) were plated in 12-well dishes 24 h prior 
to drug treatment. Twenty-four hours later, gemcitabine, decitabine, or the combination 
of the two was added to the cultures to achieve the concentrations indicated in Fig. A2-1, 
when taking the total volume (500 µl of medium and 500 µl of virus) into account. Two 
hours after drug treatment, 500 µl of virus (either MuLV or HIV) was added to each 
culture such that 20 to 30% of cells were infected in the absence of drug. Twenty-four 
hours later, the medium containing drug (or dimethyl sulfoxide) was removed and 
replaced with fresh medium that did not contain drug. Twenty-four hours after the 
medium change, U373-MAGI-CXCR4CEM cells were collected and analyzed by flow 
cytometry to determine the percentage of cells expressing GFP. Infectivity was 
normalized for each individual experiment by setting the infectivity of the untreated cells 
to 100 for each experiment and then multiplying the data from the other individual 
treatments by the number used to convert the no-drug-treated cells to 100. The 50% 
effective concentrations (EC50s) were determined in GraphPad Prism software by plotting 
the log of drug concentration versus the percent infectivity. The data were fit by 
nonlinear curve fitting using GraphPad Prism. The EC50s and 95% confidence intervals 
were determined in GraphPad using the log inhibitor-versus-response analysis. 
 
Mice.   
Female C57BL/6 mice aged 8 to 10 weeks were purchased from Jackson 
Laboratories (Sacramento, CA) and were housed in standard rodent shoebox caging 
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without a filter top at 22 ± 1°C with a 12-h light/12-h dark cycle, 60% ± 5% humidity, 
and 12 air changes/h. Mice were fed lab chow and water ad libitum. The experimental 
protocol was approved by the U.S. Department of Veterans Affairs Medical Center 
(Minneapolis, MN) IACUC committee (IACUC protocol number 0803A28341). 
 
Infection of mice with LP-BM5 MuLV.   
LP-BM5 was produced from confluent SC-1 cells by filtering the cell supernatant 
through a 0.25-µm-pore-size syringe. The filtered viral supernatant was maintained at 
−80°C until inoculation was performed. C57BL/6 mice were inoculated with two 
intraperitoneal injections of 0.25 ml of viral supernatant or DMEM spaced 3 days apart. 
 
Drug treatment of LP-BM5 MuLV-infected mice.  
 C57BL/6 mice were randomly divided into the groups shown in Table A2-2. All 
mice were treated daily with either gemcitabine, decitabine, both decitabine and 
gemcitabine, or phosphate-buffered saline (PBS) for 8 weeks beginning at 1 week 
postinfection. Animals were weighed daily to achieve proper dosing and to detect 
changes in body mass due to toxicity or infection. Animals did not receive drug treatment 
24 h prior to sacrifice. 
 
Sacrifice of animals.   
Animals were euthanized 8 weeks after drug treatment. Animals were weighed 
and given 100 mg/kg ketamine plus 10 mg/kg xylazine prior to blood collection from the 
submandibular vein. After euthanasia, necropsy was performed to assess gross 
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abnormalities in any organs. Spleens were removed, weighed, and sectioned for 
histopathological analysis as well as for the quantification of proviral levels. Samples of 
lymph nodes (when detected) and liver were collected. Tissues for histopathological 
analysis were fixed in 10% neutral buffered formalin, routinely processed into paraffin, 
sectioned at a thickness of 4 µm, and stained with hematoxylin and eosin. 
 
Spleen and lymph node histology.   
Histological examination and scoring of spleen and lymph nodes were performed 
by an ACVP board-certified veterinary pathologist (M.G.O.) from the University of 
Minnesota Masonic Cancer Center Comparative Pathology Shared Resource. The 
severity of lymphoproliferation was scored using a previously published scoring system 
(49). 
 
Determination of provirus levels from spleen.   
At 8 weeks posttreatment, defective BM5 (BM5def) DNA content was assayed 
from genomic DNA isolated from spleen. Total cellular DNA was isolated using a Roche 
kit as per the manufacturer's instructions. BM5def DNA was quantified by real-time PCR 
assay as previously described (39). The amount of BM5def DNA in spleen was 
calculated by interpolation of the experimentally determined plasmid standard curve and 
was normalized to the amount of 18S rRNA. SYBR green master mix (Applied 
Biosystems) containing genomic DNA (1 µl) and 25 pM primers was used. The primers 
used to detect BM5def were 5′-CCTTTATCGACACTTCCCTTTT-3′ and 5′-
TGGCAGAGGAGG AAGGTT-3′. The primers used to detect 18S rRNA were 5′-
	   122 
GTAACCCGTTGAACC CCATT (forward) and 5′-CCATCCAATCGGTAGTAGGG 
(reverse). Conditions for amplification of BM5def and 18S rRNA included an initial heat 
activation of the polymerase at 95°C for 13 min, followed by 40 cycles of 95°C for 15 s 
and 62°C for 1 min. Samples were then heated to 72°C for 5 min and 95°C for 1 min, 
prior to performing a melt curve analysis from 55°C to 95°C. Data were used for analysis 
only when the standard curve for each primer set yielded an R2 value of >0.99 with an 
efficiency of 90 to 110%, single peaks were observed in the melt curves, and template 
controls gave no detectable amplification. Provirus levels normalized to 18S rRNA levels 
were determined in triplicate for each set of reactions, and 2 to 3 independent assays were 
performed with each sample, depending on the amount of tissue available for analysis. 
 
Determination of drug synergy.   
The fractional inhibitory concentration (FIC) method was used to determine the 
presence or absence of drug synergy as previously described (78, 91). Briefly, the FIC for 
gemcitabine was calculated by dividing the concentration of gemcitabine used in the 
combination treatment by the concentration of gemcitabine required to achieve the same 
degree of inhibition when used alone. The FIC for decitabine was calculated using the 
same equation with decitabine concentrations in place of gemcitabine concentrations. To 
determine synergy, the FIC of each drug was added to obtain a FIC index. A FIC index of 
≤0.7 is indicative of synergy. 
 
Statistical analysis.   
Comparisons among treatment groups for Fig. 1C, 2, and 4 were analyzed by one-
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way analysis of variance (ANOVA), followed by the Tukey-Kramer posttest. Since the 
treatment groups in this study (see Table A2-2) did not contain the same number of 
animals, the Tukey-Kramer posttest was used since this posttest allows comparisons 
among groups containing different numbers of animals. 
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Figure A2-1. 1`Decitabine and gemcitabine have anti-MuLV activity in cell culture. 
MuLV containing GFP was produced from 293T cells and used to infect U373- MAGI-
CXCR4CEM cells that were treated with decitabine (A) or gemcitabine (B) at the 
indicated concentrations. The data represent the average SD of three independent 
experiments. (C) Potentiation of anti-MuLV activity when decitabine (Dec) and 
gemcitabine (Gem) are used in combination. U373-MAGI- CXCR4CEM cells were 
treated with the indicated concentrations of decitabine, gemcitabine, or the combination 
of the two for 2 h prior to infection. The data represent the average SD of three 
independent experiments. Statistical significance was assessed using one-way ANOVA 
with the Tukey-Kramer posttest. Data with the same letters indicate no statistical 
difference, while data with different letters indicate a statistical difference (P<0.05). For 
Determination of drug synergy. The fractional inhibitory concentra-
tion (FIC)method was used to determine the presence or absence of drug
synergy as previously described (11, 13). Briefly, the FIC for gemcitabine
was calculated by dividing the concentration of gemcitabine used in the
combination treatment by the concentration of gemcitabine required to
achieve the same degree of inhibition when used alone. The FIC for de-
citabine was calculated using the same equation with decitabine concen-
trations in place of gemcitabine concentrations. To determine synergy,
the FIC of each drugwas added to obtain a FIC index. A FIC index of!0.7
is indicative of synergy.
Statistical analysis. Comparisons among treatment groups for Fig.
1C, 2, and 4 were analyzed by one-way analysis of variance (ANOVA),
followed by the Tukey-Kramer posttest. Since the treatment groups in this
study (see Table 2) did not contain the same number of animals, the
Tukey-Kramer posttest was used since this posttest allows comparisons
among groups containing different numbers of animals.
RESULTS
The combination of decitabine and gemcitabine inhibitsMuLV
infectivity in cell culture. Our previous studies showed that de-
citabine and gemcitabine have potent anti-HIV-1 activity in cell
culture (8) and that gemcitabine alone has anti-MuLV activity
using theMAIDSmodel (7). To determine if the LP-BM5/MAIDS
modelwas an acceptablemodelwithwhich to examine the efficacy
and toxicity of decitabine and gemcitabine, we first examined the
anti-MuLV activities of the drugs alone and in combination in cell
culture. To do this, MuLV expressing GFP was pseudotyped with
vesicular stomatitis virus glycoprotein G (VSV-G) and then used
to infect target cells that had beenpretreatedwith decitabine, gem-
citabine, or the combination of the two. Flow cytometry was then
used to determine the percentage of infected cells. Figure 1A andB
show that both decitabine and gemcitabine potently inhibit
MuLV infectivity, with EC50s in the nanomolar range. Figure 1C
further demonstrates that the antiviral activity of decitabine and
gemcitabine was potentiated when they were used in combina-
tion. Although the potentiation was not as great as what is seen
with HIV-1 (8), similarities in the potencies of these drugs (Table
1) suggested that the MAIDS model would be a valid model for
examining the efficacy and toxicity of these drugs.
The combination of decitabine and gemcitabine inhibits
progression of MAIDS as detected by spleen weight and histo-
pathology. The data shown in Fig. 1 demonstrate that decitabine
and gemcitabine inhibit MuLV infectivity in cell culture. To de-
termine if decitabine and gemcitabine inhibit MuLV in vivo, mice
were infectedwith LP-BM5 and treated dailywith saline (control),
a lowdose of decitabine, a lowdose of gemcitabine, or lowdoses of
both decitabine and gemcitabine (Table 2). The dose of gemcit-
abine was chosen on the basis of our previously published dose-
response analysis performed in theMAIDSmodel (7). The dose of
decitabine was chosen on the basis of our preliminary studies
showing that 0.15 mg/kg decitabine decreased the ratio of spleen
weight to body weight, while 0.1 mg/kg had minimal effect on the
spleen weight to body weight in mice with MAIDS (data not
shown). These low doses that demonstrated minimal anti-MuLV
activity were chosen so that any potentiation of the drugs when
used in combination would be easily observed, as we have previ-
ously described (8).
Infection ofmicewith LP-BM5 is characterized by lymphopro-
TABLE 1 Anti-MuLV and anti-HIV-1 activities of decitabine and
gemcitabine in cell culturea
Virus Drug EC50 (nM) 95% confidence interval
HIV-1 Decitabine 354 208–601
MuLV Decitabine 361 127–1,029
HIV-1 Gemcitabine 16.3 8.7–31
MuLV Gemcitabine 1.6 1.1–2.5
a The data shown are the average from three independent experiments.
FIG 1 Decitabine and gemcitabine have anti-MuLV activity in cell culture. MuLV containing GFP was produced from 293T cells and used to infect U373-
MAGI-CXCR4CEM cells that were treated with decitabine (A) or gemcitabine (B) at the indicated concentrations. The data represent the average! SD of three
independent experiments. (C) Potentiation of anti-MuLV activity when decitabine (Dec) and gemcitabine (Gem) are used in combination. U373-MAGI-
CXCR4CEM cells were treated with the indicated concentrations of decitabine, gemcitabine, or the combination of the two for 2 h prior to infection. The data
represent the average! SD of three independent experiments. Statistical significance was assessed using one-way ANOVAwith the Tukey-Kramer posttest. Data
with the same letters indicate no statistical difference, while data with different letters indicate a statistical difference (P" 0.05). For example, the results for the
decitabine and gemcitabine treatment groups are not statistically different, while the result for the gemcitabine treatment group is significantly different from that
for cells treated with both decitabine and gemcitabine. ND, no drug.
TABLE 2 Description of treatment groups
Treatment
group Infection status Drug treatment (drug dose/day)
No. of
animals
1 Not infected No drug 4
2 Not infected 1.0 mg/kg gemcitabine 4
3 Not infected 0.1 mg/kg decitabine 4
4 Not infected 1.0 mg/kg gemcitabine# 0.1 mg/kg
decitabine
4
5 Infected No drug 4
6 Infected 1.0 mg/kg gemcitabine 5
7 Infected 0.1 mg/kg decitabine 6
8 Infected 1.0 mg/kg gemcitabine# 0.1 mg/kg
decitabine
8
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Determination of drug synergy. The fractional inhibitory concentra-
tion (FIC)method was used to determine the presence or absence of drug
synergy as previously described (11, 13). Briefly, the FIC for gemcitabine
was calculated by dividing the concentration of gemcitabine used in the
combination treatment by the concentration of gemcitabine required to
achieve the same degree of inhibition when used alone. The FIC for de-
citabine was calculated using the same equation with decitabine concen-
trations in place of gemcitabine concentrations. To determine synergy,
the FIC of each drugwas added to obtain a FIC index. A FIC index of!0.7
is indicative of synergy.
Statistical analysis. Comparisons among treatment groups for Fig.
1C, 2, and 4 were analyzed by one-way analysis of variance (ANOVA),
followed by the Tukey-Kramer posttest. Since the treatment groups in this
study (see Table 2) did not contain the same number of animals, the
Tukey-Kramer posttest was used since this posttest allows comparisons
among groups containing different numbers of animals.
RESULTS
The combination of decitabine and gemcitabine inhibitsMuLV
infectivity in cell culture. Our previous studies showed that de-
citabine and gemcitabine have potent anti-HIV-1 activity in cell
culture (8) and that gemcitabine alone has anti-MuLV activity
using theMAIDSmodel (7). To determine if the LP-BM5/MAIDS
modelwas an acceptablemodelwithwhich to examine the efficacy
and toxicity of decitabine and gemcitabine, we first examined the
anti-MuLV activities of the drugs alone and in combination in cell
culture. To do this, MuLV expressing GFP was pseudotyped with
vesicular stomatitis virus glycoprotein G (VSV-G) and then used
to infect target cells that had beenpretreatedwith decitabine, gem-
citabine, or the combination of the two. Flow cytometry was then
used to determine the percentage of infected cells. Figure 1A andB
show that both decitabine and gemcitabine potently inhibit
MuLV infectivity, with EC50s in the nanomolar range. Figure 1C
further demonstrates that the tiviral activity of decitabine and
gemcitabine was potentiated when they wer used in combina-
tion. Although the pote tiation was not as great as wha is seen
with HIV-1 (8), similarities in the potencies of these drugs (Table
1) suggested that the MAIDS model would be a valid odel for
examining the efficacy and toxicity of these drugs.
The combination of decitabine and gemcitabine inhibits
progression of MAIDS as detected by spleen weight and histo-
pathology. The data shown in Fig. 1 demonstrate that decitabine
and gemcitabine inhibit MuLV infectivity in cell culture. To de-
termine if decitabine and gemcitabine inhibit MuLV in vivo, mice
were infectedwith LP-BM5 and treated dailywith saline (control),
a lowdose of decitabine, a lowdose of gemcitabine, or lowdoses of
both decitabine and gemcitabine (Table 2). The dose of gemcit-
abine was chosen on the basis of our previously published dose-
response analysis performed in theMAIDSmodel (7). The dose of
decitabine was chosen on the basis of our preliminary studies
showing that 0.15 mg/kg decitabine decreased the ratio of spleen
weight to body weight, while 0.1 mg/kg had minimal effect on the
spleen weight to body weight in mice with MAIDS (data not
shown). These low doses that demonstrated minimal anti-MuLV
activity were chosen so that any potentiation of the drugs when
used in combination would be easily observed, as we have previ-
ously described (8).
Infection ofmicewith LP-BM5 is characterized by lymphopro-
TABLE 1 Anti-MuLV and anti-HIV-1 activities of decitabine and
gemcitabine in cell culturea
Virus Drug EC50 (nM) 95% confidence interval
HIV-1 Decitabine 354 208–601
MuLV Decitabine 361 127–1,029
HIV-1 Gemcitabine 16.3 8.7–31
MuLV Gemcitabine 1.6 1.1–2.5
a The data shown are the average from three independent experiments.
FIG 1 Decitabine and gemcitabine have anti-MuLV activity in cell culture. MuLV containing GFP was produced from 293T cells and used to infect U373-
MAGI-CXCR4CEM cells that were treated with decitabine (A) or gemcitabine (B) at the indicated concentrations. The data represent the average! SD of three
independent experiments. (C) Potentiation of anti-MuLV activity when decitabine (Dec) and gemcitabine (Gem) are used in combination. U373-MAGI-
CXCR4CEM cells were treated with the indicated concentrations of decitabine, gemcitabine, or the combination of the two for 2 h prior to infection. The data
represent the average! SD of three independent experiments. Statistical significance was assessed using one-way ANOVAwith the Tukey-Kramer posttest. Data
with the same letters indicate no statistical difference, while data with different letters indicate a statistical difference (P" 0.05). For example, the results for the
decitabine and gemcitabine treatment groups are not statistically different, while the result for the gemcitabine treatment group is significantly different from that
for cells treated with both decitabine and gemcitabine. ND, no drug.
TABLE 2 Description of treatment groups
Treatment
group Infection status Drug treatment (drug dose/day)
No. of
animals
1 Not infected No drug 4
2 Not infected 1.0 mg/kg gemcitabine 4
3 Not infected 0.1 mg/kg decitabine 4
4 Not infected 1.0 mg/kg gemcitabine# 0.1 mg/kg
decitabine
4
5 Infected No drug 4
6 Infected 1.0 mg/kg gemcitabine 5
7 Infected 0.1 mg/kg decitabine 6
8 Infected 1.0 mg/kg gemcitabine# 0.1 mg/kg
decitabine
8
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example, the results for the decitabine and gemcitabine treatment groups are not 
statistically different, while the result for the gemcitabine treatment group is significantly 
different from that for cells treated with both decitabine and gemcitabine. ND, no drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2-2. Ratio of spleen weights to body weights from mice infected with LP- 
BM5 MuLV. Each symbol (circles, squares, and triangles) represents one mouse. The 
average SD within each treatment group is shown. Treatment groups that were 
statistically significantly different from one another, as determined by one-way ANOVA 
with the Tukey-Kramer posttest (P<0.05), are indicated by different letters. For example, 
the uninfected, untreated group and the group uninfected but treated with Gem are 
labeled with “a,” indicating that there is no statistically significant difference. Dec, mice 
treated with 0.1 mg/kg decitabine; Gem, mice treated with 1 mg/kg gemcitabine; Dec 
Gem, mice treated with 0.1 mg/kg of Dec and 1.0 mg/kg Gem. Each data point represents 
liferation, which is detected histologically as a marked expansion
of white pulp in the spleen. This expansion also leads to spleno-
megaly, which is another indicator of disease progression (30).
Thus, to examine the extent of disease progression, spleens were
removed and weighed immediately after sacrifice. The effect of
drug treatment on disease progression was examined by compar-
ing the ratio of spleenweight to bodyweight. As expected, infected
but untreated animals demonstrated splenomegaly, as indicated
by the high ratio of spleen weight to body weight compared to the
uninfected animals (Fig. 2). Treatment with the individual drugs
had no effect on the ratio of spleenweight to bodyweight, whereas
the combination of decitabine and gemcitabine significantly de-
creased spleen weight compared to the infected but untreated
group. Spleens from these animals were further examined for his-
topathological changes associated with LP-BM5 infection. Lym-
phoproliferation was scored using a previously described system
(7, 15). Briefly, LP-BM5 causes proliferation of lymphoid cells,
leading to marked expansion of the spleen’s white pulp (Fig. 3;
compare Fig. 3A and B). Therefore, the histopathological changes
in the spleen are based on the ratio of white pulp to red pulp,
which increases with disease progression. Animals with normal
spleen histopathology were rated with an N, while animals with
increasing lymphoproliferation were given a score of 1, 2, or 3,
indicating mild, moderate, and severe lymphoproliferation, re-
spectively. Table 3 demonstrates the number and percentage of
animals identified as having significant lymphoproliferation (as
indicated by a score of 2 or 3). None of the uninfected animals had
significant lymphoproliferation (Table 3 and Fig. 3A), whereas all
spleens from the infected but untreated animals had significant
lymphoproliferation (Table 3 and Fig. 3B). Treatment with a low
dose of decitabine or gemcitabine alone had little effect on spleen
histopathology compared to that for the untreated but infected
animals. In contrast, the combination of decitabine and gemcit-
abine reduced the number of animals identified as having signifi-
cant lymphoproliferation within the spleen (Table 3 and Fig. 3C).
Treatment with the combination of decitabine and gemcit-
abine decreases MAIDS-associated lesions in the lymph nodes.
Infection with LP-BM5 markedly alters lymph node architecture,
making lymph node histopathology a useful indicator of disease
progression (30).When detected, the lymph nodes were also eval-
uated for lymphoproliferation, which was scored on the basis of
the extent to which the lymph node architecture and content dif-
fered from that expected of a normal, uninfected animal (7). Sim-
ilar to the spleen scoring system, lymph nodes from animals with
FIG 2 Ratio of spleen weights to body weights from mice infected with LP-
BM5 MuLV. Each symbol (circles, squares, and triangles) represents one
mouse. The average ! SD within each treatment group is shown. Treatment
groups that were statistically significantly different from one another, as deter-
mined by one-way ANOVA with the Tukey-Kramer posttest (P " 0.05), are
indicated by different letters. For example, the uninfected, untreated group
and the group uninfected but treated with gemcitabine are labeled with “a,”
indicating that there is no statistically significant difference. Dec, mice treated
with 0.1 mg/kg decitabine; Gem, mice treated with 1 mg/kg gemcitabine;
Dec#Gem, mice tre ted with 0.1 mg/kg of ecitabi e and 1.0 mg/kg gemcit-
abine. Each data point represents a single measurement of spleen weight and
body weight from an individual animal.
FIG 3 Effect of drug treatment on spleen histopathology. Spleen tissue was
fixed in 10% neutral buffered formalin, routinely processed into paraffin, sec-
tioned at a thickness of 4 !m, and stained with hematoxylin and eosin. Each
panel shows spleen at the same magnification, and arrows indicate the white
pulp. (A) Spleen from an uninfected animal; (B) spleen from an infected but
untreated animal showing marked expansion of the white pulp (arrow); (C)
spleen from an infected animal treated with 0.1 mg/kg decitabine and 1.0
mg/kg gemcitabine showing marked attenuation of MuLV-induced lym-
phoproliferation. Bars$ 500 !m.
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a single measurement of spleen weight and body weight from an individual animal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2-3. Effect of drug treatment on spleen histopathology. Spleen tissue was 
fixed in 10% neutral buffered formalin, routinely processed into paraffin, sectioned at a 
thickness of 4um, and stained with hematoxylin and eosin. Each panel shows spleen at 
the same magnification, and arrows indicate the white pulp. (A) Spleen from an 
liferation, which is detected histologically as a marked expansion
of white pulp in the spleen. This expansion also leads to spleno-
megaly, which is another indicator of disease progression (30).
Thus, to examine the extent of disease progression, spleens were
removed and weighed immediately after sacrifice. The effect of
drug treatment on disease progression was examined by compar-
ing the ratio of spleenweight to bodyweight. As expected, infected
but untreated animals demonstrated splenomegaly, as indicated
by the high ratio of spleen weight to body weight compared to the
uninfected animals (Fig. 2). Treatment with the individual drugs
had no effect on the ratio of spleenweight to bodyweight, whereas
the combination of decitabine and gemcitabine significantly de-
creased spleen weight compared to the infected but untreated
group. Spleens from these animals were further examined for his-
topathological changes associated with LP-BM5 infection. Lym-
phoproliferation was scored using a previously described system
(7, 15). Briefly, LP-BM5 causes proliferation of lymphoid cells,
leading to marked expansion of the spleen’s white pulp (Fig. 3;
compare Fig. 3A and B). Therefore, the histopathological changes
in the spleen are based on the ratio of white pulp to red pulp,
which increases with disease progression. Animals with normal
spleen histopathology were rated with an N, while animals with
increasing lymphoproliferation were given a score of 1, 2, or 3,
indicating mild, moderate, and severe lymphoproliferation, re-
spectively. Table 3 demonstrates the number and percentage of
animals identified as having significant lymphoproliferation (as
indicated by a score of 2 or 3). None of the uninfected animals had
significant lymphoproliferation (Table 3 and Fig. 3A), whereas all
spleens from the infected but untreated animals had significant
lymphoproliferation (Table 3 and Fig. 3B). Treatment with a low
dose of decitabine or gemcitabine alone had little effect on spleen
histopathology compared to that for the untreated but infected
animals. In contrast, the combination of decitabine and gemcit-
abine reduced the number of animals identified as having signifi-
cant lymphoproliferation within the spleen (Table 3 and Fig. 3C).
Treatment with the combination of decitabine and gemcit-
abine decreases MAIDS-associated lesions in the lymph nodes.
Infection with LP-BM5 markedly alters lymph node architecture,
making lymph node histopathology a useful indicator of disease
progression (30).When detected, the lymph nodes were also eval-
uated for lymphoproliferation, which was scored on the basis of
the extent to which the lymph node architecture and content dif-
fered from that expected of a normal, uninfected animal (7). Sim-
ilar to the spleen scoring system, lymph nodes from animals with
FIG 2 Ratio of spleen weights to body weights from mice infected with LP-
BM5 MuLV. Each symbol (circles, squares, and triangles) represents one
mouse. The average ! SD within each treatment group is shown. Treatment
groups that were statistically significantly different from one another, as deter-
mined by one-way ANOVA with the Tukey-Kramer posttest (P " 0.05), are
indicated by different letters. For example, the uninfected, untreated group
and the group uninfected but treated with gemcitabine are labeled with “a,”
indicating that there is no statistically significant difference. Dec, mice treated
with 0.1 mg/kg decitabine; Gem, mice treated with 1 mg/kg gemcitabine;
Dec#Gem, mice treated with 0.1 mg/kg of decitabine and 1.0 mg/kg gemcit-
abine. Each data point represents a single measurement of spleen weight and
body weight from an individual animal.
FIG 3 Effect of drug treatment on spleen histopathology. Spleen tissue was
fixed in 10% neutral buffered formalin, routinely processed into paraffin, sec-
tioned at a thickness of 4 !m, and stained with hematoxylin and eosin. Each
panel shows spleen at the same magnification, and arrows indicate the white
pulp. (A) Spleen from an uninfected animal; (B) spleen from an infected but
untreated animal showing marked expansion of the white pulp (arrow); (C)
spleen from an infected animal treated with 0.1 mg/kg decitabine and 1.0
mg/kg gemcitabine showing marked attenuation of MuLV-induced lym-
phoproliferation. Bars$ 500 !m.
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uninfected animal; (B) spleen from an infected but untreated animal showing marked 
expansion of the white pulp (arrow); (C) spleen from an infected animal treated with 0.1 
mg/kg decitabine and 1.0 mg/kg gemcitabine showing marked attenuation of MuLV-
induced lymphoproliferation. Bars 500 um. 
 
 
 
 
 
 
 
 
 
Figure A2-4. Provirus levels in mice infected with LP-BM5 MuLV. Genomic DNA 
was extracted from mouse spleen and quantitative real-time PCR was performed to detect 
the defective MAIDS provirus. Provirus levels were normalized to the level of the 18S 
rRNA gene. Each symbol (squares, circles, and triangles) represents one animal. The 
average SD for each treatment group is shown. The CT (threshold cycle) method was 
used to assess gene expression. Statistical significance was assessed by one-way ANOVA 
with the Tukey- Kramer posttest, with a P value of 0.05 designated significant. Treatment 
groups labeled with different letters are statistically different from one another, while 
treatment groups labeled with the same letter are not statistically different from one 
another. For example, the result for provirus from the untreated animals (no drug [ND]) is 
statistically different from that for provirus from animals treated with both decitabine and 
gemcitabine, while the result for provirus from animals treated with gemcitabine only is 
not statistically different from provirus from animals treated with both decitabine and 
increasing lymphoproliferation were given scores of 1, 2, or 3,
indicating mild, moderate, and severe lymphoproliferation, re-
spectively. As expected, lymph nodes were difficult to detect in the
uninfected animals, whereas lymph nodes were enlarged and eas-
ily detected in infected but untreated animals. In fact, all of the
infected but untreated animals demonstrated moderate to severe
lymphoproliferation (Table 3). Treatment of animals with low
doses of either decitabine or gemcitabine alone had little effect on
the percentage of animals with scores of 2 or 3 (Table 3). In con-
trast, the combination of decitabine and gemcitabine reduced the
percentage of animals with lymphoproliferation scores of 2 or 3
compared to animals treatedwith the drugs individually (Table 3).
Effects of decitabine and gemcitabine on provirus levels.The
decrease in LP-BM5-mediated spleen lymphoproliferation and
splenomegaly suggests that treatment with decitabine and gemcit-
abine reduced disease progression, which is expected to correlate
with a reduction in provirus levels in animals treated with the
combination of decitabine and gemcitabine. To examine provirus
levels in the infectedmice, genomicDNAwas isolated from spleen
sections and proviral DNA was assessed by real-time quantitative
PCR using the 18S rRNA gene for normalization. Consistent with
the histopathology data, neither treatment with decitabine alone
nor treatment with gemcitabine alone reduced provirus levels
compared to those in the infected but untreated animals (Fig. 4).
In contrast, the combination of decitabine and gemcitabine sig-
nificantly reduced provirus levels compared to those in infected
but untreated animals (Fig. 4). Although the average provirus level
from animals treated with both decitabine and gemcitabine was
lower than the average provirus level from gemcitabine-treated
mice, the averages were not statistically significantly different be-
tween these two treatment groups.
Toxicity of decitabine and gemcitabine determined by
changes in body weight and liver histopathology. Loss of body
weight is often used as an indicator of drug-associated toxicity in
mice. Therefore, all mice were weighed daily, and the change in
body weight during the course of the study was compared among
the treatment groups. None of the treatment groups showed a
significant loss of bodyweight during the study, indicating that the
drugs were well tolerated (data not shown). Similarly, no signifi-
cant changes in liver histopathology were seen in animals treated
with the combination of decitabine and gemcitabine (data not
shown), further supporting the suggestion that these drugs were
well tolerated in these animals.
DISCUSSION
The high mutation rate combined with the rapid replication of
HIV-1 drives the emergence of drug resistance under suboptimal
treatment conditions. Resistance to one drug often confers drug
resistance to other drugs in the same drug class, emphasizing the
need for new drugs that exploit novel drug targets. Our previous
studies demonstrated the anti-HIV-1 activity of two FDA-ap-
proved drugs, decitabine and gemcitabine (8), that appear to in-
hibit HIV-1 replication through lethal mutagenesis, a process
where the mutation rate prevents the virus from replicating with
enough fidelity to remain viable. In this study, we examined the
antiretroviral activity of decitabine and gemcitabine in vivo using
the LP-BM5 MuLV model (a murine AIDS model). This is an
efficient model with which to examine the in vivo efficacy and
toxicity of potential anti-HIV-1 compounds and has been vali-
dated with approved anti-HIV-1 drugs (10, 21, 24, 25). The dis-
ease induced by LP-BM5, the infectious agent of MAIDS, has
striking similarities to that induced by HIV-1, including (i) a de-
pendence on CD4! T cells for disease initiation, (ii) early onset of
hypergammaglobulinemia, (iii) loss of B and T cell responses with
disease progression, (iv) splenomegaly, and (v) increased suscep-
tibility to opportunistic infections with disease progression. How-
ever, there are notable differences in the diseases induced by
MuLV and HIV-1, which emphasizes the need to confirm the
anti-MuLV activity in cell culture before moving into the animal
model.
The results presented here show that decitabine and gemcit-
abine inhibitedMuLV in cell culture at nanomolar concentrations
(Fig. 1 and Table 1), indicating that the LP-BM5/MAIDS model
would be a suitable model for examining the efficacies and toxic-
ities of these drugs in vivo. While the potency of the individual
drugs was similar when comparingMuLV andHIV-1, the combi-
nation of decitabine and gemcitabine did not synergistically in-
hibitMuLV replication, as determined by the FICmethod of eval-
FIG 4 Provirus levels in mice infected with LP-BM5 MuLV. Genomic DNA
was extracted from mouse spleen and quantitative real-time PCR was per-
formed to detect the defective MAIDS provirus. Provirus levels were normal-
ized to the level of the 18S rRNA gene. Each symbol (squares, circles, and
triangles) represents one animal. The average" SD for each treatment group
is shown. The##CT (threshold cycle) method was used to assess gene expres-
sion. Statistical significance was assessed by one-way ANOVAwith the Tukey-
Kramer posttest, with a P value of $0.05 designated significant. Treatment
groups labeledwith different letters are statistically different fromone another,
while treatment groups labeled with the same letter are not statistically differ-
ent from one another. For example, the result for provirus from the untreated
animals (no drug [ND]) is statistically different from that for provirus from
animals treated with both decitabine and gemcitabine, while the result for
provirus from animals tr ated with gemcitabine only is ot statistically differ-
ent from provirus from animals treated with both decitabine and gemcitabine.
TABLE 3 Effect of treatment on spleen histopathologya
Treatment group
No. of animals with
histopathology score of 2 or
3/total no. of animals (%)
Spleen Lymph node
Not infected, no drug 0/4 (0) NA
Not infected, decitabine! gemcitabine 0/4 (0) NA
Infected, no drug 4/4 (100) 4/4 100
Infected, gemcitabine 4/5 (80) 4/5 (80)
Infected, decitabine 6/6 (100) 6/6 (100)
Infected, decitabine! gemcitabine 2/8 (25) 2/8 (25)
a See Materials and Methods for scoring system. NA, not enough tissue from these
animals was obtained for histopathological analysis.
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gemcitabine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2-1. Anti-MuLV and anti-HIV-1 activities of decitabine  
and gemcitabine in cell culturea 
Determination of drug synergy. The fractional inhibitory concentra-
tion (FIC)method was used to determine the presence or absence of drug
synergy as previously described (11, 13). Briefly, the FIC for gemcitabine
was calculated by dividing the concentration of gemcitabine used in the
combination treatment by the concentration of gemcitabine required to
achieve the same degree of inhibition when used alone. The FIC for de-
citabine was calculated using the same equation with decitabine concen-
trations in place of gemcitabine concentrations. To determine synergy,
the FIC of each drugwas added to obtain a FIC index. A FIC index of!0.7
is indicative of synergy.
Statistical analysis. Comparisons among treatment groups for Fig.
1C, 2, and 4 were analyzed by one-way analysis of variance (ANOVA),
followed by the Tukey-Kramer posttest. Since the treatment groups in this
study (see Table 2) did not contain the same number of animals, the
Tukey-Kramer posttest was used since this posttest allows comparisons
among groups containing different numbers of animals.
RESULTS
The combination of decitabine and gemcitabine inhibitsMuLV
infectivity in cell culture. Our previous studies showed that de-
citabine and gemcitabine have potent anti-HIV-1 activity in cell
culture (8) and that gemcitabine alone has anti-MuLV activity
using theMAIDSmodel (7). To determine if the LP-BM5/MAIDS
modelwas an acceptablemodelwithwhich to examine the efficacy
and toxicity of decitabine and gemcitabine, we first examined the
anti-MuLV activities of the drugs alone and in combination in cell
culture. To do this, MuLV expressing GFP was pseudotyped with
vesicular stomatitis virus glycoprotein G (VSV-G) and then used
to infect target cells that had beenpretreatedwith decitabine, gem-
citabine, or the combination of the two. Flow cytometry was then
used to determine the percentage of infected cells. Figure 1A andB
show that both decitabine and gemcitabine potently inhibit
MuLV infectivity, with EC50s in the nanomolar range. Figure 1C
further demonstrates that the antiviral activity of decitabine and
gemcitabine was potentiated when they were used in combina-
tion. Although the potentiation was not as great as what is seen
with HIV-1 (8), similarities in the potencies of these drugs (Table
1) suggested that the MAIDS model would be a valid model for
examining the efficacy and toxicity of these drugs.
The combination of decitabine and gemcitabine inhibits
progression of MAIDS as detected by spleen weight and histo-
pathology. The data shown in Fig. 1 demonstrate that decitabine
and gemcitabine inhibit MuLV infectivity in cell culture. To de-
termine if decitabine and gemcitabine inhibit MuLV in vivo, mice
were infectedwith LP-BM5 and treated dailywith saline (control),
a lowdose of decitabine, a lowdose of gemcitabine, or lowdoses of
both decitabine and gemcitabine (Table 2). The dose of gemcit-
abine was chosen on the basis of our previously published dose-
response analysis performed in theMAIDSmodel (7). The dose of
decitabine was chosen on the basis of our preliminary studies
showing that 0.15 mg/kg decitabine decreased the ratio of spleen
weight to body weight, while 0.1 mg/kg had minimal effect on the
spleen weight to body weight in mice with MAIDS (data not
shown). These low doses that demonstrated minimal anti-MuLV
activity were chosen so that any potentiation of the drugs when
used in combination would be easily observed, as we have previ-
ously described (8).
Infection ofmicewith LP-BM5 is characterized by lymphopro-
TABLE 1 Anti-MuLV and anti-HIV-1 activities of decitabine and
gemcitabine in cell culturea
Virus Drug EC50 (nM) 95% confidence interval
HIV-1 Decitabine 354 208–601
MuLV Decitabine 361 127–1,029
HIV-1 Gemcitabine 16.3 8.7–31
MuLV Gemcitabine 1.6 1.1–2.5
a The data shown are the average from three independent experiments.
FIG 1 Decitabine and gemcitabine have anti-MuLV activity in cell culture. MuLV containing GFP was produced from 293T cells and used to infect U373-
MAGI-CXCR4CEM cells that were treated with decitabine (A) or gemcitabine (B) at the indicated concentrations. The data represent the average! SD of three
independent experiments. (C) Potentiation of anti-MuLV activity when decitabine (Dec) and gemcitabine (Gem) are used in combination. U373-MAGI-
CXCR4CEM cells were treated with the indicated concentrations of decitabine, gemcitabine, or the combination of the two for 2 h prior to infection. The data
represent the average! SD of three independent experiments. Statistical significance was assessed using one-way ANOVAwith the Tukey-Kramer posttest. Data
with the same letters indicate no statistical difference, while data with different letters indicate a statistical difference (P" 0.05). For example, the results for the
decitabine and gemcitabine treatment groups are not statistically different, while the result for the gemcitabine treatment group is significantly different from that
for cells treated with both decitabine and gemcitabine. ND, no drug.
TABLE 2 Description of treatment groups
Treatment
group Infection status Drug treatment (drug dose/day)
No. of
animals
1 Not infected No drug 4
2 Not infected 1.0 mg/kg gemcitabine 4
3 Not infected 0.1 mg/kg decitabine 4
4 Not infected 1.0 mg/kg gemcitabine# 0.1 mg/kg
decitabine
4
5 Infected No drug 4
6 Infected 1.0 mg/kg gemcitabine 5
7 Infected 0.1 mg/kg decitabine 6
8 Infected 1.0 mg/kg gemcitabine# 0.1 mg/kg
decitabine
8
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Table A2-2. Description of treatment groups 
Determination of drug synergy. The fractional inhibitory concentra-
tion (FIC)method was used to determine the presence or absence of drug
synergy as previously described (11, 13). Briefly, the FIC for gemcitabine
was calculated by dividing the concentration of gemcitabine used in the
combination treatment by the concentration of gemcitabine required to
achieve the same degree of inhibition when used alone. The FIC for de-
citabine was calculated using the same equation with decitabine concen-
trations in place of gemcitabine concentrations. To determine synergy,
the FIC of each drugwas added to obtain a FIC index. A FIC index of!0.7
is indicative of synergy.
Statistical analysis. Comparisons among treatment groups for Fig.
1C, 2, and 4 were analyzed by one-way analysis of variance (ANOVA),
followed by the Tukey-Kramer posttest. Since the treatment groups in this
study (see Table 2) did not contain the same number of animals, the
Tukey-Kramer posttest was used since this posttest allows comparisons
among groups containing different numbers of animals.
RESULTS
The combination of decitabine and gemcitabine inhibitsMuLV
infectivity in cell culture. Our previous studies showed that de-
citabine and gemcitabine have potent anti-HIV-1 activity in cell
culture (8) and that gemcitabine alone has anti-MuLV activity
using theMAIDSmodel (7). To determine if the LP-BM5/MAIDS
modelwas an acceptablemodelwithwhich to examine the efficacy
and toxicity of decitabine and gemcitabine, we first examined the
anti-MuLV activities of the drugs alone and in combination in cell
culture. To do this, MuLV expressing GFP was pseudotyped with
vesicular stomatitis virus glycoprotein G (VSV-G) and then used
to infect target cells that had beenpretreatedwith decitabine, gem-
citabine, or the combination of the two. Flow cytometry was then
used to determine the percentage of infected cells. Figure 1A andB
show that both decitabine and gemcitabine potently inhibit
MuLV infectivity, with EC50s in the nanomolar range. Figure 1C
further demonstrates that the antiviral activity of decitabine and
gemcitabine was potentiated when they were used in combina-
tion. Although the potentiation was not as great as what is seen
with HIV-1 (8), similarities in the potencies of these drugs (Table
1) suggested that the MAIDS model would be a valid model for
examining the efficacy and toxicity of these drugs.
The combination of decitabine and gemcitabine inhibits
progression of MAIDS as detected by spleen weight and histo-
pathology. The data shown in Fig. 1 demonstrate that decitabine
and gemcitabine inhibit MuLV infectivity in cell culture. To de-
termine if decitabine and gemcitabine inhibit MuLV in vivo, mice
were infectedwith LP-BM5 nd treated dailywith salin (control),
a lowdose f decitabine, a lowd se of gemcitabine, or lowdoses of
both decitabine and g mcitabine (Table 2). The dose of g mcit-
abine was chosen on the basis of our previously published dose-
response analysis performed in theMAIDSmodel (7). The dose of
decitabine was chosen on the basis of our preliminary studies
showing that 0.15 mg/kg decitabine decreased the ratio of spleen
weight to body weight, while 0.1 mg/kg had minimal effect on the
spleen weight to body weight in mice with MAIDS (data not
shown). These low doses that demonstrated minimal anti-MuLV
activity were chosen so that any potentiation of the drugs when
used in combination would be easily observed, as we have previ-
ously described (8).
Infection ofmicewith LP-BM5 is characterized by lymphopro-
TABLE 1 Anti-MuLV and anti-HIV-1 activities of decitabine and
gemcitabine in cell culturea
Virus Drug EC50 (nM) 95% confidence interval
HIV-1 Decitabine 354 208–601
MuLV Decitabine 361 127–1,029
HIV-1 Gemcitabine 16.3 8.7–31
MuLV Gemcitabine 1.6 1.1–2.5
a The data shown are the average from three independent experiments.
FIG 1 Decitabine and gemcitabine have anti-MuLV activity in cell culture. MuLV containing GFP was produced from 293T cells and used to infect U373-
MAGI-CXCR4CEM cells that were treated with decitabine (A) or gemcitabine (B) at the indicated concentrations. The data represent the average! SD of three
independent experiments. (C) Potentiation of anti-MuLV activity when decitabine (Dec) and gemcitabine (Gem) are used in combination. U373-MAGI-
CXCR4CEM cells were treated with the indicated concentrations of decitabine, gemcitabine, or the combination of the two for 2 h prior to infection. The data
represent the average! SD of three independent experiments. Statistical significance was assessed using one-way ANOVAwith the Tukey-Kramer posttest. Data
with the same letters indicate no statistical difference, while data with different letters indicate a statistical difference (P" 0.05). For example, the results for the
decitabine and gemcitabine treatment groups are not statistically different, while the result for the gemcitabine treatment group is significantly different from that
for cells treated with both decitabine and gemcitabine. ND, no drug.
TABLE 2 Description of treatment groups
Treatment
gr up I fection status Drug treatment (drug dos /day)
No. of
animals
1 Not infected No drug 4
2 Not infected 1.0 mg/kg gemcitabine 4
3 Not infected 0.1 mg/kg decitabine 4
4 Not infected 1.0 mg/kg gemcitabine# 0.1 mg/kg
decitabine
4
5 Infected No drug 4
6 Infected 1.0 mg/kg gemcitabine 5
7 Infected 0.1 mg/kg decitabine 6
8 Infected 1.0 mg/kg gemcitabine# 0.1 mg/kg
decitabine
8
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Table A2-3. Effect of treatment on spleen histopathologya 
increasing lymphoproliferation were given scores of 1, 2, r 3,
indicating mild, m d rate, and seve e lymphoproliferation, re-
spectively. As exp cted, lymph nodes were difficult to detect in the
ninfected animals, hereas lymph nodes were enlarged and eas-
ily detected in infected but untreated animals. In fact, all of the
infected but untreated animals demonstrated moderate to severe
lymphoproliferation (Table 3). Treatment of animals with low
doses of either decitabine or gemcitabine alone had little effect on
the percentage of animals with scores of 2 or 3 (Table 3). In con-
trast, the combination of decitabine a d gemcitabine reduced the
percentage of animals with lymphoproliferatio scores of 2 or 3
compared to animals treatedwith the drugs individually (Table 3).
Effects of decitabine and gemcitabine on provirus levels.The
decrease in LP-BM5-mediated spleen lymphoproliferation and
splenomegaly suggests that treatment with deci bine an g mcit-
abine reduced disease progression, which is expected to correlate
with a reduction in provirus levels in animals treated with the
combination of decitabine and gemcitabine. To examine provirus
levels in the infectedmice, genomicDNAwas isolated from spleen
sections a proviral DNA was ass ssed by real-time quantitative
PCR using t e 18S rRNA gene for normalizati n. Consistent with
the histopathology data, neither treatment with decitabine alone
nor treatment with gemcitabine alone reduced provirus levels
compared to those in the infected but untreated animals (Fig. 4).
In contrast, the combination of decitabine and gemcitabine sig-
nificantly reduced provirus levels compared to those in infected
but untreated animals (Fig. 4). Although the average provirus level
from animals treated with both decitabine and gemcitabine was
lower than the average provirus level from gemcitabine-treated
mice, the averages were not statistically significantly different be-
tween these two treatment groups.
Toxicity of decitabine and gemcitabine determined by
changes in body weight and liver histopathology. Loss of body
weight is often used as an indicator of drug-associated toxicity in
mice. Therefore, all mice were weighed daily, and the change in
body weight during the course of the study was compared among
the treatment groups. None of the treatment groups showed a
significant loss of bodyweight during the study, indicating that the
drugs were well tolerated (data not shown). Similarly, no signifi-
cant changes in liver histopathology were seen in animals treated
with the combination of decitabine and gemcitabine (data not
shown), further supporting the suggestion that these drugs were
well tolerated in these animals.
DISCUSSION
The high mutation rate combined with th rapid replication of
HIV-1 drives the emergence of drug resistance un r suboptimal
treatment conditions. Resistance to one drug often confers drug
re istance to other drugs in the same drug clas , emphasizing the
need for new drugs that exploit novel drug targets. Our previous
studi s demons rated the anti-HIV-1 a tivity of two FDA- p-
proved drugs, d citabine and gemcitabine (8), that appear to in-
hibit HIV-1 r plication through lethal mutagenesis, a process
where the mutation rate prevents the virus from replicating with
enough fidelity to remain viable. In this study, we examined the
antiretroviral activity of decitabine and gemcitabine in vivo using
the LP-BM5 MuLV model (a murine AIDS model). This is an
efficient model with which to examine the in vivo efficacy and
toxicity of potential anti-HIV-1 compounds and has been vali-
dated with approved anti-HIV-1 drugs (10, 21, 24, 25). The dis-
ease induced by LP-BM5, the infectious agent of MAIDS, has
striking similarities to that induced by HIV-1, including (i) a de-
pendence on CD4! T cells for disease initiation, (ii) early onset of
hypergammaglobulinemia, (iii) loss of B and T cell responses with
disease progression, (iv) splenomegaly, and (v) increased suscep-
tibility to opportunistic infections with disease progression. How-
ever, there are notable differences in the diseases induced by
MuLV and HIV-1, which emphasizes the need to confirm the
anti-MuLV activity in cell culture before moving into the animal
model.
T resul s presented here s ow that deci abine and gemcit-
abine inhibitedMuLV in cell culture at nanomolar concentrations
(Fig. 1 and Table 1), indicating that the LP-BM5/MAIDS model
would be a suitable model for examining the efficacies and toxic-
ities of these drugs in vivo. While the potency of the individual
drugs was similar when comparingMuLV andHIV-1, the combi-
nation of decitabine and gemcitabine did not synergistically in-
hibitMuLV replication, as determined by the FICmethod of eval-
FIG 4 Provirus levels in mice infected with LP-BM5 MuLV. Genomic DNA
was extracted from mouse spleen and quantitative real-time PCR was per-
formed to detect the defective MAIDS provirus. Provirus levels were normal-
ized to the level of the 18S rRNA gene. Each symbol (squares, circles, and
triangles) represents one animal. The average" SD for each treatment group
is shown. The##CT (threshold cycle) method was used to assess gene expres-
sion. Statistical significance was assessed by one-way ANOVAwith the Tukey-
Kramer posttest, with a P value of $0.05 designated significant. Treatment
groups labeledwith different letters are statistically different fromone another,
while treatment groups labeled with the same letter are not statistically differ-
ent from one another. For example, the result for provirus from the untreated
animals (no drug [ND]) is statistically different from that for provirus from
animals treated with both decitabine and gemcitabine, while the result for
provirus from animals treated with gemcitabine only is not statistically differ-
ent from provirus from animals treated with both decitabine and gemcitabine.
TABLE 3 Effect of treatme t on spleen histopathologya
Treatment group
No. of animals with
histopa ology score of 2 or
3/total no. of animals (%)
Spleen Lymph node
Not infected, no drug 0/4 (0) NA
Not infected, decitabine! gemcitabi e 0/4 (0) NA
Infected, no drug 4/4 (100) 4/4 100
Infected, gemcitabine 4/5 (80) 4/5 (80)
Infected, decitabine 6/6 (100) 6/6 (100)
Infected, decitabine! gemcitabine /8 (25) 2/8 (25)
a See Materi ls and Methods for scor ng system. NA, not enough tissue from these
animals was obtained for histopathological analysis.
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Introduction 
 
 The quasispecies model describes how rapidly evolving viruses exist within a 
mutation–selection balance (35, 77).  The model asserts that high viral mutation rates 
drive the formation and maintenance of the quasispecies and allow for these viruses to 
readily adapt to a changing environment. However, the quasispecies also presents a 
significant obstacle in the successful treatment of rapidly evolving viruses such as human 
immunodeficiency virus type 1 (HIV-1). It has been predicted that a purposeful increase 
in viral mutation rate would cause an irreversible meltdown of the genetic information 
(11, 54, 84, 209).  This process, termed extinction catastrophe, has been exploited as a 
novel therapeutic approach, yet findings from short-term cell-culture-based studies fail to 
predict the shortcomings observed clinically. For example, RNA viruses have been 
lethally mutagenized in vitro by various nucleoside analogs, including ribavirin, 5-
flurouracil, and 5-azacytidine (5-AZC) (59, 206).  Specifically, ribavirin was shown to 
lethally mutagenize poliovirus and hepatitis C virus (53, 54), while 5-flurouracil was 
shown to be an active viral mutagen against foot-and-mouth disease virus (206).  The 
compound 5-AZC was also demonstrated to lethally mutagenize HIV-1 in cell culture 
through induction of G-to-C mutations (59).  A related compound, KP1212 was shown to 
lethally mutate HIV-1 in cell culture; however, the compound did not decrease viral loads 
or increase viral mutation loads in patient samples (94, 158).  Similarly, abundant 
mutations were identified in patient-derived hepatitis C virus, suggesting purposeful 
mutagenesis by the ribavirin–interferon regimen (56); however, a second study showed 
only a transient increase in mutation rate in patients on ribavirin monotherapy, indicating 
that lethal mutagenesis may not be the sole antiviral mechanism (136). 
	   131 
 Lethal mutagenesis can be induced not only by drugs but also by the APOBEC3 
(A3) family of proteins (21, 46, 95, 127, 140, 144, 196, 218, 236, 238).  These proteins 
have emerged as innate restriction factors that induce targeted hypermutagenesis of viral 
genomes. While their importance is suggested by the rapid evolutionary expansion of the 
A3 locus, most APOBEC3 proteins seem to be active against retroviruses and 
retroelements. However, A3G and A3F exert potent anti-HIV-1 activity through lethal 
mutagenesis (reviewed in Refs. (5, 188)).  Both A3G and A3F, along with A3B, possess 
the capacity to restrict other retroviral genera, including murine leukemia virus 
(gammaretrovirus) (21, 95, 140), human T-lymphotrpic virus 1 (deltaretrovirus) (196), 
foamy viruses (spumavirus) (64), and equine infectious anemia virus (lentivirus) (140).  
In addition to retroviruses, hepatitis B virus (hepadnavirus) and adeno-associated virus 
(parvovirus) are also susceptible to members of the A3 family (46, 218). 
 The mechanism by which A3G hypermutates retroviral genomes has been well 
established (reviewed in Refs. (47, 96, 139)). Briefly, A3G is packaged into budding 
virions, after which the virion matures and binds to a target cell. In the target cell, A3G 
deaminates cytosines (C) present in the single- stranded negative-sense viral DNA during 
reverse transcription process. The deamination of C leads to uracil (U), and this pre-
mutatgenic lesion can template for adenine (A) during plus-strand DNA synthesis rather 
than guanine (G). The deamination of C by A3G during reverse transcription generates 
G-to-A mutation signatures in the resulting provirus (95).  However, the ability of A3G to 
mutate the viral genome depends on its ability to overcome viral countermeasures, such 
as the HIV-1 Vif protein. In a host-specific manner, Vif targets A3 proteins for 
proteosomal degradation. However, through saturating A3G levels or less stringent Vif 
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alleles, A3G proteins can gain access to the nascent virions and mutate the viral genome 
as described above. The ability of A3G to escape Vif is evident in patient samples where 
signature mutations indicative of A3G have been observed (167, 225).  A deaminase- 
independent mechanism has been proposed for HIV-1, but this model remains 
controversial (20, 34, 199, 204). 
 Many of the compounds that lethally mutagenize HIV-1 are C analogs including 
KP1212, 5-OH-dC, and 5-AZC (59, 94, 132).  Competitive replacement by C mutagens 
could interfere with A3G-mediated deamination. For instance, the kinetics of 5-AZC- and 
A3G-generated mutations indicate that 5-AZC incorporation into viral DNA precedes the 
ability of A3G to catalyze cytosine deamination. Replacement of C with 5-AZC may 
remove potential sites that would otherwise be mutated by A3G. Therefore, compounds 
targeting C residues may not be the most efficient at inducing lethal mutagenesis in the 
presence of APOBEC3 proteins. To examine this type of interaction, we investigated 
mutagen- specific alterations to both mutation spectra as well as the mutational load. 
Interestingly, our results show that exposure of HIV-1 to both 5-AZC and A3G 
concomitantly increased the frequency of G- to-A mutations at the expense of G-to-C 
mutagenesis. Furthermore, the diminution of G-to-C mutations was dependent on A3G 
catalytic activity. This is the first demonstration for potentiation of the mutagenic effect 
of a cytosine analog by A3G expression, resulting in concomitant HIV-1 lethal 
mutagenesis. 
Results  
 
Concomitant antiviral effects of 5-AZC and A3G 
 A single-cycle vector assay was used to assess the concomitant antiviral effect of 5-
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AZC and A3G (Fig. A3-1). This HIV-1 vector system utilizes a dual reporter cassette to 
monitor both infection efficiency and mutant frequency. Infectious vector virus was 
produced by transfection of an HIV-1 vector (pHIG) and vesicular stomatitis virus 
glycoprotein (VSV-G) envelope expression plasmid into previously characterized 293 
cell lines that stably express A3G at physiologically relevant levels (192).  These cell  
lines, previously characterized by our laboratory, were used in this study: (1) a 293-A3G 
null vector control that does not express A3G, (2) a cell line expressing low A3G levels 
(293-A3G clone 4), and (3) a cell line expressing high A3G levels (293-A3G clone 10) 
(192).  Virus produced from the A3G-expressing cells results in packaging of A3G into 
the virus particles. These virus particles are used to infect permissive target cells that 
have been treated with a range of 5-AZC (10–200 µM). Our assay allows for both HIV-1 
mutagens to be present during reverse transcription. Any decrease in antiviral activity can 
be assessed by flow cytometry as a decrease in double-positive murine heat-stable 
antigen (HSA) + /green fluorescent protein (GFP)+ -expressing cells. 
 Similar to previous reports (95, 140, 238), A3G decreased HIV-1 replication (Fig. 
A3-2A), and this decrease was greater as the expression of A3G increased (293-A3G 
clone 4 versus 293-A3G clone 10) (192).  Specifically, vector virus produced from 293-
A3G clone 4 reduced viral infectivity by one-third, while virus produced from 293-A3G 
clone 10 reduced viral infectivity by two-thirds. When permissive target cells were 
treated with various concentrations of 5- AZC (i.e., 10 µM, 50 µM, or 200 µM), A3G 
increased 5-AZC's antiviral effect (Fig. A3-2A). For example, virus treated with 50 µM 
5-AZC reduced infectivity by 2- fold compared to vector alone; however, this inhibitory 
effect was potentiated by 3.4- and 5.8- fold with concomitant exposure to 293-A3G clone 
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4 and 293-A3G clone 10, respectively (Fig. A3-2A). This same trend was observed with 
concomitant treatment of 200 µM 5-AZC and increasing amounts of A3G, indicating that 
A3G increased the inhibitory activity of 5-AZC (Fig. A3-2A). 
 The concept of lethal mutagenesis suggests that decreased infectivity should 
correlate with an increase in mutation frequency. Therefore, we investigated if the loss of 
infectivity seen in Fig. A3-2A correlated with an increase in mutant frequency. To do 
this, we used the single-cycle assay, but the data were analyzed for expression of marker 
genes. For example, targets cells expressing a single marker gene (i.e., [HSA+/GFP−] or 
[HSA−/GFP+]) would likely indicate a loss-in-phenotype mutation that occurred during 
reverse transcription. As indicated in Fig. A3-2B, A3G expression increased viral mutant 
frequency. Similarly, the mutant frequency was significantly increased when target cells 
were treated with either 50 µM or 200 µM 5-AZC. Again, the 5-AZC-mediated increase 
in mutant frequency was further increased by A3G expression. For instance, vector virus 
treated with 50 µM 5-AZC increased the mutant frequency by 3.2-fold, while 
concomitant A3G exposure potentiated this effect by 4.3- and 4.6-fold, 293-A3G clone 4 
and 293-A3G clone 10, respectively (Fig. A3-2B). Similar trends were found with 
concomitant A3G exposure in the presence of 200 µM 5-AZC (Fig. A3-2B). 
 
Concomitant exposure to 5-AZC and A3G alters HIV-1 mutation spectra 
 The increase in mutant frequency suggests that viral genomes were heavily mutated 
by the action of A3G and 5-AZC. Since both mutagens target cytosines and induce 
distinct mutations, we examined proviruses that had been exposed to either A3G or 5-
AZC (EC50 concentration) or to both. Since the resulting proviruses were expected to 
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have a very high mutational load, primers were designed to minimize PCR bias caused by 
heavily mutated sequences (as described in Materials and Methods).  Table A3-1 shows 
the cumulative mutation spectra with each mutation type denoted as the percentage of 
total number of mutations. As expected, A3G levels correlated to an increase in the 
percentage of G-to-A mutations. As an example, 65% of all mutations identified were G 
to A when sequencing proviruses exposed to low A3G levels (i.e., 293-A3G clone 4), 
whereas 70% of mutations were of mutations per viral clone (Table A3-2 and Fig. A3-
3A-F). As expected, the G-to-A mutational load increased from 0.03% to 0.35% and 
0.37%, when comparing viral clones unexposed to A3G to those exposed to A3G low and 
A3G high levels, respectively (Table A3-2). The G-to-C mutational load was also 
increased to 0.31% relative to no drug controls (Table A3-2). Unexpectedly, the G-to-A 
mutational load was 18% higher (p = 0.026) when A3G and 5-AZC exposures were 
combined, compared to this amount of A3G alone (Table A3-2). Moreover, the 
concomitant exposure of A3G and 5-AZC also diminished the G-to-C mutational load by 
36% (p=0.013) compared to drug alone. These results suggest that 5-AZC and A3G may 
interact to influence the G-to-A and G-to-C mutational load. 
 Since both A3G and 5-AZC induce mutations by targeting C residues, we next 
examined viral mutation spectra of combined expression of A3G with 5-AZC treatment. 
As shown in Table A3-1, viral genomes exposed to the 5-AZC EC50 with increasing 
levels of A3G significantly decreased the percentage of G-to-C transversion mutations 
(Fig. A3-3B, E, F). In particular, 61% of the mutations in viruses that were exposed to 5-
AZC alone were G-to-C mutations, whereas 41% of the mutations in viruses exposed to 
both 5-AZC and a low level of A3G were G-to-C mutations. Finally, only 20% of 
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mutations in viruses exposed to both 5-AZC and a high level of A3G were G-to-C 
mutations. The general increase in mutational loads suggests that A3G and 5-AZC 
significantly increased the viral mutation frequency, which is consistent with lethal 
mutagenesis. 
 The hotspot prediction algorithm CLUSTERM was used to determine whether 5-
AZC-induced G- to-C mutations or A3G-induced G-to-A mutations were influenced by 
preference sites (i.e., hotspots). As expected by the random substitution of 5-AZC for C 
bases, the hotspot prediction algorithm found no G-to-C hotspots within GFP. 
Alternatively, as described in previous A3G studies, the clustering of G-to-A mutations at 
GG dinucleotides was predicted by CLUSTERM (185, 186).  Of the 51 di-G nucleotide 
positions in the plus-strand DNA of GFP, 26 bases were found to represent A3G 
preference sites. 
 
Disparate mutational load with concomitant 5-AZC and A3G exposure 
 While mutational spectra analysis offers a population view of the 5-AZC- and 
A3G-exposed virus, analysis of mutational load can discern differences among individual 
viral clones. The mutational load was determined for each mutation type of interest (i.e., 
G to C and G to A) by finding the mean number of mutations per viral clone (Table A3-2 
and Fig. A3-3A-F). As expected, the G-to-A mutational load increased from 0.03% to 
0.35% and 0.37%, when comparing viral clones unexposed to A3G to those exposed to 
A3G low and A3G high levels, respectively (Table A3-2). The G-to-C mutational load 
was also increased to 0.31% relative to no drug controls (Table A3-2). Unexpectedly, the 
G-to-A mutational load was 18% higher (p = 0.026) when A3G and 5-AZC exposures 
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were combined, compared to this amount of A3G alone (Table A3-2). Moreover, the 
concomitant exposure of A3G and 5-AZC also diminished the G-to-C mutational load by 
36% (p=0.013) compared to drug alone. These results suggest that 5-AZC and A3G may 
interact to influence the G-to-A and G-to-C mutational load. 
 
A3G catalytic activity is required for reductions in 5-AZC-mediated G-to-C mutations 
 Since A3G has been shown to possess catalytic-independent antiviral activity, we 
next examined the effect of a catalytically inactive A3G on the infection efficiency. It 
was observed that the A3G_E259Q mutant had no effect on either the efficiency of 
infection or mutant frequency compared to that of vector only (Fig. A3-4A and B). 
Importantly, there was no difference in G-to-C mutation spectra under concomitant 
exposure to 5- AZC and A3G_E259Q compared to that of 5-AZC alone, that is, 57% 
versus 59%, respectively (Table A3-3). Immunoblot analysis of A3G virion incorporation 
demonstrated that A3G_E259Q was as efficiently packaged into HIV-1 particles as wild-
type A3G, indicating that the lack of efficient incorporation of A3G_E259Q was not 
responsible for these observations (Fig. A3-4C). Taken together, these data indicate that 
A3G catalytic activity is necessary in order to observe the decrease in infection efficiency 
as well as the potentiation of the mutagenic effect of 5-AZC by A3G expression, which 
results in concomitant HIV-1 lethal mutagenesis. 
 
Discussion 
 
 Lethal mutagenesis as a therapeutic strategy has gained momentum, especially after 
ribavirin and KP-1212 gained clinical use (53, 158).  Most of the exploratory HIV-1 
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mutagens target C analogs including the triazole base 5-AZC. Since the APOBEC3 
protein subfamily also targets C bases for deamination, these mutagens may exert 
redundant mechanisms when combined. This would suggest that compounds targeting C 
bases could be less effective mutagens in the presence of A3G. Alternatively, 
incorporation of 5-AZC could have secondary effects by altering A3G substrate 
specificity or target-site architecture. In this study, we examined concomitant exposure of 
HIV-1 to 5-AZC and A3G. The ability of A3G to induce G-to-A hypermutagenesis 
provides an example of an evolutionary conserved mechanism that eliminates HIV-1 
infectivity by lethal mutagenesis. Editing of retroviral genomes by A3G in the face of 
concomitant mutagen exposure has not been previously explored. 
 5-AZC is a first-in-class hypomethylating agent as substitution of N-5 can no 
longer be methylated (114).  The ribonucleoside 5-AZC undergoes anabolic metabolism 
to the corresponding triphosphate, but a fraction is converted to the nucleotide 
triphosphate 5-aza-2′-deoxycytidine and is substituted for dCTP in DNA (131, 168).  
Because aza-pyrimidines are chemically unstable, ring-opened intermediates may have 
the potential for non-Watson–Crick base pairing, leading to base mispairing (187).  In 
fact, 5-AZC has been implicated in several studies as a mutagen, specifically introducing 
a rare GC-to-CG transversion type (57, 59, 109, 171).  Experimentation with an HIV-1 
vector system found that 5-AZC increased the preponderance of only G-to-C mutations, 
suggesting that the mutagenic product of azacytosine is able to template for C:C 
mispairings when incorporated during minus-strand DNA synthesis (59). 
 Intriguingly, the majority of retroviral minus- strand DNA is also transiently single-
stranded during replication, and single-stranded DNA (ssDNA) is the preferential 
	   139 
substrate of the APOBEC3 subfamily (95).  During HIV-1 reverse transcription, A3G 
gains access to ssDNA, targeting cytosine residues for deamination to pre-mutagenic 
lesions (234).  These kinetics, of A3G and 5-AZC-based mutagenesis, suggest that access 
to minus-strand ssDNA by A3G is subsequent to reverse transcriptase incorporation of 5-
aza-2′-deoxycytidine during minus-strand DNA synthesis. 
 The interaction between A3G and the noncanonical 5-azacytosine base could result 
in two possible obvious outcomes: (1) A3G is unable to engage 5- azacytosine or its ring-
opened decomposition products. This would be observed as a decrease in G-to-A 
mutations with no difference in the number of G-to- C mutations; 5-azacytosine would 
effectively antagonize A3G deaminase activity. (2) A3G is able to catalyze deamination 
of 5-azacytosine to 5-azauracil, and this uracil analog results in increased G-to-A 
mutations at the expense of G-to-C mutation types. However, other mechanisms cannot 
be excluded at this time, such as the ability of 5- azacytosine (or its ring-opened products) 
to alter local DNA secondary structure and subsequent ssDNA availability or the 
influence of 5-azacytosine on A3G processivity or substrate specificity due to close-
proximity base interactions, as suggested by Rausch et al (182). 
 In order to better understand mutation type- specific differences of concomitant 
mutagen exposure, we sequenced proviral DNAs. The G-to-A mutational load (i.e., 
number of G-to-A mutations/ proviral clone) was increased up to 18% in virus exposed to 
both 5-AZC and A3G, as compared to A3G exposure alone. This effect was at the 
expense of a 36% decrease in the 5-AZC-induced mutational load (i.e., number of G-to-C 
mutations/sequence). These results suggest a model whereby 5-AZC incorporation into 
retroviral DNA causes complex interactions with A3G, to inversely shift the G-to-A and 
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G-to-C mutational loads. Furthermore, the E259Q catalytically inactive A3G, in 
conjunction with 5-AZC, showed no difference in G-to-C transversions compared to drug 
alone, suggesting a requirement for fully functional A3G in order to observe the increase 
in G-to-A mutations at the expense of G-to-C mutations. 
 One potential concern regarding the sequencing data is biased amplification due to 
the oligonucleotides selected. Particular attention to primer design helped ensure 
universal and unbiased PCR. For example, the location of each oligonucleotide was 
carefully adjusted such that no di-GG nucleotide motif was positioned in the forward 
primer (and no di-CC nucleotide motif in the reverse primer) in order to eliminate the 
potential for mis-annealing due to the creation of A3G signatures. Moreover, no more 
than two G nucleotides were positioned at the forward primer regions (no more than two 
C nucleotides in the reverse primer region), while these potentially mutable bases were 
substituted with the degenerate S (50% G and 50% C), to exclude 5-AZC biased 
amplification. These primers amplified heavily mutated sequences in each treatment 
group (23 mut/720 bp), indicating that the sequenced DNAs were not biased against any 
mutation type. 
 Presently, concomitant use of viral mutagens and chain terminators shows efficacy 
against RNA viruses (50, 169, 170, 174-176).  For example, Perales et al. demonstrated 
that, in foot-and-mouth disease virus, sequential treatment with a traditional antiviral 
inhibitor followed by the viral mutagen ribavirin was much more effective in 
extinguishing picornavirus replication than these compounds used together or either one 
alone (176).  Future progress of mutagen utilization hinges on understanding the 
mutational constraints within RNA virus population structure. For example, sub-
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restrictive editing of retroviral genomes by APOBEC3 proteins has the potential to 
negatively influence therapeutic intervention, by rapid generation of drug-resistant 
mutants (116, 157).  Furthermore, quasispecies theory predicts that populations will 
evolve more robust genomes, termed survival of the flattest, in the face of increased 
mutational load (51, 194).  Alternative adaptive strategies include selection of anti-
mutator viral polymerases (12, 129, 179) or enhanced discrimination between correct and 
mutagenic nucleotides (205).  Evolution of drug resistance, or increased robustness, of 
mutagens can threaten such therapeutic approaches; yet, discovery of novel viral 
mutagens, as well as optimal applications, may lead to alternative therapeutic strategies. 
 Understanding molecular details of potential mutagens as well as sequence space 
limitations of specific viral pathogens may provide a rationale for tailored therapeutic 
intervention rather than lengthy small-molecule screening. Generally, HIV-1 viral 
mutagens are stealth nucleosides directly utilized by RT during replication to induce site-
specific mutations. These compounds are referred to as universal bases because they can 
mispair with more than one of the canonical Watson–Crick base pairs. For instance, the 
viral mutagen KP1212 can base pair with either G or A due to a tautormeric shift in the 
pyrimidine base. 5-AZC, a close derivative to KP1212, induces a unique G-to-C 
transversion mutational pattern during HIV-1 replication because of its ability to mispair 
with C bases (59, 109, 187).  Even by understanding specific molecular details, viral 
mutagens still lack a reliable framework to help predict successful treatment outcomes. 
Many parameters involved in understanding virus population dynamics and genetic 
diversity are not fully understood, including sequence space, mutational robustness, and 
effective population size, as well as the natural fitness landscape. Similarly, since 
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nucleotide base composition among viral genera is known to be quite distinct, purposeful 
alterations to the mutational bias of a particular virus may pose a greater defect to viral 
fitness. For example, since HIV-1, like other lentiviruses, has an unusually A-rich 
genome (19), it is not clear if mutagens that cause more N-to-A mutations (versus A-to-
N) are more detrimental to viral fitness. 
 In summary, we describe concomitant HIV-1 mutagenesis using two unrelated 
classes of viral mutagens. Our findings indicate a combined, yet intricate, interaction 
between 5-AZC and A3G. The combined antiviral effect observed indicated that A3G 
potentiated the mutagenic effect of 5-AZC. Sequencing analysis revealed that the 
combined mutagenic effect resulted in an increase in the frequency of G-to-A mutations 
at the expense of G-to- C mutations, suggesting a complex interaction between A3G and 
5-AZC upon incorporation into viral DNA. Future studies will provide greater details into 
the molecular mechanisms involved in concomitant HIV-1 lethal mutagenesis by A3G 
and 5-AZC. 
 
Materials and Methods  
 
Plasmids constructs and cell lines 
 The HIV-1 vector pHIG has been previously described (59).  Briefly, a ∼2.0-kbp 
dual reporter cassette composed of the HSA, an internal ribosome entry site element, and 
eGFP was placed in-frame and 3′ to the NL4-3 nef start codon. The G protein of vesicular 
stomatitis virus (VSV-G) envelope expression plasmid HCMV-G was used to pseudotype 
virions and was a kind gift from J. Burns (University of California, San Diego). The 
A3G-expressing cell lines 293-A3G clone 4 and 293-A3G clone 10 were previously 
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characterized in Sadler et al (192).  The APOBEC- expression plasmids pcDNA3.1 + -
A3G-3xHA and pcDNA3.1+-A3G_E259Q-3xHA were a kind gift from R. Harris 
(University of Minnesota). U373-MAGICXCR4 target cells lines were obtained from the 
AIDS Reagent Program (from M. Emerman). 
 
Single-cycle transduction and mutant frequency assays 
 Vector virus was produced by transient transfection of 293 cell lines with pHIG. 
Producer cell lines were transfected with 10 µg pHIG and 1 µg VSV-G env plasmids 
using Genjet ver. II reagent (SignaGen Rockville, MD) as per manufacturer's 
recommendations. Twenty- four hours post-transfection, viral supernatants were collected 
and filtered through a 0.2-µm filter. Viral stocks were normalized by transfection 
efficiency, measured by %GFP-expressing producer cells. Viral stocks were either used 
to infect target cells or stored at −80°C. The single-cycle infection efficiency for the 
control A3G null virus was set to 30%. U373-MAGICXCR4 target cells were plated in 
flat-bottom 12-well dish at a concentration of 6.25 × 106 cells per milliliter 24h prior to 
infection. Experiments with the viral mutagen 5-AZC (Sigma- Aldrich, St. Louis, MO) 
included a 2-h pre-treatment of 1:1000 dilution prior to addition of normalized viral 
supernatant up to 1 ml total volume. At 24 h postinfection, media were replaced with 
fresh cell culture media. 
 
Flow cytometry analysis 
 Target cells were prepared for flow cytometry to quantify transduction efficiency 
(via both GFP and HSA reporter gene expression) and mutant phenotype (via lack of 
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GFP or HSA reporter gene expression). At 72 h postinfection, cells were collected and 
stained with 1:250 anti-HSA-PE (BD Pharmingen). Following a 20-min incubation at 
4°C, cells were washed 1× in phosphate- buffered saline/2% FC3 and resuspended for 
flow cytometry. Mutant frequency analysis was determine from the % target cells 
expressing a single reporter gene relative to the total infected cell population (i.e., 
%[HSA+/ GFP−] plus %[HSA−/GFP+] divided by % of total infected cells). Mutant 
frequencies were set relative to virus null for A3G in the absence of drug. Cells were 
analyzed with a FACScan (BD Biosciences) and CellQuest software. Cells were gated by 
morphology (forward scatter channel versus side scatter channel) by counting 10,000 
cells for fluorescence analysis. Excitation was done at 488 nm; fluorescence channel 1 
detected GFP emission at 507 nm, and fluorescence channel 2 detected PE emission at 
578 nm. Compensation was set based on single-color controls to eliminate spill-over and 
re-verified based on the geometric mean of single-color positive to negative-detected 
populations. 
 
Proviral DNA sequence analyses 
 Approximately 25,000 target cells from each treatment group (+/− A3G and +/− 5-
AZC) were collected for total genomic DNA isolation (Roche High Pure PCR Template 
Preparation Kit) and subjected to nested PCR of the GFP gene in the HIV-1 vector 
proviral DNA. Primer sets were carefully designed as to remove any bias in amplicon 
pool considering mutagenic potential of the agents used. Specifically, forward primers 
did not contain any 5′-GG- 3′ motifs, while reverse primers were absent of 5′-CC-3′ 
motifs to remove the selection by A3G. Additionally, forward primers were located to 
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regions containing only two Gs (same for reverse; however, regions contained only two 
Cs), but these sites were designed to contain a G or C, denoted by S. This approach 
limited the 5-AZC- induced G-to-C bias that may be excluded from the amplicon pool. 
Within the pHIG vector, these primer sets would amplify a 944bp region of GFP: outer 
primer pair, 5′-CTCAATSCCACASCCATA-3′ and 5′-GTSTTSTTTGGGAGTGAA 
TTAG -3′; inner primer pair, 5′- CTCTCCTCAASCSTATTCAAC-3′ and 5′-
GGTATGGSTGATTATGATSTAGAGT-3′. PCR reactions used the Platnium PCR 
Supermix (Invitrogen), and the initial PCR reaction was purified with GenElute PCR 
Clean-up Kit (Sigma-Aldrich). Amplicons were verified for correct size and purity by 
DNA gel imaging prior to ligation into the pGEM-T vector (Promega). Plasmids were 
transformed into Escherichia coli, and insert-containing-vectors were purified 
(DirectPrep 96 Miniprep Kit; Qiagen) and sequenced. Sequence alignments were 
performed using SeqMan of Lasergene 7 (DNAStar, Madison, WI). Only DNA 
sequences covering the entire GFP gene (720 bp) were used for sequence analysis. This 
region was chosen because it has been previously used for sequencing analysis of A3G- 
and 5- AZC-mediated viral mutagenesis (59, 89, 95, 132). 
 
Immunoblot analysis of transiently transfected A3G-containing particles 
 293 cells were transfected with 10 µg pHIG, 1 µg HCMV-G env, and either 5µg 
pcDNA3.1 + -A3G-3xHA or pcDNA3.1 + -A3G_E259Q-3xHA or 5 µg empty vector, 
using Genjet ver. II reagent as per manufacturer's recommendations. Twenty-four hours 
after transfection, cell culture supernatants were collected and passed through a 0.2-µm 
filter. Next, 1.5 ml of cell culture supernatant was centrifuged at 16,000g for 2 h at 4°C. 
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Virus particle pellets were resuspended in 2.5 µl of 10× RIPA buffer, and 2.5 µl of a 10× 
protease inhibitor cocktail was added and incubated on ice for 15 min. Samples were then 
denatured by the addition of 6× loading dye and boiled for 10 min prior to SDS-PAGE 
with a 4–20% denaturing gel. Proteins were transferred to nitrocellulose and A3G and 
A3G_E259Q-containing virus particles were was probed with a primary monoclonal 
antibody, HA.11 (Covance, Emeryville, CA), followed by a goat anti-mouse horseradish 
peroxidase conjugate (Invitrogen). To detect HIV-1 capsid (p24) protein, we incubated 
the nitrocellulose membrane with a rabbit anti-p24 antibody (Advanced Biotechnologies, 
Columbia, MD) followed by a goat anti- rabbit IgG (H + L)-horseradish peroxidase 
conjugate (BioRad). Detection of protein location on the nitrocellulose membranes was 
determined using a BioRad ChemiDoc Imager with Quantity One software (version 
4.5.2; BioRad). 
 
Statistical analyses 
All statistical analyses and graphical representation were done using GraphPad 
Prism version 5.0 (GraphPad Software, La Jolla, CA). Bars graphs of infection efficiency 
and mutant frequency data were established with the mean±SD. Statistical analysis of 
mutational load differences was performed using a chi-squared contingency table, 
comparing the number of mutated sites to the number of non-mutated sites with each 
mutation type (i.e., G to A and G to C). A3G hotspot prediction was determined using 
CLUSTERM†‡. This algorithm predicts a hotspot threshold for the number of mutations 
at a particular site. The threshold number is established by analyzing the frequency 
distribution of mutations among a predetermined genomic region (186). 
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Figure A3-1. HIV-1 vector assay for analysis of viral mutagens. The HIV-1 vector, 
pHIG, was co-transfected with a VSV-G envelope expression plasmid into previously 
characterized APOBEC3G (A3G)-expressing 293 cell lines (192). Cell culture 
supernatants were collected and filtered, and virus was used to infect U373-
MAGICXCR4 target cells. Following normalization of virus titers, target cells were pre-
treated for 2 h with 5-AZC and infected with HIV-1 at a multiplicity of infection of 0.30. 
Seventy-two hours postinfection, cells were collected for analysis. Abbreviations: HSA, 
murine heat stable antigen CD24; IRES, internal ribosome entry site; A3G, APOBEC3G; 
FL1-H, fluorescence channel 1, height of intensity; FL2-H, fluorescence channel 2, 
height of intensity. 
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Figure 4-1.  HIV-1 vector assay for analysis of viral mutagens.  The HIV-1 vector 
(Dapp et al.) was co-transfected with a VSVG envelope plasmid into previously charac-
terized 293 cell lines, expressing a physiologic range in APOBEC3G protein levels 
(Sadler et al.).  Cell culture supernatants were collected, filtered, and virus was titred on 
permissive U373-MAGICXCR4 target cells.  After respective viral titre normalization, tar-
get cells were pre-treated for 2-hr with 5-AZC and transduced at an MOI of 0.30.  72-hr 
post-transduction, cells were collected for flow cytometry and sequence analysis.  MOI, 
multiplicity of infection.  VSVG, vesicular stomatitis virus glycoprotein.  HSA, murine 
heat stable antigen (CD24).  IRES, internal ribosome entry site.  GFP, green fluorescent 
protein.  A3G, APOBEC3G.  FL1-H and FL2-H, fluorescence channel, 1 and 2, height of 
intensity. 
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Figure A3-2. Concentration-dependent inhibition of HIV-1 in the presence of 5-AZC 
and A3G. (A) HIV-1 infectivity in the presence of 5-AZC and/or A3G. Virus stocks, 
produced from the A3G-expressing cell lines 293-A3G clone 4 and 293-A3G clone 10,37 
were normalized by transfection efficiency. U373-MAGICXCR4 cells were pretreated 
for 2 h with the indicated concentrations of 5-AZC prior to infection. Infection levels 
!
97!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. Concentration-dependent inh bition of 5-AZC of HIV-1 replication in 
the presence of A3G.  A) Viral stocks, produced from A3G-expressing cell lines (Sadler 
et al. 2010) were normalized.  U373-MAGICXCR4 cells were pretreated for 2-hr with the 
indicated concentrations of 5-AZC prior to addition of viral supernatant.  Transduction 
efficiency determined by positive exp es ion f both marker genes.  B) Fold-change 
shows mutant frequency relative to vector + vehicle control.  Data represent mean fold 
change ± SD from at least 3 independent replicates.  Mutant frequency calculated by 
phenotypic expression of marker genes within pHIG vector, see Materials and Methods. 
A) 
B) 
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were determined by expression of both the HSA and GFP marker genes. (B) Relative 
mutant frequency. The mutant frequency is shown relative to the vector + vehicle control.  
Data represent the mean fold change ± SD from at least three independent replicates. 
Mutant frequency was calculated as described in Materials and Methods.  
 
	   150 
 
 
 
 
 
!
98!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) 
B) 
	   151 
 
 
 
 
!
99!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C) 
D) 
	   152 
 
 
!
100!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E) 
	   153   
!
10 !
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F) 
	   154 
Figure A3-3. Mutation spectra analysis from recovered proviruses.  Total genomic 
DNA from infected cells was purified, and proviral HIV-1 DNA was amplified, cloned, 
and analyzed by DNA sequencing. (A) Vector + dimethyl sulfoxide (DMSO), (B) vector 
+ 5-AZC, (C) 293-A3G clone 4 + DMSO, (D) 293-A3G clone 10 + DMSO, (E) 293-A3G 
clone 4 + 5-AZC, and (F) 293- A3G clone 10 + 5-AZC. Each gray horizontal line 
represents an individual GFP gene sequence (720 bp) from a recovered provirus (5′ to 3′). 
Mutation locations are indicated by colored rectangular boxes (G-to-A mutations, orange; 
G-to-C mutations, blue; other base substitution types, black) or by triangles (insertion 
mutations, black; deletions, white). Broken vertical lines indicate base locations in the 
GFP gene sequences that are predicted to be A3G hotspots, as determined using 
CLUSTERM (as described in Materials and Methods). Below each experimental set (A-
F) of GFP gene sequences are summary pie charts that indicate total numbers of G to A, 
G to C, and other mutation types characterized in experiments. The first column shows 
colored pie charts and the proportion of recovered clones with no mutations, white; 
without either G-to-A or G-to-C mutations, gray; with G-to-A mutations, red; with G-to-
C mutations, blue; with G-to-A and G-to-C mutations, purple. The other three columns 
show pie charts indicating the number of mutations per proviral sequence (i.e., 1, 2, 3, 
etc.) from the total recovered clones (second column), G-to-C-only mutated clones (third 
column), or G-to-A only mutated clones (fourth column). The total number of proviral 
clones is indicated by the number at the center of the pie chart. N/A, not applicable. 
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Figure A3-4. Requirement of APOBEC3G catalytic activity for reducing the 
frequency of 5-AZC-mediated G-to-C mutations.  293T cells were transfected with the 
HIV-1 vector (pHIG), VSV-G envelope expression plasmid, and a A3G- expression 
vector, the A3G(E259Q) catalytically inactive mutant expression vector, or vector only. 
Twenty-four hours post-transfection, cell culture supernatants were harvested and used to 
infect 5-AZC-treated target cells to assay for either viral infectivity (A) or viral mutant 
frequency (B) determined or used for immunoblot analysis of HIV-1 Gag or A3G (C). 
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Table A3-3. Effect of catalytically inactive A3G expression in 
virus-producing cells on mutation spectra in the GFP gene of 
vector proviruses 
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Table 4-3. Effect of catalytically inactive 3  expression in 
virus-producing cells on mutation spectra in the GFP gene 
of vector proviruses  
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